|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡Gªü¤å10138375 µoªí®É¶¡:2016/5/19 ¤U¤È 12:05:10²Ä 1520 ½g¦^À³
|
°ò¥»ÄѤj, §Ú¦Û¤vªº¸ÑÄÀ¦p¤U ¦³Global-H+²£¥Í§ÜÅé(§K¬Ì¨t²Î°·¥þ) : 50% ¦³Global-H+¨S²£¥Í§ÜÅé(¥i¯à§K¬Ì¨t²Î¤w±Y¼ì) : 30% ¨S¦³Global-H+§K¬Ì¨t²Î°·¥þ : 12% ¨S¦³Global-H+§K¬Ì¨t²Î¤w±Y¼ì : 8% ¹êÅç²Õ¨S§K¬Ì¤ÏÀ³ªÌ:¯f¤H¥»¨§K¬Ì¨t²Î¤w±Y¼ìªÌ¦û76%(30+8)/(30+8+12) ¹ï·Ó²Õ¥þÅé:¯f¤H¥»¨§K¬Ì¨t²Î¤w±Y¼ìªÌ¦û38%(30+8)/(30+8+12+50) ©Ò¥H¹êÅç²Õ¨S§K¬Ì¤ÏÀ³ªÌÀ³¸Ó¤ñ¹ï·Ó²Õ¥þÅé®t |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2016/5/19 ¤W¤È 11:42:54²Ä 1519 ½g¦^À³
|
¹êÅç²Õ¨S¤ÏÀ³ªºªí²{¦ü¥G§C©ó¹ï·Ó²Õ, ¤p§Ìı±o³o¤£¬OÀ³¸Ó«Ü¦X²z¶Ü?¦]¬°¹êÅç²Õ¥¼²£¥Í§ÜÅé´N¬O§K¬Ì¤O¶W®z¤F,¹ï·Ó²Õ¤¤¨ä¹ê¬O¦³§K¬Ì¤O±jªº,¥u¬O¨S¥´¨ì822,¦]¬°³o¨âÓ²Õ§O¬Ý°_¨Ó,¬Û·í©ó³£¥u¥´¤FC, ¦ý¬O¾ãÅé¹ï·Ó²Õªº§K¬Ì¤O¬O°ª©ó¹êÅç²Õ¥¼²£¥Í§ÜÅ骺,¦]¦¹¥X¨Óªº²Îp¼Æ¦r¤]¬O¤ÏÀ³³oÓ,¦n¹³¸ò¹B®ð¤£¤@©w¬ÛÃö? |
|
|
·|û¡G°ò¥»ÄÑ10141110 µoªí®É¶¡:2016/5/19 ¤W¤È 11:17:48²Ä 1518 ½g¦^À³
|
«D±`·PÁÂCliff¤jªº¾ÉŪ¡A¤p§Ì¬Ý§¹«á¦³¤@ÂIºÃ°Ý: ´NºKn¤º®e¨Ó¬Ý¡A¹êÅç²Õ¨S¤ÏÀ³ªºªí²{¦ü¥G§C©ó¹ï·Ó²Õ¡A ³o³¡¤À°£¤FÂk©S¹B®ð¤£¨Î¤§¥~(§K¬Ì¨t²Î¸û®tªºè¦n³£¥h¹êÅç²Õ¤F)¡A ÁÙ¦³¥i¯à¬O¨º¨Ç¦]¯À³y¦¨©O?? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/5/19 ¤W¤È 10:21:55²Ä 1517 ½g¦^À³
|
¡u ¡v¤º±Ôz¨ú¦Û©xºô¤¤¤åª©822ºKn ¡u348¨Ò±wªÌ±µ¨ü¬ã¨sÃĪ«©Î¦w¼¢¾¯ªvÀø¡A168¨Ò±wªÌ(48%)§¹¦¨9¦¸ª`®gÀøµ{¡C¡v ©Ò¥H168¦ì¥]§t¤F¸ÕÅç²Õ¤Î¹ï·Ó²Õ¡A©|¤£ª¾¹D¨â²Õ±wªÌ¤À¥¬±¡§Î¡C ¤£¹L¡A¡u¦³50%ªº¹êÅç²Õ±wªÌ¡A¹ï OPT-822/OPT-821²£¥Í Globo H ¯S²§IgG §ÜÅé (³o¬O«ü§ÜÅé®Ä»ù´¿¦bªvÀø´Á¶¡¤º¹F¨ì ≥ 1:160)¡C¡v ¬O«ü²£¥ÍIgG¡A¤£¬O¥H©¹¤@´ÁÁ{§É¸ÕÅçµ²ªGªºIgM¤ÀªR³á¡A¦³50¢H¹êÅç²Õ±wªÌ¡A²£¥Íanti-GH IgG titer≥160¡A¤@¯ë¬O¥H40¬°°ò·Ç¥h¤ñ¸ûª`®g«e«áªº§ÜÅé´£¤Éµ{«×¡A¤]´N¬O¦³¤@¥bªº¸ÕÅç²Õ±wªÌ±µ¨ü822ª`®g«á²£¥Í¤F4¿¥H¤Wªº§ÜGlobo H ªºIgG¡]¥]§t²£¥Í§ÜÅé®Ä»ù¹F160¡B320¡B640¬Æ¦Ü1280¥H¤Wªº¡K¡A®Ä»ù¶V°ª¡Aªí¥Ü©Ò²£¥Íªº§ÜÅé¿@«×¶V°ª¡^¡C ¦pªGÂX¤j¥[ptiter≥80¡]²£¥Í2¿¥H¤Wªº§ÜÅé¡^ªº¸Ü¡A¬O¤£¬O¦³¾÷·|±µªñ°|ªø©Ò»¡ªº80%¡H ÁÙ¦³¡A³oùØ¥u´£¨ìanti-GH IgG¦Ó¤w¡A¦pªG¥[panti-SSEA-3»Panti-SSEA-4ªºIgG©O¡H ¡]²q´útiter80~160ªº±wªÌ¡A¥i¯à§e²{PR©ÎPD¡AY¸¨¦bPRªÌ¡A¤´¦³¯q©óORRªº¼Æ¾Ú¡C¡^ ¡u¹ïOPT-822/OPT-821²£¥ÍGlobo H ¯S²§IgG§ÜÅé (³o¬O«ü§ÜÅé®Ä»ù´¿¦bªvÀø´Á¶¡¤º¹F¨ì ≥ 1:160)¡C³o¨Ç²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A·í»P¹ï·Ó²Õ¤ñ¸û¡A¦³¥H¤Uµ²ªG: PFS¡GHR = 0.71 [95%CI 0.52-0.97]¡Ap= 0.029¡F OS¡GHR=0.57 [95%CI 0.33-0.97]¡Ap = 0.04¡F¡v °£¤F¬Ý²Îp®Ä«×pȦ³¨S¦³¤p©ó0.05¥~¡AÁÙn¬ÝHRªº¼Æ¦r·U§C·U¦n¡F¥Bnª`·NCI¡]«H¿à°Ï¶¡¡^¦³¨S¦³¸ó¶V1¡C HR¬O·ÀI¯à¦]¥ÎÃĦӰ§C¦h¤Öªº«ü¼Ð¡AY¬OHR=0.71¡Aªí¥Ü«e²Õ¤ñ«á²Õªº·ÀI°¤F29¢H¡C CI¡]«H¿à°Ï¶¡¡^³£¤p©ó1¡A¨S¦³¸ó¶V1¡Aªí¥Ü¨C¦ì«e²Õ±wªÌ´X¥G³£¦³®ÄªG¡A¥u¬O®ÄªG¤j¤p®t§O¦Ó¤w¡A¤]´N»¡¨ºÓHR¡Õ1ªºµ²ªG¤£¬O³Qpooling¥X¨Óªº¡C ¡u²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A©MµL§K¬Ì¤ÏÀ³±wªÌ¤ñ¸û¡A¦³¥H¤Uµ²ªG: PFS¡GHR = 0.52 [95%CI 0.37-0.71]¡Ap< 0.0001¡F OS¡GHR = 0.52 [95%CI 0.29-0.92]¡Ap= 0.025¡]µ²ªG¸g°ò¦¯e¯fª¬ºA/²üº¸»XÀøªk¨Ï¥Î±¡ªp®Õ¥¿)¡C³o¨âÓµ²ªGÅã¥Ü¡A²£¥Í§K¬Ì¤ÏÀ³±wªÌªºPFS ©MOS³£¦³ÅãµÛ§ïµ½¡C¡v ¨ú¦¸¸s¤ÀªR¡A®³²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A©MµL§K¬Ì¤ÏÀ³±wªÌ°µ¤ñ¸û¡APFS»POSªºHRȧó§C¡ACI Range§ó»·Â÷1¡FpȤ]§óÅãµÛ¡Aªí¥Ü¥i«H«×§ó°ª¡C ¡u¸g®É¶¡¬Û¨ÌCox ¤ÀªR¨Ã»P¹ï·Ó²Õ¬Û¤ñ¤§«á¡A¹ï©ó§¹¦¨9¦¸OPTª`®gÀøµ{ªÌ¡A¨äPFS¤]¦³§ïµ½ÁͶÕ(HR = 0.66 [95% CI 0.42-1.01]¡AP = 0.057)¡C¡v ³o¤@¬q´N¤ñ¸û¤£º}«G¡ACI Range²[»\1¥BP>0.05¡C ±µ¤U¨Ó 1.µ¥«áÄò§ó¦h§ó²Óªº¦¸¸s¤ÀªRµ²ªG¡A§ó¯à¤F¸Ñ822ªº»ùÈ¡AÁö»¡¥¼¹F¥DnÀø®Ä«ü¼Ð¡A¦ýFDAÀ³·|¬Ý¨ì¥B«µø¨ä¤¤©Ò³zÅSªº°T¸¹¡A°T¸¹Y¬O¤Ó¤p¡A¨º¦b¤U¦¸·s¤T´Á¸ÕÅçÀ³¥i¸g¥Ñ¦nªº³]p±N¥¦¹üÅã¡A¤£¥i¯àµø¦Ó¤£¨£¡CY²{¦bªºµ²ªG´NÅýFDA¤j¬°ªY½à¡A¨º´N¦³±o·Q¹³¤F¡C 2.¥ñµ§¡GNED¤H¼Æ¡BORR¡B¤T³±¨ÅÀùÀø®Ä¡Banti-SSEA-3 Ab titer¡Banti-SSEA-4 Ab titer¡K¡K¡H 3.¦^ÅU¹L¥h´X¦¸±i¸³»P°|ªø©Ò¨¥¡A´¢¼¯¤@¤U¬°¦ó·|¨º¼Ë»¡¡H 4.Åwªï«ü¥¿¡C ªþ¥ó¡F BMS Ipilimumab¡]Yervoy¡^ in Patients with Metastatic Melanoma¡F2010/08/19 CR+PR+SD¡×61 ORR= 61/403=15.1% Àq§J/½÷·ç Avelumab¡]PD-L1¡^¨ÅÀùªºÁ{§É³ø§i; 2015/12¤ëSABCS CR+PR+SD=47 ORR= 47/168 = 28.0% ù¤óAtezolizumab¡]MPDL3280A¡^¡]PD-L1¡^¤T³±©Ê¨ÅÀù¡A21ÓPD-L1¶§©Ê¯f±w¤¤¡A ORR=CR+PR= 4/21 =19% Àq§JPembrolizumab (Keytruda) with epacadostat; Phase I/II: ORR=10/19=52.6% KEYTRUDA with IMLYGIC; Phase Ib: ORR=9/265= 0.3% KEYTRUDA with Ipilimumab: Phase I/II : ORR=40/72=55.5% 822 ORR¡×¡H ·PÁ¦ѥv¤j¡B¬P±á¤j¡C |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/5/19 ¤W¤È 10:01:50²Ä 1516 ½g¦^À³
|
¦Ñ´¤jÁ¿ªº¤Ó½ÆÂø¤F¡A§Ú¬Ý¤F·|ÀY·w¡A«¢¡I §Ú³ßÅw§â°ÝÃD²³æ¤Æ¡A³o¼Ë¤ñ¸û®e©ö¤F¸Ñ¡I ¤å¤¤³o¥y¸Ü¡G ¦³50%ªº¹êÅç²Õ±wªÌ¡A¹ï OPT-822/OPT-821 ²£¥Í Globo H ¯S²§IgG §ÜÅé (³o¬O«ü§ÜÅé®Ä»ù´¿¦bªvÀø´Á¶¡¤º¹F¨ì ≥ 1:160)¡C³o¨Ç²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A·í»P¹ï·Ó²Õ¤ñ¸û¡A¦³¥H¤Uµ²ªG: PFS¡AHR = 0.71 [95%CI 0.52-0.97]¡Ap= 0.029¡FOS¡AHR=0.57 [95%CI 0.33-0.97]¡Ap = 0.04¡F²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A©MµL§K¬Ì¤ÏÀ³±wªÌ¤ñ¸û¡A¦³¥H¤Uµ²ªG: PFS¡AHR = 0.52 [95%CI 0.37-0.71]¡Ap< 0.0001¡FOS¡AHR = 0.52 [95%CI 0.29-0.92]¡Ap= 0.025¡]µ²ªG¸g°ò¦¯e¯fª¬ºA/²üº¸»XÀøªk¨Ï¥Î±¡ªp®Õ¥¿)¡C³o¨âÓµ²ªGÅã¥Ü¡A²£¥Í§K¬Ì¤ÏÀ³±wªÌªºPFS ©MOS³£¦³ÅãµÛ§ïµ½¡C ¥H¤W¡AÁ`µ²¤@¥y¸Ü¡G ¦³50%ªº¹êÅç²Õ±wªÌªºPFS ©MOS³£¦³ÅãµÛ§ïµ½¡C ³o¼Ë¨S¡uÂ_³¹¨ú¸q¡v§a¡I |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/5/19 ¤W¤È 09:35:02²Ä 1515 ½g¦^À³
|
MoneyDJ·s»D 2016-05-19 09:24:48 °OªÌ ·s»D¤¤¤ß ³ø¾É ¯E¹©(4174)¤µ(19)¤éµo¥¬«¤j°T®§«ü¥X¡A¨ÅÀù·sÃÄOBI-822ªº¤G/¤T´ÁÁ{§É¸ÕÅç½×¤å¡A§Y±N©ó6¤ë3¦Ü7¤é¦b¬ü°êªÛ¥[ô¥«Á|¦æªº¬ü°êÁ{§É¸~½F¾Ç·|ASCO¦~·|¤¤¤½¶}µoªí¡C ¯E¹©«ü¥X¡A¤µ¦¹¸ÕÅçµû¦ôOBI-822Àù¯g¥D°Ê§K¬ÌÀøªk¡A¦bªvÀøÂಾ©Ê¨ÅÀù±wªÌªºÁ{§ÉÀø®Ä©M§K¬Ì»¤µo¯à¤O(§K¬Ìì©Ê)¡F§¹¾ã¬ã¨sµ²ªG±N©ó¤j·|¤fÀY³ø§iµoªí¡C ¯E¹©ªí¥Ü¡A½×¤å³ø§i¥DÁ¿¤H¬°¬ü°ê¥[¦{¤j¾Çª÷¤s¤À®Õ®üÛ.}°Çºî¦XÀù¯g¤¤¤ß¨ÅÀùÂå¾Ç©MÁ{§É¸ÕÅç±Ð¨|¥D¥ô±Ð±ÂHope S. RugoÂå¾Ç³Õ¤h¡F¸Ó½×¤å³ø§i²Ä¤@§@ªÌ¬°¶À«T¤ÉÂå¾Ç³Õ¤h¡B²{¥ô¥x¤jÂå¾Ç°|¥~¬ì±Ð±Â¡B¥x¤j¨ÅÀùÂå¾Ç¤¤¤ß¥D¥ô¡C ¯E¹©Á`¸g²z¶À¨q¬üªí¥Ü¡A«Üºa©¯¯à¦bASCO¦~·|µoªí¥D°Ê§K¬ÌÀøªkOBI-822/821ªvÀøÂಾ©Ê¨ÅÀùªº¬ã¨s¼Æ¾Ú¡A®i²{¯E¹©¦bÀù¯gªvÀø»â°ìªº§V¤O¦¨ªG¡F§Æ±æ³oÓ¬ã¨s¡A¯à¹ïÂಾ©Ê¨ÅÀùªºªvÀø¡A±a¨Ó°^Äm¡C ¯E¹©¨Ã«ü¥X¡AOBI-822¬O¤@ºØ¬ãµo¤¤ªº³Ð·s¥D°Ê¦¡Àù¯g§K¬ÌÀøªk¡C¥¦¬O¥Ñ¸~½F¬ÛÃöÁÞ§Üì(TACA) Globo H¡A»P¸üÅé³J¥ÕKLH¦@»ùµ²¦Xªº¦X¦¨ÁÞ³J¥Õ¡COBI-821¬O¨m?«¬¦õ¾¯¡CGlobo H¦b¦hºØ¤W¥Ö´c©Ê¸~½Fªºªí±°ª«×ªí²{¡A¦p¨ÅÀù¡B«e¦C¸¢Àù¡BGÀù¡BªÍÀù¡Bµ²¸zÀù¡B¯ØŦÀù©M§Z±_Àùµ¥¡CGlobo H »PKLHµ²¦X¬°OBI-822(Globo H-KLH)¡A¨Ã»P¦õ¾¯OBI-821¤@¨Öµ¹ÃÄ¡A¥H´£ª@§Ü쪺§K¬Ìì©Ê¡C¸ÓÃĪ«¥ÑSloan-Kettering¬ö©ÀÀù¯g¤¤¤ß(MSKCC)¿W®a±ÂÅvµ¹¯E¹©¡C ¯E¹©¥»¦¸½×¤åºKn¤¤¤å¥þ¤å³sµ²ºô§}¡G www.obipharma.com/index.aspx?lang=chi&fn=news_content&no=72 |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/5/19 ¤W¤È 08:51:32²Ä 1514 ½g¦^À³
|
Results: 349 pts were randomized, 348 received study drug (ITT), 168 (48%) received all 9 injections. 348Ó¯f¤H¸Ì¥u¦³168(48%)¤E°w³£¥´§¹,¨ä¤¤¨â²Õ³£¦³¥]§t,©Ò¥H¹êÅç²Õ233¸Ì¦³´XÓ´X%¥´§¹,¹ï·Ó²Õ116¸Ì ¦³´XÓ´X%¥´§¹,¦b³oÁ٬ݤ£¥X(ì«h¤W2:1=¹êÅç²Õ¬ù100Ó¥´§¹)------------³o¤]´N¬OMichaelÁ¿ªº´£¦¤T®¶¥X§½ªº¤Ó¦h¤F! 70% had hormone receptor positive BC, 13% were triple negative, and 62% received hormone therapy. ¨â²Õ³£¬O¦P¼Ëªº¾÷·|,©Ò¦³hormone therapy¤zÂZµ²ªGªº¾÷·|¬Ûµ¥----------RCT¸Ñ¨Mphase I®Éªº°ÝÃD! No difference was observed in PFS (HR, 0.96 [95% CI, 0.74-1.25] P = .77) or in interim OS (HR, 0.79 [95% CI, 0.51-1.22] P = .29). ¾ãÅé¬Ý¨â²Õ¶¡ªºPFS,OS¨S¦³®t²§! However, PFS and OS were significantly improved in the 50% of pts who developed a Globo H specific IgG response to OPT-822/OPT-821 with a titer ≥ 1:160 at any time during treatment ¦ý¬O¹êÅç²Õ¸Ì¦pªG¹ïglobo H²£¥ÍIgG¥B¦bªvÀø´Á¥ô¦ó®É¶¡titer ≥ 1:160(µ}ÄÀ4¦¸?)ÁÙ¦³§ÜÅ骺¯f¤H¤¤ ¦³50%ªº¯f¤HPFS,OS³£«Ü¦n. ¡´³o50%¤£¤@©w¥´§¹¤E°w,¦³¥i¯àÁÙ¬O¦³100Ó¥ª¥kªº¯f¤H(¹êÅç²Õ233´î±¼loss)¡A¦Ó¤£¬O¥´§¹¤E°wªº¹êÅç²Õ¤¤ ªº50%(¨º¥i¯à¥u³Ñ50Ó¥ª¥k)¡´ vs control (HR, 0.71 [95% CI, 0.52-0.97] P = .029 for PFS; HR, 0.57 [95% CI, 0.33-0.97] P = .04 for OS) and ³o50%ªº¯f¤H©M¹ï·Ó²Õ¤ñ PFS¤H¼Æ¬O¹ï·Ó²Õªº0.71¿ OS¤H¼Æ¬O¹ï·Ó²Õªº0.57¿ vs nonresponders (HR, 0.52 [95% CI, 0.37-0.71] P< .0001 for PFS; HR, 0.52 [95% CI, 0.29-0.92] P = .025 for OS), ³o50%ªº¯f¤H©M¨S¦³§K¬Ì¤ÏÀ³ªº¤ñ PFS¤H¼Æ¬O¹ï·Ó²Õªº0.52¿ OS¤H¼Æ¬O¹ï·Ó²Õªº0.52¿ adjusted for baseline disease status/hormone use. ³o¨Ç³£¤w¸g§â¤@¶}©lªº¯e¯fµ{«×©Mhormone therapyªº¼vÅTpºâ¶i¥h¤F! In a time-dependent Cox model, PFS was improved in pts who received all 9 injections of OPT vs control (HR, 0.66 [95% CI, 0.42-1.01] P= .057). ¸g®É¶¡¬Û¨ÌCox ¤ÀªR ¥´§¹¤E°wªº¹êÅç²Õ(100¦hÓ)©M¹ï·Ó²Õ(¬ù116´î±¼loss)¤ñ PFS¤]¦³§ïµ½ªºÁͶջÕPFS¤H¼Æ¬O¹ï·Ó²Õªº0.66¿)¡A¦ý¬O²Îp¤W®t¤@ÂI´NÅãµÛP=.057 ¡´©Ò¦³¥´§¹¤E°wªº¹êÅç²Õ,¤£ºÞIgG titer ¬O¤£¬O≥ 1:160¡´ ¡´¤£¤@©w¥´§¹¤E°wIgG titer´N·|≥ 1:160,¦³¨Ç¥u¥´4°wªºIgG titer´N·|≥ 1:160¡´ ²Å¦X±Ð¥D«á¨Óªº¦^µª¡G±N¨Ó·|¦³¤@Óscreen in period¡÷¥´3~4°w¡A§ÜÅé¶q¤W¤É4¿ªº¤~¯Ç¤J OPT-822/OPT-821 was well tolerated; the most common drug-related adverse event was grade 1/2 injection reaction. ¥Í¬¡«~½è!¥Í¬¡«~½è!¥Í¬¡«~½è! Conclusion: Vaccination with OPT-822/OPT-821 did not improve PFS in the ITT; however, PFS and interim OS were significantly improved in pts who developed an immune response to the vaccine. These subgroup data will be used to design a definitive Ph III trial. Clinical trial information: NCT01516307 µ²½×:Michael&¤½¦Ð¥ý¥Í¨S¦³ÄF¤H!¨S¦³ÄF¤H!¨S¦³ÄF¤H!µo¤F!µo¤F!µo¤F! |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/5/19 ¤W¤È 08:44:35²Ä 1513 ½g¦^À³
|
§O§Ñ¤F¡A¹êÅ窺¹ï¶H¬O¡u¸g¹L¦Ü¤Ö¤@ºØ§ÜÀùÀøµ{ªvÀø«á¡A¦³³Ì¦h2¦¸¯e¯f´c¤Æ (PD) ¥H¤Î¹F¨ì¯e¯féw (SD) ªºÂಾ©Ê¨ÅÀù±wªÌ¡v...¬Q¤é±oª¾¦Ñ±Cªº©h©hªÍÀù¤G´Á¡A¯E¹©¥[ªo°Ú... |
|
|
·|û¡G10©`¦Ì10141458 µoªí®É¶¡:2016/5/19 ¤W¤È 08:43:44²Ä 1512 ½g¦^À³
|
¬Ý¨ì³o¨Ç¼Æ¾ÚÁٯ໡¤°»ò?¥u¯à»¡¶W´ÎDER¡I¦Ó¥B¦pªG»~§PPDªº¤ñ¨Ò¦A¤Ö¤@ÂI¸ò¨ü¸ÕªÌ¤£nÁÙ¨S²£¥Í§K¬Ì¤ÏÀ³´N¤É¤Ñªº¸Ü¡A¨º¥i¾A¥Î¤ñ¨Òµ´¹ï·|¶W¹L50w§ó¦h¡C ¬Û¹ï³o¨Ç§Ú§óÃö¤ßASCO¨ì®É¤½¥¬ªºNED¤ñ¨Ò¦³¦h°ª¡H¥i¥H°ª¨ìÅý¤½¦Ð¥ý¥Í»y¥XÅå¤H»¡¥i¥H´Â§¹¥þªv¡»P¹w¨¾µo®i¡C |
|
|
·|û¡G¤p¤á10140918 µoªí®É¶¡:2016/5/19 ¤W¤È 08:40:32²Ä 1511 ½g¦^À³
|
¹ï©ó§¹¦¨ 9 ¦¸OPTª`®gÀøµ{ªÌ¡A¨äPFS¤]¦³§ïµ½ÁͶÕ(HR = 0.66 [95% CI 0.42-1.01]¡AP = 0.057)¡C ¯E§J¤j, §Úªº¸ÑŪ¬O, ¥un¥´§¹9°w, ºÞ§A¤°»ò±Ú¸s, ´X¥G¥þ³¡³£¦³®Ä (¬O ~100%³á!!) ¦³§K¬Ì¤ÏÀ³ªº(≥1:160)·|§ó¦³®Ä. ³o¼Ëªº¼Æ¾Ú, ¹ï¤ñ¤§«e¦Ñ¥v¤j´£¨Ñªº¨ä¥L§K¬Ì¸ê®Æ, FDA¯à¤£¤ß°Ê¶Ü~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/5/19 ¤W¤È 08:38:20²Ä 1510 ½g¦^À³
|
²³¤j¤j ®¥³ß¤j®a¼Æ!!! ¼Æ¾ÚªGµM«GÄR(¦p¤½¥q¤G¤ëªk»¡·|ªº»¡©ú) ³o¤]¥Nªí¤½¥q»P¤½¦Ð©Ò¨¥Äݹê 1 ¹êÅç²Õ²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A·í»P¹ï·Ó²Õ¤ñ¸û¡A¦³¥H¤Uµ²ªG: (²Õ¶¡¤ñ¸û) PFS¡AHR = 0.71 [95%CI 0.52-0.97]¡Ap= 0.029¡F(PFS ¤w¹F¨ìÅãµÛ®t²§significant) OS¡AHR=0.57 [95%CI 0.33-0.97]¡Ap = 0.04¡F(OS ¤w¹FÅãµÛ®t²§Significant ¹w´Á©¹«á·|³v¨B©Ô¤j®t²§) 2¹êÅç²Õ²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A©MµL§K¬Ì¤ÏÀ³±wªÌ¤ñ¸û (²Õ¤º¤ñ¸û) PFS¡AHR = 0.52 [95%CI 0.37-0.71]¡Ap< 0.0001¡F(PFS ¹F¨ì·¥«×ÅãµÛ®t²§Extremely significant) OS¡AHR = 0.52 [95%CI 0.29-0.92]¡Ap= 0.025 (OS ÁÙ¦bÆ[¹î¤¤¤w¹FSignificant¹w´Á©¹«á·|³v¨B©Ô¤j®t²§) ¡]µ²ªG¸g°ò¦¯e¯fª¬ºA/²üº¸»XÀøªk¨Ï¥Î±¡ªp®Õ¥¿)¡C (·ÀI¤ñ¶V§C¶VÅãµÛ,°§Cªº·ÀI¶V¤j)HR = 0.52 ªí¥Ü°§C48% ªº·ÀI) ³o¨âÓµ²ªGÅã¥Ü¡A²£¥Í§K¬Ì¤ÏÀ³±wªÌªºPFS ©MOS³£¦³ÅãµÛ§ïµ½¡C Ó¤H¤ß±o: ¨ÅÀùOBI822°ª¦w¥þ©Ê,°ª¥Í¬¡«~½è»P°ª¬I¥´¤è«K©Ê»P®aÄÝ·ÓÅU,¨Ã¤w¦b¬ì¾Ç¤WÃÒ¹ê³oÁûÃĪ«ªºªv¯f¾÷¨îMOA,¦b»sµ{¤W¥i¤j¶q¦X¦¨»s³y«~½èéwªº²£«~,¥[¤W¤µ¤Ñ¤½§GªºÀø®Ä¤ÀªR(¥H¤W¯SÂI¤w²Å¦XÀò±o¬ü°ê ¼Ú·ù¥xÆWÃÄÃÒªº±ø¥ó) ¥H¤WÓ¤H¤À¨É»P¸ÑŪ ¶È¨Ñ°Ñ¦Ò ¦³¿ù½Ð§ó¥¿ P value Wording Summary < 0.0001 Extremely significant **** 0.0001 to 0.001 Extremely significant *** 0.001 to 0.01 Very significant ** 0.01 to 0.05 Significant * ≥ 0.05 Not significant www.graphpad.com/guides/prism/7/statistics/index.htm?extremely_significant_results.htm |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/5/19 ¤W¤È 08:37:58²Ä 1509 ½g¦^À³
|
¤p§Ì«DÂåÃıM·~¡A¥H¤Uµo¨¥¶È¨Ñ°Ñ¦Ò¡C ¬I¥´¤E°wªÌ¦û48%¡A³o·í¤¤¥]¬A¹êÅç²Õ»P¹ï·Ó²Õ¡A¥un²Ä37©PÁÙ¥¼PD´N·|¥´§¹¡C©Ò¥H¾ãÓ¨ü´ú348¤Hªº¾ãÅéPFS¤j¬ù¦b36©P(¤EÓ¤ë)¡C¤S¦]¬°¹êÅç²Õ»P¹ï·Ó²ÕªºPFSµL®t²§¡A¥i¥H±À´ú¹ï·Ó²ÕªºM PFS¤]¦b¦b36©P¥ª¥k¡A»·°ª©ó§Ú̹L¥h©Òª¾¡C ³o¼Ë¬Ý¨Ó¡A¹êÅç²Õ»P¹ï·Ó²Õ³£¦³¤@¥b¤H¥´§¹¤E°w¡C¦ý¬OÅÞ¿è¤W¥´§¹¤E°w»P¦³µL§K¬Ì¤ÏÀ³©Î¬O¶i¤@¨B¦³µLÅãµÛÀø®Ä³£¨S¦³µ´¹ïÃöÁp¡A©Ò¥H¬JµM¦³¤@³¡¤À¯f¤H¥´§¹¤E°wÁÙ¨S¦³§K¬Ì¤ÏÀ³(¦ý¬O¥L̤]¨S¦³PD)¡A¨º¤]´NÀ³¸Ó¦³¤@³¡¤À¹êÅç²Õªº¯f¤HÁöµM¦³§K¬Ì¤ÏÀ³¡A¦ý¬O¦]¬°³Q§P©wPD¦Ó¨S¦³¥´§¹¤E°w¡C¦pªG³o¨Ç¯f¤HÄ~Äò¬I¥´822¡A¯f±¡À³¸Ó¦³§ïµ½¾÷·|¡A¥i¥H¶i¤@¨B´£°ªOS¡C ¦³§K¬Ì¤ÏÀ³ªÌ¥e50%¡A¨Ã¤£¬O»¡¹ï³o50%±wªÌ³£¦³Àø®Ä(»y·N·t¥Ü¦³¬Û¦PªºÀø®Ä)¡C³o´N¹³HER2+¦û©Ò¦³¯f¤Hªº23%¡A¤£ªí¥Ü¶PÀù¥¹ï³o23%ªº¯f¤H³£¦³¬Û¦PªºÀø®Ä¡C ¦ü¥GÀ³¸Ó»¡¡A³o50%²£¥Í(1:160)§K¬Ì¤ÏÀ³ªº¨ü¸ÕªÌ¦³µÛ°ª§C¤£¤@ªºÀø®Ä¡A©Ò¥Hȱo¹Á¸Õ¨Ï¥Î822¡C¥H¼Ë¥»¨Ó§ë®g¨ì¥ÀÅé¡A¦pªGFDA»{¦P³o¼Ëªº¥ÎÃÄ«ü«n¡A³oÓÃĪº¥Ø¼Ð¥«³õ´N¥i¯à¬O©Ò¦³¥½´Á¨ÅÀù±wªÌªº¤@¥b¡C ¥Ñ©ó¸ò¹ï·Ó²Õ¬Û¤ñ¡A³o50%¦³§K¬Ì¤ÏÀ³¨ü¸ÕªÌªºOSªºHRÈÀ£§C¦b0.6¥H¤U(¸ò¹ï·Ó²Õ¤ñ¬O0.57¡A¸òµL§K¬Ì¤ÏÀ³ªÌ¤ñ¬O0.52)¡AÀ³¸Ó¬O«Ü®¶¾Äªº¼Æ¦r¡CKeytrudaªº¤T´ÁÁ{§ÉOSªºHRȬO0.63/0.69 (¨â²Õ¨Ã¤Hªº¾¯¶q¤£¦P¡A³£¬O¸ò¹ï·Ó²Õ¤ñ¸û)¡A·Ó¼Ë®³ÃÄÃÒ¡C ¤p§Ì³oÓ¥~¦æ¤H¬Ý¨Ó¡A¤£¥u¬OPFSªºPȤ£¨ã¦³¨M©w©Ê¡A±qOSªºPÈ¥i¯à¤]¬Ý¤£¤Ó¥X822ªºÀø®Ä¡COS¼Æ¦r¥Ñ©ó®É¶¡¤£°÷¡A©Ò¥H²Îp¤WªºÅãµÛ©Ê¤£°÷«G²´¡C¦pªGÄ~Äò¨«¤U¥hPÈÀ³¸Ó§ó¤p¡C¦ý¬OPÈ¥u¯à´£¨Ñ²ÎpÅãµÛ©Ê¡A¦ÓHR«h¬O¬ÝÁ{§ÉªºÅãµÛ©Ê¡C¦pªG»¡FDA¯uªº¹³¥¦¦b²³ø¤¤»¡ªºª`«Á{§ÉÀø®ÄÅãµÛ©Ê³Ó¹L²ÎpÅãµÛ©Ê¡A¨º822´N«Ü¦³¾÷·|¤F¡C ©Ò¥HYn¸ÑŪ822ªº®ÄªG¡A¤p§Ì»{¬°¬ÝOSªºPȤ£¦p¬ÝHRÈ¡C ÁٽЦU¦ì¤j¤j´£¨Ñ¨ä¥L¥½´Á¨ÅÀùÃĪ«ªºOS/HR¼Æ¦r¤ñ¸û¡A¤×¨ä¬OER+ÃĪ«ªº¼Æ¦r¡C(¥»¦¸¨ü´úªÌ·í¤¤ER+¤ñ¨Ò·¥°ª¡A¦ý¬OºKn·í¤¤¨Ã¨S¦³¹ï©ó¤£¦P¦¸±Ú¸sªºÀø®Ä¤ÀªR) ·íµM¡A822ªº¦w¥þ©Ê¬O¥¦ªºP³Ó±À±ì¡A¬°¨ä¥LÃĪ«©Ò¤£¤Î¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/19 ¤W¤È 07:29:45²Ä 1508 ½g¦^À³
|
¤ß±o °Q½× 1.50%°Ñ»PªÌ¥´¤E°w Àø®Ä±µªñ0.05ÅãµÛ ªí¥Ü¥¼¨Ó¼sªxªvÀø±Ú¸s¬O¨ÅÀù¤@¥b±Ú¸s ¬ù¶PÀù¥¨â¿¡A¤]·t¥Ü¯f±¡Ã©w«á ¤@ª½¥´ «O°·¹w¨¾¥Î 2.©úÅãIgG§ÜÅé¤ÏÀ³¡n160,Àø®ÄÅãµÛ¡A¨ã¦³ºë·Ç²`«×Àø®Ä¡AÁö¥¼ª¾¨ä©Ò¦û¤ñ¨Ò¡A¦ý¥i¯àµ¹»Pªv·Uªº¾÷·| |
|
|
·|û¡GJeffrey10142180 µoªí®É¶¡:2016/5/19 ¤W¤È 07:11:01²Ä 1507 ½g¦^À³
|
I´º¡G Globo H ¬O¤@ºØ¦b¨ÅÀù²ÓM¤¤°ª«×ªí²{ªºÁޯ׽è¡C¦b¨âӨϥΥD°Ê§K¬ÌÀøªkOPT-822(Globo H-KLH½Æ¦XÅé)¤Î¦õ¾¯OPT-821ªº¤@´ÁÁ{§É¸ÕÅçÅã¥Ü¡A¦¹¥D°Ê§K¬ÌÀøªk¥i»¤¾É²£¥ÍGlobo H ¯S²§©Ê§ÜÅé¡A¨ä©óÅé¥~¸ÕÅçÅã¥Ü¥i»Pªí²{Globo Hªº¨ÅÀù²ÓMµ²¦X¡A¨Ã²£¥Í²ÓM¬r±þ§@¥Î¡C ¤èªk¡G ¦b¦¹¦h°ê¡B¦h¤¤¤ß¡BÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº¤G/¤T´ÁÁ{§É¸ÕÅç¡]NCT01516307) ¤¤¡A¸g¹L¦Ü¤Ö¤@ºØ§ÜÀùÀøµ{ªvÀø«á¡A¦³³Ì¦h2¦¸¯e¯f´c¤Æ (PD) ¥H¤Î¹F¨ì¯e¯féw (SD) ªºÂಾ©Ê¨ÅÀù±wªÌ¡A¥H2:1ªº¤ñ¨Ò¡A¦b²Ä 1¡B2¡B3¡B5¡B9¡B13¡B17¡B25 ©M 37 ©P¡A¥Ö¤Uª`®g OPT-822 (30 £gg Globo H)/OPT-821 (100 £gg) ©Î¹ï·Ó¾¯ (PBS) ¤Î§C¾¯¶qÀôÁCñQÓi (cyclophosphamide) (300 mg/m2) ªvÀø¡Aª½¨ì¯e¯f´c¤Æ(PD)©Î¥´§¹9°w¡C¥i¦P®Éµ¹¤©²üº¸»XÀøªk¡C¥Dn©M¦¸nÀø®Ä«ü¼Ð¤À§O¬°µL´c¤Æ¦s¬¡´Á (PFS) ©MÁ`¦s¬¡´Á (OS)¡C µ²ªG¡G ¦@¦³349¦W±wªÌ°Ñ»PÀH¾÷¤À²Õ¸ÕÅç¡A¨ä¤¤ 348 ¨Ò±wªÌ±µ¨ü¬ã¨sÃĪ«©Î¦w¼¢¾¯ªvÀø¡e·N¹ÏªvÀø (ITT)¡f¡A168 ¨Ò±wªÌ (48%) §¹¦¨ 9 ¦¸ª`®gÀøµ{¡C70% ¬°²üº¸»X¨üÅ鶧©Ê¨ÅÀù±wªÌ¡C13% ¬°¤T³±©Ê¨ÅÀù±wªÌ¡C62% ±wªÌ±µ¨ü²üº¸»XªvÀø¡C¥»¸ÕÅçµ²ªG¥¼Æ[¹î¨ìµL´c¤Æ¦s¬¡´Á(PFS)¹F¨ì²ÎpÅãµÛ®t²§(HR = 0.96 [95% CI 0.74-1.25]¡Ap= 0.77)¡AÁ`¦s¬¡´Á(OS)ªº´Á¤¤¤ÀªR(Interim OS)¥ç¥¼¹FÅãµÛ®t²§(HR = 0.79 [95% CI 0.51-1.22]¡Ap = 0.29)¡C¦ý¬O¡A¦³50%ªº¹êÅç²Õ±wªÌ¡A¹ï OPT-822/OPT-821 ²£¥Í Globo H ¯S²§IgG §ÜÅé (³o¬O«ü§ÜÅé®Ä»ù´¿¦bªvÀø´Á¶¡¤º¹F¨ì ≥ 1:160)¡C³o¨Ç²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A·í»P¹ï·Ó²Õ¤ñ¸û¡A¦³¥H¤Uµ²ªG: PFS¡AHR = 0.71 [95%CI 0.52-0.97]¡Ap= 0.029¡FOS¡AHR=0.57 [95%CI 0.33-0.97]¡Ap = 0.04¡F²£¥Í§K¬Ì¤ÏÀ³ªº±wªÌ¡A©MµL§K¬Ì¤ÏÀ³±wªÌ¤ñ¸û¡A¦³¥H¤Uµ²ªG: PFS¡AHR = 0.52 [95%CI 0.37-0.71]¡Ap< 0.0001¡FOS¡AHR = 0.52 [95%CI 0.29-0.92]¡Ap= 0.025¡]µ²ªG¸g°ò¦¯e¯fª¬ºA/²üº¸»XÀøªk¨Ï¥Î±¡ªp®Õ¥¿)¡C³o¨âÓµ²ªGÅã¥Ü¡A²£¥Í§K¬Ì¤ÏÀ³±wªÌªºPFS ©MOS³£¦³ÅãµÛ§ïµ½¡C¸g®É¶¡¬Û¨ÌCox ¤ÀªR¨Ã»P¹ï·Ó²Õ¬Û¤ñ¤§«á¡A¹ï©ó§¹¦¨ 9 ¦¸OPTª`®gÀøµ{ªÌ¡A¨äPFS¤]¦³§ïµ½ÁͶÕ(HR = 0.66 [95% CI 0.42-1.01]¡AP = 0.057)¡C¾ãÅé¦Ó¨¥¡AOPT-822/OPT-821 @¨ü©Ê¨}¦n¡F³Ì±`¨£ªºÃĪ«¬ÛÃö¤£¨}¨Æ¥ó¬° 1¡B2 ¯Åªºª`®g³¡¦ì¥Ö½§¤ÏÀ³¡C µ²½×¡G ¥»Á{§É¸ÕÅçPFSÁö¥¼¹F¨ì²ÎpÅãµÛ®t²§¡AµM¦Ó¡A¹ï©ó¦³²£¥Í§K¬Ì¤ÏÀ³±wªÌªºPFS ©MInterim OS§¡¦³ÅãµÛ§ïµ½¡C¥¼¨Ó±N¨Ï¥Î³o¨Ç¦¸±Ú¸s¤ÀªR¼Æ¾Ú¡A³]p©ú½Tªº¤T´ÁÁ{§É¸ÕÅç¡C |
|
|
·|û¡GJeffrey10142180 µoªí®É¶¡:2016/5/19 ¤W¤È 07:05:50²Ä 1506 ½g¦^À³
|
¼Æ¾ÚªG¯uº}«G!! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/5/19 ¤W¤È 05:41:06²Ä 1505 ½g¦^À³
|
Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer. Abstract: Background: Globo H is a glycolipid that is highly expressed in breast cancer (BC). Active immunotherapy with OPT-822, a Globo H¡VKLH conjugate, and the adjuvant OPT-821 in 2 phase (Ph) I trials, induced Globo H specific antibodies which could mediate in vitro binding and cytotoxicity to Globo H expressing BC cells. Methods: In this international, randomized, double-blind, placebo-controlled Ph II/III trial (NCT01516307), patients (pts) with metastatic BC who had ≤ 2 events of progressive disease (PD) and who achieved at least stable disease (SD) after ≥ 1 anticancer regimen were randomized 2:1 to receive subcutaneous OPT-822 (30 £gg Globo H)/OPT-821 (100 £gg) or control (PBS) on weeks 1, 2, 3, 5, 9, 13, 17, 25, and 37 or until PD, in combination with low-dose cyclophosphamide (300 mg/m2). Hormone therapy was allowed. The primary and secondary efficacy end points were progression-free survival (PFS) and overall survival (OS), correlated with humoral antibody response. Results: 349 pts were randomized, 348 received study drug (ITT), 168 (48%) received all 9 injections. 70% had hormone receptor positive BC, 13% were triple negative, and 62% received hormone therapy. No difference was observed in PFS (HR, 0.96 [95% CI, 0.74-1.25] P = .77) or in interim OS (HR, 0.79 [95% CI, 0.51-1.22] P = .29). However, PFS and OS were significantly improved in the 50% of pts who developed a Globo H specific IgG response to OPT-822/OPT-821 with a titer ≥ 1:160 at any time during treatment vs control (HR, 0.71 [95% CI, 0.52-0.97] P = .029 for PFS; HR, 0.57 [95% CI, 0.33-0.97] P = .04 for OS) and vs nonresponders (HR, 0.52 [95% CI, 0.37-0.71] P< .0001 for PFS; HR, 0.52 [95% CI, 0.29-0.92] P = .025 for OS),adjusted for baseline disease status/hormone use. In a time-dependent Cox model, PFS was improved in pts who received all 9 injections of OPT vs control (HR, 0.66 [95% CI, 0.42-1.01] P= .057). OPT-822/OPT-821 was well tolerated; the most common drug-related adverse event was grade 1/2 injection reaction. Conclusion: Vaccination with OPT-822/OPT-821 did not improve PFS in the ITT; however, PFS and interim OS were significantly improved in pts who developed an immune response to the vaccine. These subgroup data will be used to design a definitive Ph III trial. Clinical trial information: NCT01516307 |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/17 ¤U¤È 09:47:07²Ä 1504 ½g¦^À³
|
¤p§Ì¦Û°Ý¦Ûµª ¦n¤F ³oÓ³Õ¤h¾¯Ê n°µ²ÓM°ö¾i ²ÓM¨tªºÁc´Þ ·dÂ÷¤ß¾÷ ²`«×¹LÂoµ¥µ¥¹êÅç¤u§@ ·Pı³£¬O¤@´Á¤§«e ¥Í²z»PÃIJz¬ã¨sªº°ò¦¤u§@ ©Î³\¬On°w¹ï¨ä¥L¾AÀ³¯g¨Ó¬ãµo ¬Ý¬Ý822©Î833¹ï¨ä¥¦¾AÀ³¯gÀù²ÓM¬r±þª¬ªp ¥H¤WY¦³¿ù»~ ·q½Ð«ü¥¿ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/16 ¤U¤È 10:20:37²Ä 1503 ½g¦^À³
|
½Ð±Ð¤j®a ³oÓ³Õ¤h¾¦ì ¬On°µ²ÓM¨tªº°ö¾i»P¬ãµo ¬O¤ñ¸ûÄÝ©ó¤@´Á¤§«eªº¬ãµo¤u§@¶Ü?¥i¯à¬OOBI888³Q°Ê§K¬Ì³æ®è§ÜÅé³oÃþ¶Ü?ÁÙ¬O¨ä¥L? |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/16 ¤U¤È 10:11:40²Ä 1502 ½g¦^À³
|
Cell line and Cell culture Process Development Senior Scientist ¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q ¥»¤½¥q¨ä¥L¤u§@ §ÚnÀ³¼x Àx¦s¤u§@ ¨â¶g¤ºÀ³¼x¤H¼Æ 5¤H¥H¤U0~5¤HÀ³¼x FB ¤À¨É Âà±H ÀËÁ| ¤u§@¤º®e 1.Supervise staff and resources to meet program objectives. Provide technical direction to other research staff, engineering associates, Responsible for executing scientific plans by generating experimental results. 2.Carry on stable cell line generation 3.Design and execute cell culture process experiments for <10L bioreactors 4.Innovate to make process robust, high yield, and easy to operate and scale-up 5.Perform pilot scale centrifuge operation for cell culture harvest operation and depth filtration 6.Write technical reports and campaign summaries 7.Perform other items requested by supervisors. ¾°ÈÃþ§O¡G ÂåÃĬãµo¤Hû¡B¥Íª«¬ì§Þ¬ãµo¤Hû ¤u§@«Ý¹J¡G ±Ä³ ¤u§@©Ê½è¡G ¥þ¾ ¤W¯Z¦aÂI¡G ¥x¥_¥««n´ä°Ï¶é°Ïµó3¸¹19¼Ó ºÞ²z³d¥ô¡G ¤£»Ýt¾áºÞ²z³d¥ô ¥X®t¥~¬£¡G µL»Ý¥X®t¥~¬£ ¤W¯Z®É¬q¡G ¤é¯Z ¥ð°²¨î«×¡G ¨Ì¤½¥q³W©w ¥i¤W¯Z¤é¡G ¤£ »Ý¨D¤H¼Æ¡G 1 ¤H ±ø¥ón¨D ±µ¨ü¨¥÷¡G ¤W¯Z±Ú ¤u§@¸g¾ú¡G 5¦~¥H¤W ¾Ç¾ún¨D¡G ³Õ¤h ¬ì¨tn¨D¡G ¤Æ¾Ç¬ÛÃö¡B¤Æ¾Ç¤uµ{¬ÛÃö¡B¥Íª«¾Ç¬ÛÃö »y¤å±ø¥ó¡G ¤£©ë ¾Õªø¤u¨ã¡G ¤£©ë ¤u§@§Þ¯à¡G ¤£©ë ¨ä¥L±ø¥ó¡G •PhD in in Chemical/Biochemical Engineering, Cell Biology or other Life Sciences with 5+ years of direct related experience. •Considered an expert in cell culture process development and scale-up including cell expansion, bioreactor operations, cell culture process optimization, culture metabolite analysis, media development, turbidity measurement, amino acid and antibody titer HPLC analysis. •Proficiency with data acquisition softwares. •Excellent communication skills. •Experience in supervision of scientists in process development. •Be positive and forward thinking, hard working, and team-work oriented. •Prior industry working experience ~~~~~~~~~~~~~~~ ¤½¥q¼x¨D³Õ¤h³á §@¦³Ãöcell line generation ¥[ºò¬ãµoÂP |
|
|
·|û¡GJeffrey10142180 µoªí®É¶¡:2016/5/12 ¤U¤È 10:08:38²Ä 1501 ½g¦^À³
|
©êºp«e±¶K¿ù ¦b6/4 «e¤i¡A³o´X¤Ñ±ß¤WºÎı®É³£§â¯E¹©2/22©Ò¶}ªºªk»¡·|¤º®e·í§@ºÎ«e¬G¨Æ¦bÅ¥¡A·|¤¤±i¸³Á¿¤F¦n´X¦¸¡A³oÓÃĦ³¡¨ÅãµÛªºÀø®Ä¡¨¡A¦³§ÜÅé´N¦³Àø®Ä¡C¥B¦bFDA®Öã·sÃĪº¤TÓ«n±ø¥ó1.¦w¥þ©Ê2.ÅãµÛªºÀø®Ä3.¥Í¬¡«~½è¡C¯E¹©¤TªÌݨã¡C¦b«á±¦^µª°ÝÃD®É¤S¦bÁ¿¤@¦¸¡A¥´¤F°w´N·|¦³§ÜÅé¡A¦³§ÜÅé´N¦³«Ü¡¨ÅãµÛªºÀø®Ä¡¨¡A©Ò¥H¦³¨S¦³Àø®Ä¡A³oÓ°ÝÃD±i¸³¤w¸gÁ¿¤F«Ü¦h¦¸¡A³oÂI¤w¸g¦b¤½¥¬¼Æ¾Ú¤§«e¡A¤w¸g²@µLºÃ°Ý¡C AMY ¦³¸É¥RFDA®ÖãÁÙn¬ÝMOA¡C³o¦¸Á{§É¤w¸g¦³«Ü©ú½TªºMOA ³o¤]¬O«Ü«nªº¡C¦]¬°FDA¦b®Öã¹Lµ{·í¤¤MOA¬O«Ü«nªº¤@ÓÀô¸`¡CAMY¦b·|¤¤Á¿¤F¨â¦¸¡AASCO¤§«á·|¬Ý¨ìPFS¼Æ¾Ú¬O¦³¹LÃöªº(«á±¦³Á¿¨ì¦b¬Æ»òª¬ªp¤U·|¹LÃö)¡AÀHµÛ®É¶¡§Ön¨ì¨Ó¡A¤ß¤¤¤Ï¦Ó§ó½ñ¹ê¡AÁöµMªÑ»ù©|¥¼¤W¨Ó¡A¦ý¬Û«H¬O¿ð¦ªº¨Æ¡C¤j®a¥[ªo¡C |
|
|
·|û¡GJeffrey10142180 µoªí®É¶¡:2016/5/12 ¤U¤È 10:01:29²Ä 1500 ½g¦^À³
|
news.bioon.com/article/6682410.html |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/5/8 ¤U¤È 10:31:03²Ä 1499 ½g¦^À³
|
¦b¦¹¸ÛÀµªº´£¿ô ªÅ¤è¶Â¤âÌ¡KÁ|ÀY¤T¤Ø¦³§P©x¡K ®É¾÷¥¼¨ì¡A¤£¬O¤£³ø¡I ¦p¦¹ÁVÁϽî½ñ¤@¥N¨}ÃÄ¡K¦]¤v¤§§QªÉÅU¤Ñ¤U»a¥Í¤§¥Í©R ±o¤F¿ú°]¤]§é¤F¹Ø¡I ´«Ó¨Åé¿ú°]¦A¦h¤]¤£¬O±zªº¤F¡K ¦^ÀY¬O©¤§a¡K |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/5/8 ¤U¤È 10:21:01²Ä 1498 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡G «_¥¢¡K«_¥¢¡I©êºp¡K©êºp¡I ±z¦p¦¹´£¥Ü§ÚÀ³¸Ó²z¸Ñ{¸Ô²Ó¤ÀªRªº»ùÈ}¤F¡K ¬O§Ú¦Û¤v·Q°¾¤F¡K ü¡K¯E¹©¬°¤F°Ñ¥[¤@ÓASCO...¡H³o°Ó·~»ùÈÀ³¸Ó«Ü°ª§a¡H ¬°ASCO«O¯dÁ{§É¼Æ¾Ú¡A³o¨âÓ¤ë¯E¹©ºë^¸s¥I¥Xªº¥N»ù¯uªº¬O¤Ó¤j¤F¡K ¤HÃþ¥vªº¤@¥N½å¤~¡K^¤~¡K¥xÆW¤§¥ú¡K²{¦b¤j·§°ß¦³¬ß»a¤Ñ¦³²´¡K§Ú¦ò·O´d¡K ÁÂÁ±z«e½ú¡K |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/5/8 ¤U¤È 09:46:22²Ä 1497 ½g¦^À³
|
999¤j §Ú¥H«e´£¨ì¬ü°ê¬O²Îpªv°ê¡A±q¤@°ï¼Æ¦r¤¤¬Û¤¬¤ñ¸û¤ÀªR¡A±q¥¤Z¤¤§ä«D¤Z¡A±q¥¢±æ¤¤§ä§Æ±æ¡A±q¥²H¤¤§äÅå©_¡A±q¶Â·t¤¤§ä¥ú©ú¡A±q³h½C¤¤§ä¨U¤g¡C |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/5/8 ¤U¤È 08:16:04²Ä 1496 ½g¦^À³
|
¥xÆWn°Ñ¥[WHA ¤@ÂI¦a¦ì³£¨S¦³...®z°êµL¥~¥æ¡A¥xÆW¯E¹©n¥[ªo... |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/5/8 ¤U¤È 07:06:49²Ä 1495 ½g¦^À³
|
·x·x¤j¡Awalker¤j¡G ÁÂÁ¹ªÀyªº¦^À³...... ¥u¬O¬ðµM¬Ý¨ì¥xÁަѮvªº{ªì¨B¤ÀªR¦³»ùÈ¡H}== ÁÙ¬O{¸Ô²Ó¤ÀªR¦³»ùÈ¡H}== ¬Ýªº¤@´h...¤@´hªº... ³o¬O¤°»ò·N«ä¡H¡H¡H Ãø¹Dªk»¡·|©Ò¨¥ÁÙ·|¦³·N¥~ªºÅܼơH¡H¡H ÁÂÁ¡AÁÂÁ¡I ¥i¯à§Ú·Q°¾¤F¡C |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/5/8 ¤U¤È 01:21:41²Ä 1494 ½g¦^À³
|
999¤j §Ú¤£¬O³o¤è±±M®a, ¦ý´N¤@¯ë¹ï¹êÅç¼Æ¾Úªº¸ÑªR, ¦³¦h¤Ö¤H²£¥Í§ÜÅé¤ÏÀ³... ³oÀ³¸Ó«Ü§Ö´N¯àª¾¹D, ¤£¥Î·d¨ì¤TӤ몺¤ÀªR ¦Ü©ó²£¥Í§ÜÅé¦A°µ²Ó³¡¤ÀÃþ, ¤F¸Ñ¯f¥v, ³o·íµM´N±o¤[¤@ÂI ¥t¥~, ¨º¨Ç¯f¤H¤]³£«ùÄò°lÂÜ, ¨Ã¨S¦³¸Ñª¼§¹´Nµ²§ô, §Ú¬Û«H¸ê®Æ®w·|«ùÄò§ó·s»P¤ÀªRªº §Ú·Q, ´N¬Ý ASCO ¤½¥¬ªºµ²ªG§a! ¨ºn¾á«Ü«ªº³d¥ô, ¥i¾a«×À³¸Ó«D±`°ª |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/5/8 ¤U¤È 12:47:49²Ä 1493 ½g¦^À³
|
999¤j¡G¶ÀÁ`¦b2/22¸¹§ë¸ê¤H»¡©ú·|¦³»¡¦bASCO«á,§AÌ·|¬Ý¨ìPFS¬O¦³®Äªº¡]8¡G14¬í¡^¡I ©Ò¥H¬Ý°_¨Ó¸Ô²Ó¤ÀªR«áªº¬ÛÃö¼Æ¾Ú¤@©w«Üºë±m¡I ¤j®a¤@°_@¤ß´Á«Ý§a¡I |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/5/8 ¤U¤È 12:30:49²Ä 1492 ½g¦^À³
|
½Ñ¦ì«e½ú¤j¤j¡G ¨þ¨þ¡I§ÚÅãµM¬O°Ý¤F´XӶ̰ÝÃD...¡I ©êºp¡A©êºp......Àµ½Ðì½Ì§Ú³o«_¥¢ªº¥Õè¡C ¯u©êºp¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/5/8 ¤W¤È 12:55:39²Ä 1491 ½g¦^À³
|
¥xÁÞ¤j«e½ú¡G {ªì¨B¤ÀªR}¡K{¸Ô²Ó¤ÀªR} ¸Ñª¼ÁÙ¦b¶i¦æ¤¤¡A¥H¥Ø«e¤½¥q¯à´£¨Ñªº¸ê°T¡A ³o{¸Ô²Ó¤ÀªR}¬O§_¦³¾÷²v·|¤ñ{ªì¨B¤ÀªR}ªº¼Æ¾Ú®t¡H ¦A¦¸µo¥Í¦pPFS¤£¦p¹w´Áªº¨Æ¹ê©O¡H ¤]Àµ½ÐCliff¤j«e½ú¡A¤p©_¤j«e½ú¡A¦Ñ´¤j«e½ú¡A½Ñ¦ì«e½ú¤@°_°Q½×¤@¤U³o¾÷²v...©Î¨ä¥i¯à©Êªº±´°Q... ·Ð½Ð¤]·PÁ½Ѧì±M·~«e½ú«ü¾É¡C ³o{ªì¨B¤ÀªR}»P{¸Ô²Ó¤ÀªR}ªº»ùȦ³¥i¯àªº®t²§©Ê¬°¦ó¡H¡H¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/5/7 ¤U¤È 02:49:44²Ä 1490 ½g¦^À³
|
²³¤j¤j 1¦³¨Ç³ø¾É§âÁ{§Éªì¨B¤ÀªRTop-line·í°µ¸Ñª¼ªº³Ì«áµ²ªG¡A³o¥i¯à·|¥Ç¤U¿ù»~¡C 2®Ú¾Ú¤W¤ë¥ßªk°|½è¸ß(§Ñ¤F¬O¨º¦ì©eû)¡A¦^µª¬O:¥Ø«e¸Ñª¼ÁÙ¦b¶i¦æ¤¤¡C ·Q´£¿ô¤j®a¨ÅÀùOBI822¯uªº¸Ñª¼¤F¶Ü? ¤j®aÀ³¸Ó³Ì·Qn¬Ý¸Ô²Óªº¤ÀªR¡A¤£¬Oªì¨B¤ÀªR¡A¤£¬O¶Ü?¸Ô²Ó¤ÀªR¦³»ùÈÁÙ¬Oªì¨B¤ÀªR¦³»ùÈ¡A¨º¤@Ó¬O²×·¥µ²ªG¡A¤j®aÃ䨫Ãä¬Ý¡C |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/5/7 ¤U¤È 01:45:23²Ä 1489 ½g¦^À³
|
¤p©_¤j¡A±z¬O¹ïªº¡A¶ÀÁ`¬O»¡¥h¦~ªº«á±´XÓ¤ë¡A¦³®ÉÔPD¤H¼Æ¥u¦³¤@Ó¤H¡C³o¼Ëªº»¡ªk¤ñ§Ú»{¬°¦º¤`¤H¼Æ¤@¤Hn¨Óªº§ó¦³Àø®Ä¡A§Úªº²z¸Ñ¬O¡A¹êÅç²Õ¤¤¦³²£¥Í§K¬Ì§ÜÅé¤ÏÀ³ªº¯f±w¡A¥X²{¤£¿ùªº«p§À®ÄÀ³¡A§_«h¤£·|«á±´XÓ¤ëPD¤H¼Æ¦p¦¹½wºC¡A§ó¹N½×¹êÅç²Õ¦º¤`¤H¼Æ¡A°Z¤£¬O§ó¥[... QQ¤j¡A¤]ÁÂÁ±zÅý§Ú¦³¤F¥Î¥\§ä¸ê®ÆªºÂǤf¡A¥i¥H¦A¤@¦¸¾Ç²ß½Æ²ß¡A¨Ã¦³Cliff¤jªº«ü¾É¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/5/7 ¤U¤È 01:38:36²Ä 1488 ½g¦^À³
|
Cliff¤j: ÁÂÁ±z ! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/5/7 ¤U¤È 12:50:03²Ä 1487 ½g¦^À³
|
QQ¤j¡B±Û«a¤j¡B¤p©_¤j¡G IHCÀ³¸Ó´N¬OImmunoHistoChemistry¨S¿ù¡C ¤p©_¤j¡G «¢«¢«¢¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/5/7 ¤U¤È 12:19:53²Ä 1486 ½g¦^À³
|
±Û«a¤j: ÁÂÁ±z´£¨Ñªº¸ê®Æ¤Î¬ÛÃöªº¸ÔºÉ¸Ñ»¡, ¯u¬O¾ÇµL¤îºÉ°Ú. ¥Ì®¦ ! ¤p©_¤j: ÁÂÁ±z. ±z¤W½g¤å«ôŪ«Ü¤[, ÁöµM¤@¨Ç²Ó³¡ÁÙ¤£¬O¨º»ò¤F¸Ñ, ¦ýÁ`ºâ¯à¥H²ÎpªºÆ[ÂI±o¿s¨ä»ª. ÁÂÁ±zªº¥Î¤ß¤Î¥I¥X. |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/5/7 ¤U¤È 12:12:16²Ä 1485 ½g¦^À³
|
QQ¤j¡ACliff¤j¡A ¤p§Ì¤]²qIHC=§K¬Ì¬V¦âªk(Immunohistochemistry) ±Û«a¤j¡A ¤p§Ì3/31Å¥¨ìªº¶ÀÁ`Á¿ªk¬O¡A¥h¦~ªº«á±´XÓ¤ë¡A¦³®ÉÔPD¤H¼Æ¥u¦³¤@Ó¤H¡A¦º¤`¤H¼Æ¦ü¥G«h¨S¦³¯S§O´£¨ì¡A¬O§_n¦A½T»{¶ÀÁ`ªºÁ¿ªk¡H ¥t¥~OS¡u¥¿±ªºÁͶաv¡A¤p§Ìªº·Qªk»P±z¬Û¦P¡A¥u¬O¤£ª¾¹D¨ì©³¦h¥¿±¡H Cliff¤j¡A «¢«¢¡I |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/5/7 ¤W¤È 11:58:38²Ä 1484 ½g¦^À³
|
©êºp¡Aèè©Ò«üªºMOS¬O«ü¹êÅç²ÕªºMOS¡Aº|¥´¹êÅç²Õ¡C IHC¥i¯à¬O§K¬Ì²Õ´¤Æ¾Ç¬V¦âªk(immunohistochemistry; IHC)¬Oµ²¦X¤F¤TÓ¤£¦P»â°ìªº±M·~¢w§K¬Ì¾Ç(immunology)¡B²Õ´¾Ç(histology)»P¤Æ¾Ç(chemistry)¢w©Òµo®i¥X¨Óªº¤@¶µ§Þ³N¡C¥¦¯à¦b²Õ´¤Á¤ù¡B²ÓM©Ù¤ù©Î°ö¾iÀËÅé¤W¡A¹B¥Î§K¬Ì¤ÏÀ³(immune response)¤¤§Üì(antigen; Ag)©M§ÜÅé(antibody; Ab)¶¡ªº±M¤@µ²¦X©Ê¡A¨Ã¦b§ÜÅé¤W§e²{¥i¨Ñ°»´úªº°T¸¹(reporter)¡A¥H«KÆ[¹îÀËÅ餤¬O§_¦³¥Ø¼Ð§Ü쪺¦s¦b¡C |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/5/7 ¤W¤È 11:39:45²Ä 1483 ½g¦^À³
|
·PÁ¤p©_¤j¸ÔºÉ®ï¹êªº¤ÀªR¡A¶ÀÁ`´¿»¡¡A²{¦b¨CÓ¤ë°Ñ»PÁ{§É¯f±w¦º¤`¤H¼Æ¥§¡¤@¤H¥ª¥k¡A¦º¤`¤H¼Æ¬Æ§C¡A¨p¤ß§PÂ_MOSÀ³¸Ó©|¥¼¥X²{¡A©Ò¥H¦b¯E¹©¸Ñª¼·s»D½Z¤¤¡A¦³Ãö¯f¤HOS¶È¥u¯à¥¿±ªºÁͶըӪí¹F¡A¦Ó¤£¬O¥Î¥H¤UªºÁ¿ªk¡G°Ñ»P¸ÕÅ窺¯f¤HY²£¥ÍIgG¡BIgM§K¬Ì§ÜÅé¤ÏÀ³¡A¦bµL´c¤Æ¦s¬¡´ÁPFS(progression free survival) ³£¥i¬Ý¥X«D±`ÅãµÛªº§ïµ½¡C¦pªGMOS¥X²{¡A¬°¦ó¤£¥ÎÅãµÛ©Î«D±`ÅãµÛªº»¡ªk©O¡H¬Æ¦Ü¥¼¹FÅãµÛ¤]¥i¥H¡A°¾°¾¬O¼g¥¿±ªºÁͶաH TPS§Ú¦³§ä¨ì¨âÓ¥i¯à¡A¤£ª¾¬O§_¥¿½T¡H 1.¥xÆW¥ú¤l·½¡]Taiwan Photon Source, TPS¡^¡ATPS ¦P¨B¥[³t¾¹¬ã¨s½d³òÅn¬Aª«²z¡B¤Æ¾Ç¡B¥ÍÂå¬ì§Þ¡B¥b¾ÉÅé¬ì§Þ¡B¯à·½»PÀô¹Ò¬ì¾Ç¤Î§÷®Æ¬ì¾Çµ¥¡A¥Ø«e²Ä¤@´Á³W¹ºªº7®y¹êÅ篸¡A±N©óªñ´Á³°Äò§¹¦¨¡F²Ä¤G´Á18®y¥ú§ô½u¹wp©ó2022¦~§¹¦¨¡C³o¹D¤ñ¶Ç²ÎX ¥ú«G1¥ü¿ªº¥ú¨~±N§Uªø¥xÆW¬ì¬ã¡A¨Ï¥xÆW¦b³J¥Õ½èµ²ºc¤Î¥ÍÂå¼v¹³µ¥¬ã¨s¤j¨BÁÚ«e¡C 2.The Pharmaceutical Strategist (TPS)ÂåÃľԲ¤®a |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/5/7 ¤W¤È 11:29:32²Ä 1482 ½g¦^À³
|
Cliff¤j: IHC ¨ä¤¤¤@³B¥X³B´N¦b¤§«eªºµøÀW Emerging Role of Immunotheraphy in Breast Cancer ¤¤§Æ±æ¦ò»¡¥Xªº ¡K¡K¡K¡K¡K The atezolizumab trial had a more strict definition, so you had to be more positive by IHC but ¡K¡K¡K¡K¡K ¹ï·Ó«e«á»y·N©Î³\À³¸Ó¬O¤f»~ ? ¥u¬O¦L¶H¤¤¤§«e¦b¤@½gpaper (¤£¥i¦Ò)¤W¤]¦³¬Ý¨ì©Ò¥H´N±N¥¦¦C¤W¨Ó¤F. ¡uICH¡v¡GInternational Conference on Harmonization¡]°ê»ÚÃÄ«~ªk³W¨ó©M·|¡^¨S¦C¦b³æ¤l¤W, ÁÂÁ±z. »°§Ö¸É¤W. ºë·Ç½Ķ±z¬Oª©¤W³»¦y, «_¬N¥i¥H½Ð±z¦³ªÅ¦³®É¶¡¦³¤ß±¡·Q°Ê°Ê¤â«ü®É, ¯à¦Ò¼{±N¨º²M³æ¤Wªº¦WÃ㽤@¤U¶Ü ? §Ú¨ì¥Ø«e¬°¤î, ¹ï«Ü¦hÃãÁÙ¦h°±¯d¦b¥u¯à·N·|¤£¯à¨¥¶Ç¶¥¬q, ¤]·|ª°ºÃ³o·N·|¬O§_»P¨Æ¹ê¦³¥X¤J. ¦pªG±z¯à¥X¤â´N¤Ó·PÁÂ, ¤j·PÁ¤F. (½Ð®e§Ú¥ý½Ô´A¤@¤U.) TPS À³¸Ó¬O³Ìªñ¬Ý¹Lªºpaper µ¥¤U¦¸¦A¥X²{·|ºI¿ý¤U¦V±z½Ð±Ð |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/5/7 ¤W¤È 10:07:32²Ä 1481 ½g¦^À³
|
¦Ñ´¤j¡G ±z´N¬O°ª¬ñ¡IÆg¡I ¤p©_¤j¡G ¥Î¤ß«ä¦Ò¡Ï²Ó¤ß¤ÀªR¡Ï@¤ß¸Ñ»¡¡C ¡K¾÷½t¨ì¤F¦Û·|¦³¡Kªº¤@¤Ñ¡K QQ¤j¡G ¡uIHC¡v·|¤£·|¬O¡uICH¡vªº»~´Ó¡H ¡uICH¡v¡GInternational Conference on Harmonization¡]°ê»ÚÃÄ«~ªk³W¨ó©M·|¡^ ¡uTPS¡v¡H |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2016/5/7 ¤W¤È 08:19:50²Ä 1480 ½g¦^À³
|
·PÁ¤p©_¤jºëÅPªº¤ÀªR¡A ¬Û·í²M·¡¥B¥¿¤¤¹v¤ß 755¬O³õ¤Ñ®É¦a§Q¤H©Mªº¬üÄRªº·N¥~ 321¥u¬O³Q³sÀô¹Ü©R¦©¤Þ¨Ó¨I«ªº«s·T ¯E¹©822¤@©w·|¦¨¥\¡A§Ú̦³«H¤ß ¯u¥¿¦¨¥\®ÉÁٯ঳¤p¦Ï¤~¯à¤£µê¦¹¦æ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/5/6 ¤U¤È 10:24:16²Ä 1479 ½g¦^À³
|
ÁÂÁ¯E§J¤jªº®·¥R¡C 2010¦~·í®É¤½¥q¦pªG©ÈpȤ£ÅãµÛ ¥i¥HÂÇÂX¤j¼Ë¥»¼Æªº¤è¦¡ ¦ý¦h¦¬50¦ìn¦hªá¥b¦~ ¦h¦¬100¦ìn¦hªá¤@¦~ªº¦¬®×®É¶¡ PÈ´NÅãµÛ¤F ¦ý¼fÃįgªº¤H¤£·|¬Ý¤£¥X¨Ó |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/6 ¤U¤È 10:05:02²Ä 1478 ½g¦^À³
|
§ó¥¿ PÈnÅãµÛ ¥un¼Ë¥»°÷¤j ÃĪ«¤@ÂIÂI¦³®Ä§Y¥i |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/6 ¤U¤È 09:25:03²Ä 1477 ½g¦^À³
|
¤p©_¤j¡C¼gªº«D±`¸ÔºÉ §Ú¸É¥R¤@ÓÃöÁä¬Ýªk PÈ ¥un¼Ë¥»°÷¤j ÃĪ«¤@ÂIÂI¦³®Ä 822 ¬Û·í¦³®Ä ¥i±¤¼Ë¥»¤Ö ´«¨¥¤§¡CÁ{§É¦³®Ä´N¦n¡CFDA¥Dn¬O¬ÝÁ{§ÉÃÄ®Ä ¤£¬O¬Ýp |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/5/6 ¤U¤È 06:48:24²Ä 1476 ½g¦^À³
|
¦³¤@¬q¤å¦rn§ó¥¿ ÁöµM¤½¥q¥u»¡¦bOSªºªí²{¤W¬O¥¿±ªºÁͶÕ(§ÚÅ¥°_¨Ó¬O¼Æ¾Ú¤£¦¨¼ô¡Aªí¥ÜÁÙ¦³¤j¶qªº±wªÌ¤´¬¡±o¦n¦nªº¡Aªí¥ÜÁÙ¦³¤j¶qªº³]¸ê®Æ¡Aªí¥Ü«Ü¥i¯à¹êÅç²ÕªºOSªºK-M curveÁÙ¥¼¹F0.05)¡A §ó¥¿¬°¡G ÁöµM¤½¥q¥u»¡¦bOSªºªí²{¤W¬O¥¿±ªºÁͶÕ(§ÚÅ¥°_¨Ó¬O¼Æ¾Ú¤£¦¨¼ô¡Aªí¥ÜÁÙ¦³¤j¶qªº±wªÌ¤´¬¡±o¦n¦nªº¡Aªí¥ÜÁÙ¦³¤j¶qªº³]¸ê®Æ¡Aªí¥Ü«Ü¥i¯à¹êÅç²ÕªºOSªºK-M curveÁÙ¥¼¹F0.5ªº¤ô¥½u)¡A |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/5/6 ¤U¤È 06:42:46²Ä 1475 ½g¦^À³
|
Cliff¤j¡A¦U¦ì¤j¡A ¤p§Ì¹ï©ó822³o¦¸¸Ñª¼¡APFS¯à¤£¯à¹F²ÎpÅãµÛ¤ô·Çªº¥Dn¬Ýªk¦p¤U¡G ²á¤ÑªO¡A¤p©_10138298 µoªí®É¶¡:2016/4/20 ¤U¤È 03:54:45²Ä 10780 ½g¦^À³ ¦b¨S¦³¸Ñª¼¤§«e¡A¤½¥q¤]¨S¿ìªk½T©wPȬO§_¤@©w¤p©ó0.05¡A¹F²ÎpªºÅãµÛ¤ô·Ç¡A¦ý¥Ñ¨CӤ몺PD¤H¼Æ¤ÎOS¤H¼Æªº¦^³ø¡A¤½¥q¹ï©ó822ªºÁ{§ÉÀø®Ä¤w¸g¤FµM©ó¯Ý¡C822ªºPFS¤£ºÞ¦³¨S¦³¹F¨ì²Îpªº0.05¡A¦ý¥Ñ©óPD¤H¼Æ¼µ¤F«Ü¤[³£¨S¹F¨ì289¤H¡A¥B¦º¤`¤H¼Æ¤]¤@ª½¨S¦³©Ô±o«Ü§Ö(¥u¦³¤½¥q°ª¼h¬Ý¨ì)¡A³o¬O¥L̤@ª½ºû«ù¼ÖÆ[¨¥½×ªº³Ì¥Dnì¦]¡C ³o2¦~¨Ó¡A¦bCliff¤j±z¤Î²³¤j¤jªº¤À¨É¤U¡A¯E¤Íª©²Ö¿n¤F°£¤½¥q¤º³¡¤§¥~³Ì¤jªºª¾ÃÑÄ_®w¡A§Ú̫ܦ´N¤w¸g½T©w822¤£·|¹³ STN-KLH¦¨¬°¤@Ó¥¢±ÑªºÁ{§É¹êÅç¡A¤]¤£·|¬O¤@Ó¦]¬°©â¼Ë»~®t¡A©â¨ì¹êÅç²Õ»P¹ï·Ó²Õ¤@¼Ë¦nªº¥¢±ÑªºÁ{§É¹êÅç¡C¥B822¦w¥þ©Ê¨Î¡A¦b°ê»Ú¤j¼t¹ï©ó§K¬ÌÀøªkÁͤ§YÄEªºª^³ò¤U(¬Ý°ê»Ú¤j¼t¹ï©ó¤w¸g½T©w¾÷Âà¥B®³¨ìÃĵýªºPD-1/PD-L1·sÃĦb¤@´Á¥Î¶Ãºj¥´³¾¦¡ªº¤@¦¸°µ20´XºØÀù¯g¡A´Nª¾¹D¹ï©ó¤@Ó½T©w¾÷Â઺§K¬ÌÀøªk¦³¦h»ò¤jªº»Ý¨D)¡A¥unª¾¹D¨«¦b¹ïªº¹D¸ô¤W¡A822n¦bÀù¯g§K¬ÌÀøªk¦û¦³¤@®u¤§¦a¥u¬O®É¶¡ªº°ÝÃD¡A755¤£·|¬O¾ú¥v°ªÂI¡APFS¥¼¹F¼Ð¹ï©óªÑ»ùªº¼vÅT¥u¬O¤@Óµu¼Èªºªi§é¡A´XÓ¤ë«e¯à½æ¨ì700¥H¤W«Ü¦n¡A¨S¦³½æ¨ìªº¤]ÁÙ¦³¾÷·|¡A¥un¤â¤Wªº«ùªÑ¨S¦³®É¶¡ªºÀ£¤O¡A©Ò¥H©O¡A±z´N¤£¥Î§ãµÃ°Õ¡I ºJ¶}±i¸³¦b2015/3/3¤WÂd«eªk»¡ªº¤Ó¹L©ó¼ÖÆ[ªº¨¥½×¡uÁÙ¨S¹F¨ì´Á¤¤¤ÀªRªº¼Ð·Ç¡ACRªºPD¥¼¹F142¤H¡v¤£½×¡A³æ¬OLRªºPD=187©M229³o¨âӼƦr¡A¦b¹ï©ó§K¬ÌÀøªk¦bPFS¤Wªºªí²{¨S¦³¥R¤Àªº¤F¸Ñªº±¡ªp¤U¡A±À¥X¹êÅç²ÕªºÀø®Ä¬O¥H¥k°¾¤À¥¬ªºª¬ºA«BÅS§¡ÀL¦b¤j³¡¥÷¹êÅç²Õªº±wªÌªºµ²½×¬O«Ü¦ÛµMªº¨Æ¡A¦]¦¹¹êÅç²ÕM PFS=1XӤ몺µ²½×¤]¬O«Ü¦ÛµMªº¡C¦]¬°187©M229³o¨âӼƦr¤w¸g½T©w¦³¤@©wªºÀø®Ä¦b349¤H¨¤W¡A¦b±Æ°£¹êÅç²Õ»P¹ï·Ó²Õ¤@¼Ë¦nªº¥i¯à©Ê¤U¡A¹êÅç²Õ±wªÌ¨É¦³¤j³¡¤ÀªºÀø®Ä¡A¥H¥k°¾¤À¥¬¨Ó¤À°t¡APȤ@©w¹F¼Ð¡AM PFS ¤@©w¦³1XÓ¤ë¡C¦pªG§ÚÌ´£¦¬ãŪ¡Aª¾¹D§K¬ÌÀøªk¦³§K¬Ì©µ¿ð¤Î¸~½F®û¼í´£¦§PPDªº²{¶H¡A§Ú̬O§_¥i¥HÁ׶}2/21ªº°²©Êªº¡y¸Ñª¼¥¢±Ñ¡z©O¡H ¤p§Ì²`«ä¤F«Ü¤[¡A¾÷²v¤@¥b¤@¥b¡A¥i¯àÁ×±o¶}¤]¥i¯àÁפ£¶}¡A¥B¦U¦³Àu¯ÊÂI¡C¦pªG¤w¸g¤j¶q¬ãŪ¤FPD-1/PD-L1ªº¤å³¹¤§«á¡A¬Ý¤F¤@°ï§K¬ÌÀøªkPFS¨S¦³¹F¼ÐªºK-M curveªº¨Ò¤l«á¡A¹ï©ó822ªºPFSªº¸Ñª¼¥i¯à·|¨S¦³«H¤ß¡A2015¦~°£¤F11¤ë«e«áªºMSCI®ÄÀ³Åý¯E¹©ªÑ»ù¶}©l°_¸¨ì2016¦~2¤ë¤§¥~¡A¨ä¹ê¥h¦~¤j³¡¤Àªº®É¶¡³£¬O300¤W¤U½L¾ã¡A§ÚÌ·Q±o¥X¨Ó¬Jn²Å¦X187/229³o¨âӼƦr¤Sn²Å¦XPFS¨S¦³¹F¼Ðªº±Æ¦C²Õ¦X¶Ü¡H²{¦b·íµM¥i¥H²q¨ì¹êÅç²ÕªºPFS ¥²¶·§e°ª«×ªºÂù®p¤À°t(¦³¤j¶qªºµuPFS¥H¤Î¤ñ¨Ò¤£§Cªºªø§À¨Ö¦s)¡A¨Æ¹ê¤W¦b¦³¤ñ¨Ò¤£§C(¤j©ó¨â¦¨¡A¬Æ¦Ü3¦¨)ªºªø§À¥X²{ªº±¡ªp¤U¡APÈn¤j©ó0.05ªº±Æ¦C²Õ¦X¤Ï¦Ó¤ñ¸ûÃø±Æ±o¥X¨Ó¡A«á¨Óªº¸Ñªk¬O¥Î³Âªáªº²{¶H(¹êÅç²Õ¦³¤@³¡¤À¤H¤£¥u¬O»P¹ï·Ó²Õ¤@¼Ë¨S¦³Àø®Ä¡A§ó¦]¬°®û¼í²{¶H¦Ó¿éµ¹¹ï·Ó²Õ¡A¦³¨¬°÷ªº¤ñ¨Òªº¤H¥X²{®û¼í²{¶H¤~·|¥X²{©úÅã³Âªá)¡A¤~¯à±NPÈ©Ô°ª¨ì0.05¥H¤W¡C 2/21¸Ñª¼«áÅ¥¤F2/22ªºªk»¡·|¸Ñ»¡¡A»P¯E«È¤jªá¤F1Ó¦h¬P´Á°µPFSªº±Æ¦C²Õ¦X¡A¤~«j±j±Æ¥X¤@Ó§e²{Âù®p³ÂªáªºK-M curve¡A²Å¦XÁ`Åé349¤H¨Ó¬Ý¦³©úÅãÀø®Ä¦ý¨â²ÕPȤj©ó0.05ªº²Õ¦X¡C¦b2016/6ªÑªF·|®É¡A¦³¨¬°÷ªºª¾ÃѱƱo¥X¨Ó¶Ü¡H°²³]±Æ±o¥X¨Ó¦n¤F¡AµM«á¦b¯E¹©ª©¥R¤À°Q½×¡A¨º»ò¹ï¯E¹©ªº«e´ºÁÙ¨º»ò¦³«H¤ß¶Ü¡H¹ï2016¦~ªº¸Ñª¼ÁÙ·|ÃhµÛ°ª«×¹w´Á¶Ü¡H¦]¬°Yª¾¹DPFS¤£¤@©w·|¹LÃö¡AOSªº¼Æ¾Ú¤S¥I¤§Âö¦p¡A¦b¸g¾ú2015¦~8¤ëªº250§C¼é®É©ê±oºò¶Ü¡HMSCI®ÄÀ³º¦±o¨ì755¶Ü¡H©ê±o¨ì700¤¸¥H¤W½æ¶Ü¡H Y¦b2015¦~´N¤w¥R¤À°Q½×§K¬ÌÀøªk¦bPFS¤Wªº²{¶H¡AYKªº¤@¬ñ¨£¬}¥i¯à©Ê´N³Q±Æ°£¡A°µ¥þ²y¤T´Á¬O¤@Ó¥²µM©Ê¡A§ë¸ê¨Mµ¦¬O§_·|§ïÅÜ¡H¥h¦~¤¤¥H¨ÓªÑ»ùªºK½u¹Ï¬O§_¤]·|§ïÅÜ¡H¤p§Ì¤]¦b·Q³oÓ°ÝÃD¡C ¦ýµL½×§Ú̬O§_´£¦°Q½×¡AªÑ»ùK½u¹Ï¬O§_§ïÅÜ¡A822ªºÃĮĤ£·|ÅÜ¡C»¡¯uªº¡A¦P¼Ë¦bÆ[¹î¨ìªº187/229¨âӼƦr¤U¡AYPFS¬O¥k°¾¤À¥¬±o¨ìM PFS=1XӤ몺µ²ªG¤ñÂù®p¤À¥¬ªºPFS¥¼¹F0.05ªºµ²ªG¡A¹ê»Ú¤WÂù®p¤À¥¬ªºµ²ªGÀø®Ä¬O¤ñ¸û¦nªº¡C ¥H2/22±i¸³ªº¸ÑÄÀ¡A187/229©Ò±a¨Óªº¦n³B¤À°t¦b349¤H¨¤W¡A¹ï·Ó²ÕªºPFS±¡ªp·|¤ñ§Ṳ́§«e¹w´Á±o¦n¡A¹ï·Ó²ÕÀ³¸Ó·|¦³©úÅ㪺¼Æ¥Ø¨äPFS¬O¦b1XÓ¤ë¬Æ¦Ü2XÓ¤ë¡A§ÚÌ¥u¯à»¡¤½¥qCyclophosphamide¿ï±o¦n¡C¦©°£¹ï·Ó²Õ¤§«á¡A¨ä¥¦ªº¦n³B´N¤À°t¦b¹êÅç²Õ233¤H¨¤W¡AY¬O¥k°¾¤À¥¬¡A¬Ý°_¨ÓM PFS·|¦n¬Ý«Ü¦h¡APȤ]·|¹F¼Ð¡A¦ýªø§À²{¶H´N·|¤j°¡C¦ý¹ê»Ú¤W¬O¤@¤j¥bªº¤H³£¦b«e´XÓ¤ë©Îdrou out¡A©ÎPD¡A©Î¦]®û¼í¦ÓPD¡A¦bÆ[¹î¨ìªº187/229¤H¼Æ¦r¤£ÅܤU¡A¦³³\¦h¤H¦¦PD¡A´N±on¦³³\¦h¤H¤]¼µ«Ü¤[¤~PD¡A¤~¯à¤@¼ËÆ[¹î¨ì187/229³o¼Ëªº²{¶H¡A¤]´N¬O»¡¡A187/229¤£ÅܤU¡Aªø§À²{¶Hªº¤ñ¨Ò¡A¦bÂù®p¤À°t¤W¤ñ¥k°¾¤À°t¦n¦h¤F¡C¦b§K¬ÌªvÀø¤¤¡APFS¯à¹F¨ì2XӤ몺¡A³q±`¬OÁô§tµÛ±wªÌªº§K¬Ì¨t²Î¨ú±o¤F«¤jªº³Ó§Q¡A¹ï©óOS³q±`·|±a¨Óªø¤[ªº§Q¯q¡AY822ªºPFSªø§À¹F¨ì30%¡A¦bªø§À¤ñ¨Ò¤W´N§¹³Óopdivo¡Bkeytruda¡BYervoy¡BT-vex³o´XÓ§K¬ÌÀøªk¡C¥t¥~ÁÙ¦³¤£§C¤ñ¨Òªº®û¼í²{¶H¦Ó¦§PPDªº¤H¡A¥LÌ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/6 ¤U¤È 05:33:08²Ä 1474 ½g¦^À³
|
QQ¤j ·PÁ±zªº°^Äm¾ã²z |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/5/6 ¤U¤È 04:15:37²Ä 1473 ½g¦^À³
|
°O±oªìª¦¤å®É, µhWªº°£¤F^¤å´Nºâ½Ķ¥X¤¤¤å³£¤£ª¾¦b»¡Ô£¥~, ÁÙ¦³¤@Ó§xÂZ´N¬O¸g±`¥X²{ªºÁY¼g¤£ª¾¥Nªí¤°»ò, ¤]¬d¤£¨ì. ÀHµÛ«áÄò®É¶¡ªº²Ö¿n, Á`ºâ³°Äò§ä¥Xµª®×. ªñ¤éªá¤F¨Ç®É¶¡±N¤âÃ䦳ªº¾ã²z¥X¨Ó. ÁÙ¦³¨âÓ¸g±`¬Ý¨ì¦ý§ä¤£¨ìªº. §Æ±æ¯E¤Í¯à«ü¾É¶ñ¥Õ. ¾ã²z¥X¨Óªº¤£¦h, ´Á¬ß¤j®aÀH®É¬Ý¨ì´N¸É¥R, ¤è«K¦³»Ýnªº¯E¤Í°Ñ¦Ò. ±N¨ÓY¸û¦h®É, ©Î³\¥i¥H¤ÀÃþ¤@¤U. ¦Ü©ó¤¤¤å½Ķ, §Ú¦Û¦¤µ{«×¤Ó®t©È½¥X¨Ó¤@¨Ó¶M¯º¤j¤è¦AªÌY¿ù»~²£¥Í»~¾É«h »~¤w®`¤H. ³o¤è±, ¤æÁx½Ðª©¤W¦³¯à¤j¤j¯à¸É¤W¶Ü?? ·PÁ ! ADC: antibody-drug conjugate AE: adverse event BTD: breakthrough therapy designation CI: confidence interval CR: complete response CT: computed tomography DoR: duration of response ER: estrogen receptor ESMO: European Society for Medical Oncology DMFS: distant metastases free survival DRR: durable response rate DSMB: data safety and monitoring board HER2: human epidermal growth factor IHC: ? imAR: immune-mediated adverse reactions irAE: immune-related adverse events irPD: immune-related progressive disease irRC: immune-related response criteria mAbs: monoclonal antibodies MedRA: Medical Dictionary for Regulatory Activities MOA: mechanism of action MOS: median overall survival MRD: minimal residual disease MRI: magnetic resonance imaging MTD: maximum tolerated dose NE: not estimable NPHCRM: Non-Proportional Hazards Cure Rate Model NPHM: Non-Proportional Hazards Model NSCLC: non-small cell lung cancer ORR: objective response rate OS: overall survival PCI: personalized cancer immunotherapy pCR: pathological complete response PD: progressive disease PD-L1: programmed death-ligand 1 PET: positron emission tomography PFS: progression-free survival PHCRM: Proportional Hazards Cure Rate Model PHM: Proportional Hazards Model PR: partial response RECIST: Response Evaluation Criteria in Solid Tumours RFS: recurrence-free survival SD: stable disease TILs: tumor infiltrating lymphocytes TNBC: triple-negative breast cancer TPS: ? Tregs: tumor-infiltrating regulatory T cells WHO: World Health Organization |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/5/6 ¤W¤È 11:23:38²Ä 1472 ½g¦^À³
|
Faith¤j 1¯E¹©¬O¤@®a¬Û·í¦³¼ç¤Oªº¥Í§Þ¤½¥q §Ú»PFaith¤j ±ø¤j ¤@¨Ç²³¤j³£¬O¥Hªø´Á§ë¸ê°µ¬°ªºµ¦²¤,ªø´Á§ë¸ê¬Ý°ò¥»±»PÁÍ¶Õ 2¤½¥q»P§ë¸ê¤H¤@¼Ë¹ï¤@Ó¥þ·sªº»â°ì»Ýn¾Ç²ß ±´¯Á ÁA¸Ñ µo²{ 822²Ä¤@Ó²£«~¨ÅÀù¤w¸gÃÒ©úÁÞ¥i¥Î©óÀù¯gªºªvÀø ¦Ó¥B¤½¥q¤w¸g§ä¨ì²³æªº¤èªk¨Ó¿z¿ï¯f¤H 3±µ¤U¨Óªº822 833¨ä¥L¨t¦C²£«~¬ãµo¤½¥q±N¥HOS¨ú¥NPFS q¬° primary endpoint ¥H²Å¦XÀù¯g§K¬ÌÀøªkªº¯S©Ê 4¦³Â²³æªº¤èªk¨Ó¿z¿ï¯f¤H¤S¦³²Å¦XÀù¯g§K¬ÌÀøªkªº¯S©Êªºprimary endpoint,Ó¤H»{¬°³o¤@¦¸¤T´ÁÁ{§É¸ÕÅ禬Àòº¡º¡ 5¬ü°ê¤H³ßÅw¸Û¹ê, §Ú±`¦b·Q³o¤@¦¸¤T´ÁÁ{§É¸ÕÅç¦pªGprimary endpoint ¹F¼Ð,³o±N»PÀù¯g§K¬ÌÀøªkªº¯S©Ê¤£²Å¦X ¹ï¯E¹©¤£¤@©w¦³§Q ,¬ü°ê¤H³ßÅw¥Î¬ì¾ÇÃÒ¾Ú ¦A·¾³q ¨ó°Ó,OBI-822¥H²Ä¥|´ÁÂಾ©Ê¨ÅÀù¯f¤H¬°¹ï¶Hªº²Ä¤G/¤TÂùª¼Á{§É ¸ÕÅç¡AÁÙ¦³¬Û·í°ª¤ñ²vªº¤H¦³§K¬Ì¤ÏÀ³¡A¸ÓÁ{§É¼Æ¾Úµ²ªG¦³¾÷·|¦b¤µ¦~¬ü°ê¸~½FÂå¾Ç¦~·|¡]ASCO¡^¤WÅF°Ê¡C 6 ¨C¹L¤@¤Ñ¯E¹©ªº»ùȳ£¦b´£¤É, @¤ß³Ì«n, ¥h¦~¤]¶^¨ì250¤¸, ¤j®a¤]´ç¹L¤F, ³o¦¸¯E¹©¸g¹L¨âÓ¦h¬ù¤ëªºÄY¼F¦Ò Åç¯uª÷¤£©È¤õ·Ò,ÀHµÛ822 833¨t¦C²£«~ÂX¤j¬ãµo, ¶Õ¥²¯D¤õ«¥Í |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/5/6 ¤W¤È 10:08:19²Ä 1471 ½g¦^À³
|
§Ų́Ӭݤ@¤UYK¦b¸Ñª¼«á»¡©ú·|©Ò»¡ªº¸Ü¡]https://www.youtube.com/watch?v=Lp2cOFUz2X4¡^ 1.¦¹¦¸Á{§É¹êÅç¡A¾¯¶q30£gg¬O¥¿½Tªº 2.¬I¥´¤è¦¡¡Aè¶}©l±K¶°¬I¥´¤§«á¦A±Ä¸û²¨ÃP¦¡ºû«ù¤U¥h¡B9Ӥ르9°w¬O¥¿½Tªº 3.¦ý¬O¡A¯f¤HY²£¥Í§ÜÅéÀ³¸ÓÄ~Äò¬I¥´¡]Ó¤H´¢´úYK¨¥¤U¤§·N¡A¥un¯à²£¥Í§ÜÅéªÌ´NÀ³¸Ó«ù¬I¥´¡^ 4.§K¬ÌÀøªkÀ³¸Ó¥HOS°µ¬°endpoint 5.Á{§Éµ²ªG¤ÀªR¨Ã«D¥Î¶Ç²Îªº¹ï·Ó²Õ»P¹êÅç²Õ¥h¤ÀªR¡An¥Î²£¥Í§ÜÅé»P¨S¦³²£¥Í§ÜÅ骺µ²ªG¥h°µ¤ñ¸û¡]»P¯Î°|ªø»¡ªk¤@¼Ò¤@¼Ë©O!ÁÙ°O±o¥ßªk°|½è¸ß®Éªº¨º±i¹Ï¶Ü?¤£Åå¤H¶Ü?!¡^ 6.¬°¤°»ò·íªì¨S¦³¿z¿ï¨ã¦³Globo Hªº¯f¤H¡A¦¹Á{§É¹êÅç¤@¶}©l¬O¥ÑMSKCC§ÞÂà¦Ó¨Óªº¡A·í®É¨ÅÀù¯f±w¤WGlobo H´N¦³¶W¹L60¢Mªºªí²{²v¡A¤]´N¬O¤j³¡¤À¯f¤H³£¦³¡F¦¹¦¸Á{§É¹êÅç¨S¦³¿z¿ï¯f¤H¡Aµ²ªGÅã¥Ü©Ò¦³ªº¯f¤H³£¥i¯Ç¤J¡A¤£¥Î¤À±Ú¸s¡A¤Ï¦ÓÃÒ©ú·íªìªº¨M©w¬O¦³§Qªº¨M©w¡C¡]«¢«¢«¢~³o¥y¬O¤p§Ì¦Û¤v¥[¤Jªº¡^ Åó±ø±ø¤j ·PÁ±z¬Q¤é´£¨Ñ§d©v¯q³Õ¤hªº¸ê®Æ¡G ¡u¦b¼Æ¾Ú¸Ñª¼«á¡Aµ²ªG¥ç¤ä«ù¦¹¶µ½×ÃÒ¡C§Y¤£½×¥ô¦ó«¬ºAªº¨ÅÀù¯f±wª`®g¬Ì]«á¥un¯à²£¥Í¨¬°÷ªº§ÜÅé¡A¬Ò¯àÅã²{¨¬°÷ªºÀø®Ä¡C¡v ÁÙ¦³±i¸³¦b»¡©ú·|¤¤¤]¥Î¤F¡uÅå¤HªºÀø®Ä¡v¨Ó§Î®e¯à²£¥Í§ÜÅ骺¯f±w¡I ¹ï·ÓµÛ¨ä¥L¸ê®Æ¤ñ¸û¡A¯uªº«Ü´Î©O¡IÁÙ¦³¨º^¤å¡A¤p§Ì¬Ý°_¨Ó¤]¦n¦Y¤O¡A¬Ý¹Ïªí¯à§Ö¼Ö¨Ç~ÁÙ¬OÁÂÁ¦Ѵ¤j ªü¬Â¤j ·PÁ±zªº¸ê°T,833¦¬¤F4ºØÀù,¥þ¯dµ¹¥xÆW¤H¤F,¤£ª¾833ªºGÀù©O? ¥xÁÞ¤j ³Ìªñ¦£¤°»ò¡H±zÁÙ¦n¶Ü¡H¦n¤[¨S¬Ý¨ì±zÅo! |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/5/6 ¤W¤È 09:37:31²Ä 1470 ½g¦^À³
|
¦Ñ´¤j¡A ÁÂÁ±z¡A¯uªº«Ü¦n¥Î¡A¥u¤£¹L^¤å¤£¬O¤Ó¦n¡A¬Ý±o¦³ÂI²Ö ~~ «¢«¢ |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/5/6 ¤W¤È 09:13:45²Ä 1469 ½g¦^À³
|
Faith¤j,¥xÆWªº½×¤å¤£ºâ½×¤å,¤£µn¤j¶®¤§°ó©Ò¥H§ì¤£¨ì!¥H¤U³o½gÀ³¸Ó¬O°ê¤ºªººÓ³Õ¤h½×¤å¤§Ãþªº~~ SCI-hub¶ÈSCI publishedªº,¦n¥Î´N¦n,«¢«¢~~ handle.ncl.edu.tw/11296/ndltd/90102149567436458504 ±´°QGlobo H ¦b¤T³±©Ê¨ÅÀù¤º§êºtªº¨¤¦â ®}¹ÅÂ@ |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2016/5/6 ¤W¤È 08:58:27²Ä 1468 ½g¦^À³
|
833¶i«×¥Ø«e¦b¥x¤j¥u³q¹L¨ÅÀù©MªÍÀù,¤j¸zÀù³Ì§Ö¤»¤ë©³¤C¤ëªì¦¬®×.±ø¥ó:¦pªG±µ¨ü¤ÆÀø«á¶·°±ÃÄ¥|¶g¤~¦¬©ÎÂå¥Í»{¬°¤£»Ý¤ÆÀø¤~¥i¦¬.¥H¤W¬O¿Ë±±o¤j¸zª¢¥|´Á¸ß°Ý¤½¥qªº¦^µª,®¦·OÀøªk¶È©ó¨ÅÀù. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/5/6 ¤W¤È 07:42:23²Ä 1467 ½g¦^À³
|
¦Ñ´¤j «z~¤Ó¦n¥Î¤F!¯uªº¤Ó·P¿E¤F~·R¦º³oÓ®üµs¤F! Haha.. ¦ý¬O³o½g§ÚÁÙ¬O§ì¤£¨ì£z£°¡K(¬O¤p§Ì¤Ó»¹¤F¶Ü) http://handle.ncl.edu.tw/11296/ndltd/90102149567436458504 ±´°QGlobo H ¦b¤T³±©Ê¨ÅÀù¤º§êºtªº¨¤¦â ®}¹ÅÂ@ Cliff¤j «ö·Ó¦Ñ´¤jªº¤è¦¡,»´ÃP¤@«ü,´N¥þ§ì¤U¨Ó¤F!¤p§Ì°Ù°Ù¥h~ÁÂÁÂÅo! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/6 ¤W¤È 07:27:57²Ä 1466 ½g¦^À³
|
Cox propotional hypothesis model ¬O°²³]¨â²Õ¤ºªº¨ä¥LÅܶµ ¦p©Ê§O ¦~ÄÖ ¦¸±Ú¸sÅܶµ µ¥µ¥¬O¹s¬ÛÃö ¬O model free ¦ý¬O ¸U¤@ ¦³¬ÛÃö ©Î¬O»¡ ¦~ÄÖ»P¦¸¸s²ÕÅܶµ»P¹êÅç¦ÛÅܶµ¦³¥æ¤¬§@¥Î ´NµLªk¦³®ÄÀËÅç¨â±økm curveªº®t²§ ²Îp¦ÒÅç¤O ·|¤U° ´«¨¥¤§ ¹êÅç®ÄªG¤£®e©öºë½T³Qµû¦ô¥X¨Ó ·ÀIÈ»~®t·|Åܤj |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/5 ¤U¤È 10:46:52²Ä 1465 ½g¦^À³
|
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors ¬OÁ¿¶Ç²ÎOS´ú¶q ¶O®É ¤S¦³©µ¿ð¤ÏÀ³ ®ÄªG¤£¦n «Øij¥Î·s¦¡ªº´ú¶q~¨½µ{¸OOS ·|¦³§U©óÀˬdÂI§í¨î¾¯¤§Àù¯g¬ã¨s ©Î³\¯E¹©¤½¥q¥i¥H¬Ý¬Ý°Ñ¦Ò ³]p¦b¥¼¨Ó¹êÅ礤 ¥i¥HÁYµu®Éµ{ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/5/5 ¤U¤È 10:35:29²Ä 1464 ½g¦^À³
|
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis ¤p§Ì§Ö³t¬ÝºKn¸ò°Q½× ¤ß±o¬O 1.COX PH¼Æ¾Ç¼Ò¦¡°²³] ¦b²{¹ê¥Í¬¡ªºÀù¯g¤W ¦p°©Åè½Fªº¬ã¨s ¬O¤£¦Xªº ´«¨¥¤§ ¦ÒÅç¨â²ÕKM¦±½uªº®t²§ n¤p¤ß¥ý¬Ý¬O§_²Å¦XCOX°²³] 2.¨â²Õ®t²§ªºPȤ£¨ãÁ{§É·N¸q ³Ì¦n¬ÝCI«H¿à°Ï¶¡ªº¦ôp ¦pµ²¸zÀù¬ã¨s®×¨Ò Y¦³»~ ½Ð«ü¥¿ |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/5/5 ¤U¤È 10:07:27²Ä 1463 ½g¦^À³
|
Cliff¤j,¦U¦ì¤j,Y·Qn®³¨ì§K¶OSCI½×¤å,¥un¦Aªá¤¤ÀÄÁ°á¤@¦¸¥H¤U¨â½g¤å³¹ 5,000¸U¥÷½×¤å¥ô§A§ì!¦Ñ´´N¤£¦A«ÂФF.Good night~ ·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/29 ¤U¤È 11:23:06²Ä 1459 ½g¦^À³ ·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/29 ¤U¤È 11:27:42²Ä 1461 ½g¦^À³ |
|
|
·|û¡G¥ôÄP¤¸10142024 µoªí®É¶¡:2016/5/5 ¤U¤È 08:14:17²Ä 1462 ½g¦^À³
|
èè¬Ý¨ì ¤¤°ê¸~½Fµn°O¦~³ø;¤¤°ê¨C¦~·sµoÀù¯g¯f¨Ò312¸U.¨C¦~¦]Àù¯g¦º¤`270¸U ¥þ¥@¬É¨C¦~60%¥H¤WÀù¯g·s¯f¨Òµo¥Í¦b«D¬w¡B¨È¬w¡B¤¤¬ü¬w©M«n¬ü¬w¡C³o¨Ç¦a°ÏÀù¯g¦º¤`¥e¥þ²yªº70%¡C¹wp¦b¤U¤@Ó20¦~¤º¡A¥þ²y¨C¦~·sµoÀù¯g¯f¨Ò¼Æ±N¥Ñ2012¦~ªº1400¸U¤W¤É¨ì2200¸U¡C |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2016/5/5 ¤U¤È 07:46:15²Ä 1461 ½g¦^À³
|
Cilff¤j,¬Ý¨ì±z³o½g¤]¬O·PIJ¨}²`,§Ú·íªì¬O¦b«e¦~¤E¤ëÅ¥¨ì»²¤jªººt»¡,´£¨ì¤F¤T´Án¥ý¥´´X°wªº®É«á,ı±o«ç»ò·|·Qn¦b¤T´Á§ïÅܤG´Áªº³]p¦³ÂI©_©Ç,¦]¬°¦pªG¦n¦ó¥²n°µ³o¼Ëªº§ïÅÜ? ¨rÆN§Q®`¬O¦b¤£¶È¶È¥i¯àª¾ÃѤWªº¤£¹ïºÙ,¬Æ¦ÜÁÙ¦³°]°È¤Wªº·¥¤jÀu¶Õ,¥i¥H©Ô©ï©Î¬O¬å±þªÑ»ù¨Ó±j¤Æ¥«³õ©Ò»{¬°ªº°ò¥»±(¤è¦V), ³o¤~¬O¥L̯u¥¿¥i©Èªº¦a¤è. ¤£¹L©O¤p§Ìı±o¸g¹L³o¤@¦¸¤]¦n,Åý¦Û¤v¸ò¤j¹Ù̳£¾ÇÓ¸gÅç,¤£ºÞ¬O°ò¥»±©Î¬OÄw½X±¤Wªº, §ë¸êªº¸ô¤W¥»¨Ó¦n¹³´N·|µo¥Í³o¨Ç¦³ªº¨Sªº¬ðµo¨Æ¥ó, ³o¦¸¤£¨Ó¥H«á¤]·|¸I¨ìªº. ¤[¥¼µo¤å,³Ì«áÁÙ¬O§Æ±æ¤j®a¥[ªo. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/5/5 ¤U¤È 04:56:56²Ä 1460 ½g¦^À³
|
Cliff¤j ÁÂÁ±z¡I ¦^ÀY¬Ý·í®É¡A©Î³\§ãµÃ¡A¦ý¡A²{¦b¥[ºòŪ¡AÀ³¸Ó¤]ÁÙ¤£¿ð¡I°£¤Fª¾ÃѤ£¹ïµ¥¤§¥~¡A¤]³\¤]¬O¦]¬°²Ä¤@´ÁªºÁ{§Éµ²ªG«ÜÀu¡A³s±aÅý¤j®a¦³°ª«×ªº¼ÖÆ[¡A¬°¦ó²Ä¤@´Á¼Æ¾Ú«ÜÀu¡H¤p§Ì·Q¹L¡A©Î³\¬O¦]¬°¦¬®×±ø¥ó¤£°÷ÄYÂÔ¡A¨º»ò¬O§_¤]¥i±À½×¡AY³o¦¸¤G´Á¡B¤T´Áµ²ªG¬I¥´©ó«e´Á¯f¤H¤W¡A±N·|«D±`ÅãµÛ¡H¡I ¥t¥~¡A¬Ý¤F¤@¤U§Q¯A¤j¤t¤j©ó¸Ñª¼«á©Ò´£¤Îªº¡AÃö©ó¥´¤F4-5°w«á¤~²£¥Í§K¬Ì¤ÏÀ³ªº³]p¡A®Ú¥»¤£¯àºâphase2,¦ý¤½¥q¦b¸Ñª¼«á¡AYK¤]»¡¡A³o¼Ëªº³]pÃÒ¹ê¬O¹ïªº¡A³o¯uªºÅý¤p§Ìconfuse ¤F¡I ³Ìªñ¬Ý¤F¤@¨Ç¸ê®Æ«á¡Aµo²{FDAµ¹ÃÄÃÒ¬Û·í¼u©Ê¡A¤½¥qÀ³¥[§Ö»PFDA¶i¦æ¸Ñª¼«áªº·¾³q¡A«Ó¥v¤j´£¨ÑªºT-Vecªº¨Ò¤l¡A¤]¬O¤£Â_·¾³q«á®³¨ìÃÄÃÒªº¡I§Ų́Ӭݬݳo¨Ç¨Ò¤l¡G Keytruda PD-1 ¥Ø«e¤w¨ú±o4ÓÃÄÃÒ¡A¤À§O¬O¡G±ß´Á¶Â¦â¯À½F¡B«D¤p²ÓMªÍÀù¡Bµ²ª½¸zÀù¡B¸g¨å«¬²O¤Ú½F¡]³Ì«á¤@¶µ¦b2016¡B4¡B21¨ú±o¡^ ¥Ø«e¥þ¥@¬É¦³¥|Ó§K¬ÌÀøªk¨ú±oÃÄÃÒ¡]YÁÙ¦³½Ð¤j®a¦A¸É¥R¡^¡A¤À§O¬O¡G opdivo¡Bkeytruda¡BYervoy¡BT-vex ¶i¥h¬Ý¥L̨ú±oÃÄÃÒªºkeypoints¡A¦³¨Ç«D¦ýPFS¤@ÂI¤]¤£ÅãµÛ¡A¬Æ¦Ü³sOS³£´¶´¶³q³q¡AÁÙ¦³§ó¸Ø±iªº¡A³sMOA³£ÁÙ¥¼½T©w....¡A¥u¯à»¡¡AFDA¯uªº«Ü¦³¼u©Ê¡A¦]¬°¥L̯¸¦b¡u¼W¥[¯f±wªººÖ¬ç¡v¬°³Ì¤j¦Ò¶q¡I ²Î¤@§ëÅU±i¥ß¸s¸g²z¡A¦b¸Ñª¼«á¤]¦CÁ|¤Fªñ¦~³¡¥÷phase2«áª½±µ¨ú±oFDAÃÄÃÒªº¨Ò¤l¡A½Ð¬Ý²Ä7¶ http://pcmc.uni-psg.com/vip/20160226-01.pdf ¤]´N¬O»¡¡A¥HPFS¬° keypoints of Approval «D¥Dn¡A¤½¥q¦b¹êÅç®É¡A©Î³\¤wª¾¹DPFS¤£·|¹L¡A¦ý¡A¦pªG¤½¥q¦P®É¤]¬Ý¨ìOS²Îp¨}¦n©O¡H¹ï·ÓFDAªºÃÄÃҼзǡA¦ó¨Ó¥¢±Ñ¤§»¡¡H©Ò¥H¤]¥u¦³¥xÆW´CÅé·|¥Î¡u¸Ñª¼¥¢±Ñ¡v¨Ó¸ÑŪ¡I ¥þ¥@¬É¦U¤jÃļt³£¤õ³tªº¶i¦æµÛ¦U¦ÛªºÁ{§É¶µ¥Ø¡A¤£½×¬O³æ¤@¥ÎÃÄ©ÎÁp¦X¥ÎÃÄ¡A¬Ò§Æ±æµo±¸ÃĪ«ªº³Ì¤j¼ç¤O¡A¤Ï¤§¡A§ÚÌ©O¡H¥[ªo°Ú¡I ¥H¤W¦C¤F³o»ò¦h¡A§Ñ¤F´£¤@¶µ³Ì«nªº¡A¨º¥|Ó³£¬O³Q°Ê¦¡§K¬ÌÀøªk¡A¯E¹©ªº822¬O¡u¥D°Ê¦¡¡v§K¬ÌÀøªk¡A¥Ø«e¥þ¥@¬É³Ì·s¿oªº¡A©Ò¥H¡AASCO«á¡A¯à¤£¾_¾Ù¶Ü¡H ´CÅ騬°¶Ç´C¡A§óÀ³¸Ón¦³ª¾ÃÑ¡A¤~¤£·|³Q°ê»Ú¯º¸Ü§r¡I ÁÂÁÂCliff¤j¡B¬K¬î¤j´£¨Ñªº¸ê®Æ¡A¤p§Ì¥h°Ù¤F¡I «á°O¡ã¬ðµM·Q¨ì¹qµø¾÷ªºµo©ú¡A·í®É¡AÀ³¸Ó¤]¤Þµo³\¦h¤Hªºª§Ä³§a¡IÅ¥»¡ÁÙ¦³¤H¬°¤FÃÒ©ú¸Ì±¦³¤H¡A§â¹qµø¾÷©î¤F·í½äª`¡Aµ²ªG...»ó¤l¼L¤Ú«_·Ï⋯⋯«¢¡Aª¾ÃѸgÀÙªº®É¥N¡An¯à¥R¹ê¦Û¤v¡A¤~¯à¨«¦b®É¥Nªº«eºÝ¡B¤~¯àÁȨì¿ú§r¡I¥[ªo¡I¡]¤p§Ì¤@¶µ¼ÖÆ[¡A¥H«á¤p§Ìªº¸Ü¬Ý¬Ý´N¦n...¡^ ªþ±a¬Ý¤@¤U833¡ãÂI¶i¥h¡A¥´¤Ä«á«ö¶}±Ò¡A¥xÆW¡]¥þ²y¡^¦¬26¤H http://www1.cde.org.tw/ct_taiwan/search_case1.php http://www1.cde.org.tw/ct_taiwan/search_case2.php ¸ÕÅçpµe¦WºÙ ¥HOBI-833 (Globo H-CRM197)/OBI-821 (¦õ¾¯) ³v¨B¤É°ª¾¯¶q¤è¦¡ªº¥D°Ê§K¬ÌÀøªkªvÀøGÀù¡BªÍÀù¡B¤j¸zª½¸zÀù©Î¨ÅÀù±wªÌ¡Aµû¦ô¨ä¦w¥þ©Ê¤Î@¨ü©Ê¤§¶}©ñ©Ê¸ÕÅç ¸ÕÅç¥Ó½ÐªÌ¡G ¥C¥H«ä¥Í§ÞÅU°Ý¦³¤½¥q ¸ÕÅç©e°U/ÃÙ§U³æ¦ì¦WºÙ¡G ¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q ¸ÕÅçpµe®Ñ½s¸¹¡G OBI 833-001 ®Öã°õ¦æ¤å¸¹¡G 1046038824 µn¿ý¤é´Á¡G 2015-07-17 ¸ÕÅç¹wp°õ¦æ´Á¶¡¡G 2015-04-15 ¦Ü 2018-04-30 |
|
|
·|û¡G¬K¬î10139014 µoªí®É¶¡:2016/5/5 ¤U¤È 02:58:51²Ä 1459 ½g¦^À³
|
¤p§Ì¤@ª½±qª©¤W±o¨ì¦U¦ì¥ý¶iªºÄ_¶Q¸gÅç»Pª¾ÃÑ¡A¥¼¯à¦³©Ò¦^³ø¹ê¦b¦½ÃC¡C è¬Ýcliff¤j»y«¤ßªø¤§µo¤å¡A¤å¤¤´£¨ì¨â½g¤åÄm¤£¯à¤@¿s¥þ»ª¡A«Ü¬O¿ò¾Ñ¡C¥O¦b®ÇÆ[¤åªº¤p§Ì¤]²`¬°§ãµÃ¡I ¨S·Q¨ì¤p§Ì¦bºô¸ôÆ[½à¬ü¤k·Ó¤ù®É«ê¥©¬Ý¨ì»ª¦ü³o¨â½g¤åÄmªº¤å³¹¡A¦ý¦]¬°¤p§Ì¹ê¦b¬Oªù¥~º~µLªk½T©w¬O§_¥¿½T¡C ÁٽЦ³®É¶¡ªº¤j¤j̦ۦæ³sµ²¤@±´¨s³º¡C¸Ô²Ó¸ê°T¦p¤U www.sendspace.com/file/u7xghk ºÃ¦ü¦WºÙ¡GMoving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis.pdf www.sendspace.com/file/b77haj ºÃ¦ü¦WºÙ¡GMilestone Survival A Potential Intermediate Endpoint for Immune.pdf |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2016/5/5 ¤U¤È 02:00:39²Ä 1458 ½g¦^À³
|
Cliff¤j: ¬Ý§A¤@Ãä¦^ÅU¤@Ãä¾ã²z¬ÛÃö¿òº|¸ê°T¹ê¦b¦½ÃC »¡¯uªº«Ü¦h¬ÛÃöªº±M·~ª¾ÃÑ §Ú¬O¯uªº¤£À´ ©Ò¥H¹ê¦b¨S¦³¯à¤Oµo¨¥ ¤£¹L¤]¬O¦]¬°¦³³oÓ¶é°Ï §Ú¤~¥i¯à¤@¸ô«ùªÑ¶W¹L3¦~ ¤@¸ô³£¬O¶R¶i¨S¦³°Ê·n¹L ÁöµM²{¦bªºªÑ»ù§Ú¤w¸g¨S¦³Àò§Q ¦ý¬OÁÙ¬O©êªº¤ß¦w²z±o ¦]¬°¯u¥¿ªº¸Ñª¼¬O6/4 ¦b³Ì«áªº¤@Ó¤ë¬Û«H¤ß±¡¬O·Î¼õªº ¤£¹L¦ñÀHµÛÄw½X»P®ø®§ªº¨I¾ý ©Î³\¬OµL²áªº¤@Ó¤ë. §Ú¤£ª¾¹D¬O§_·|½æ¦b700¥H¤W ¦ý¬O§Ú¬Û«H¤H¦hªº¦a¤è¤£n¥h ·íªì¦b600¥H¤W¤@ª½¨ì¸Ñª¼«e ¯uªº¬O¤H³Ì¦hªº¦a¤è ¥i±¤§Ú¤]µÛÅ] ¨S½æÁÙ¥[½X ¸Ó¥´§¾ªÑ°Õ@!@~ ÁÙ¬OnÁÂÁ§Aªº¤À¨É ·P®¦! |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/5/5 ¤U¤È 12:58:15²Ä 1457 ½g¦^À³
|
··«B«B¨âÓ¦h¤ë¡A²{¦b·¼È°±¡A«B¼È·²¡A¥¤ßÀR®ð¸Ü·í¦~¡C»¡¨ìª©¤W³£¬O¤@¨¥°óªº¨¥½×¡A¤p§Ì¦³·P¡C Á|¨Ò¨Ó»¡¡A±qFaith¤j¦b¡u¯E¹©ªºÄ@´º»P»ùȵû¦ô¡vª©Page.19³B¡A2015/05/26¤W¤È08:03:27¡]²Ä270½g¦^À³¡^¶K¥X¡uEarly Termination Per Protocol PD:229/Others:37¡v¶}©l¡A¤@ª½¨ì2015/06/03ªÑªF·|¤W¤½¥q´£¥X¥¿¦¡¦^À³»P¸ÑÄÀ¬°¤î¡A¦b³oÓª©¤W¦@¦³¬ù641-270=371½g¶K¤å¡AŲ©¹¦³§U©óª¾¨Ó¡A¦b¥Ø«e³oÓµ¥«ÝASCO«eªº¤é¤lùØ¡A¤j®a¤£§«¥h¦^ÅU¤@¤U³o¬q¾ú¥v¬O«ç»ò¨«¹L¨Óªº¡A´X¥G³£¬O°¾¦V¼ÖÆ[¸ÑŪ¡Aı±oPD229¤£¥i¯à¬O´c¤Æªº¤H¼Æ¡A³sPD=Pharmacodynamic³£¥X¨Ó¤F¡A§Y¨Ï¨ì¤F5/28¤W¤È§Ú°Ý¹L¤½¥q¡AµS¿Ý¨ì¤U¤È¶K¥XPD229´N¬O´c¤Æ¤H¼Æ«á¡]²Ä387½g¦^À³¡^¡Aª©¤WÁÙ¬O«Ü¦h¤H¤£Ä@¬Û«H¡A¬Æ¦Ü½èºÃ´£¨Ñ§Ú°T®§¨Ó·½ªº¤H©~¤ß¥r´ú¡K¡F¨Æ¹ê¤W´N±`²z¦Ó¨¥¡A»`¶°Pharmacodynamicªº¸ê®Æ¬Ophase Iªº¥Øªº¡A²zÀ³¤£·|¦A¥X²{¦bPhase II¤¤¡CµM«á«á¨Ó¤S¦³¬JµM¤w¸gµo¥Í142¤H¨Æ¥ó¤F¡A¬°¦óÁÙ¬O¤£¸Ñª¼ªº°g«äªºª§½×¡A¨Æ¹ê¤W¡ARabbit¤j»P§Ú¦¦¤w¾\¹LProtocol¡A¥L«á¨Ó¤]¤@¦A¦bª©¤W·t¥Ü¤j®a¥h¤U¸ü¸Ó¤åÄm«á¦A°Q½×¡A«Ü¥i±¤¦a¡A¦ü¥G¬ÝÀ´/¤U¸üªº¤HÀ³¸Ó«Ü¤Ö¡A·í¤¤©ú¸ü¹F289¤H¨Æ¥ó®É·|/n¸Ñª¼¡A©Ò¥HPD229·íµM«ö§L¤£°ÊÄ~Äò¶i¦æ¸ÕÅç¡Fê©ó³B³B¼Ð¥ÜµÛ¾÷±K¤å¥óªº¦r¼Ë¡A¦b¸Ñª¼«e§Ú̬O¤£´±¤j³â³â¦a¦bª©¤W©ú¥Üpµe®Ñ¤º®eªº¡]²q·Q¤j´¿¦b¦Pª©5/27»¡¥L¤]Ū¹L¡FPage.18¡F²Ä325½g¦^À³¡^¡C ¤§©Ò¥H¦^ÅU³o¬q¾ú¥v¡A¬O¦]¬°§Ú¦b¸Ñª¼«á¤@ª½¦b«ä¯ÁµÛ¤@Ó°ÝÃD¡A¤@¸ô¤U¨Ó¦³¨S¦³þÓÀô¸`ÂI¬O¥i¥HÅý§ÚÌ´£¦µo²{PFSµLªk¹F¼Ðªºµïµ·°¨¸ñ¡Hµ²ªGµo²{¦ü¥Gª©¤W³£¬O°¾¦V¼ÖÆ[ªº¨¥½×¡A³sÅÒ¸Ö¤]¨Ó§U°}¡K¡]§Ú²{¦b·Q¡A©Î³\§Ú¸Ó³Q¦C¤JÀY¸¹¾Ô¥Ç¡F¬Æ¦Ü¦³¤HÃhºÃ§Ú¬O¤½¥q¬£¨Óªº¥´¤â¡K¡^¡C³o¬q¦^ÅU¯Âºé¬O¹ï¨Æ¤£¹ï¤H¡A¦U¦ì¤£n¥Í®ð¡C ¨ì¤FªÑªF·|«e¤@¤Ñ6/2¤W¤È¡A§Q¯A¤j¤t¤j²Ä¤@¦¸¦b¯E¹©ª©µo¨¥¡]2015/6/2¤W¤È09:34:52²Ä591½g¦^À³¡^¡A³o½g¶K¤å²{¦bŪ¨Ó¬Û·íĵ¥@¡A¥u¥i±¤·íªì¯àºV¿ô¦h¤Ö¤H¡HÀ³¸Ó¦³«Ü¦h¤Hı±o³o¤Ñ¥~¸¨Ó¤@µ§ªº©Ç«È¡A«ç´±«_¤j®a¤@P¬Ý¦nªº®ðª^¡A»¡¤@¨Ç¤£¬O«Ü°Q³ßªº¸Ü¡K¡A¨Æ¹ê¤W¥L´£¨ì¤F§K¬ÌÀøªk©µ¿ð¤ÏÀ³ªº·§©À¡C ¡u¡K¦]¦¹«ÂÐ¥ý«e©Òz¡A¹êÅç¤@©w·|¶]§¹¡A¬Ý¬Ý¬O§_¦³ªø§À®ÄÀ³¥X²{¡A¥H¤Îªø§À®ÄÀ³¬O§_¾A¥Î©ó¯S©w¦¸±Ú¸s¡B¦]¦¹Àø®Ä§ó¦nµ¥µ¥¡C¡K¡v ¡u¡K¥i¯àºn°ÝÃD¬O¡G822¨ì©³¯à¤£¯à©µªøOS§a¡H¨ä¦¸¡A´Nºâ¸~½FÅܤj¡A¯f¤HªºQoL (Quality of Life)¦³§ïµ½¶Ü¡]QoL¦n¹³¤]¨S¦³¦C¬°°lÂÜ«ü¼Ð¡^¡H¤ñ¦p¸~½F¦]¬°T cell®û¼í¦ÓÅܤj¡A¦ý¬O¨ä¹ê¸~½F¤º³¡Àù¯g²ÓM¤w¸g³Q²M°£¤j¥b¡H¡K¡v ¥H¤Î¥L©ó¦Pª©2015/6/2 ¤U¤È05:57:56¦A¦¸¶K¤å¡]²Ä630½g¦^À³¡^¡G ¡u¡K§Ú¬Ý¹L«D±`¦h¸Ñª¼«áPFSªºK-M curve¡Aºâ¥X¨Ó¸òì¥ýªO¤Í¼ÒÀÀ§¹¥þ¤£¤@¼Ëªº¨Ò¤l¡A¦Ó¥BPFS¨Ã¤£¯à·í¦¨¬Oµ¹ÃÄÃÒªºprimary point¡A¤@©wn¦³OS¡K¡v ²{¦bŪ¨Ó¦r¦r¯]¿Y¡A¦p¹p³e¦Õ¡A¥u¬O·í®ÉÀn¤lÅ¥¹p¡C ¥h¦~¬YÓ®ÉÔ§Ú¤]´¿°Ý¦U¦ì¡A822¦³¨S¦³¬Æ»òº|¬}©Î¬Oª¼ÂI¬O§Ų́S·Q¨ìªº¡H·íªì¦ü¥G¥u¦³IrisWu¤j´£¨ì¥i¯à¦³Åܲ§©Êªº°ÝÃD¡A¨Ã¨S¦³¤Hµo²{§K¬ÌÀøªkªº¯S©Ê¨Ã¤£§Q©óPFS¡C¦ý¬O¨Æ¹ê¤W¡A2013¦~´N¦³¤åÄm²M·¡«ü¥X¤F¡]§ãµÃ¡I§ãµÃ¡I¡^¡K ²³æ¦a»¡¡A¦pRabbit¤j»¡¹Lªº¡A³o®Ú¥»¬O¡uª¾ÃÑ¡vªº¤£¹ïºÙ¡A¯à©Ç½Ö©O¡H ³o¨â¦~¦h¨ÓŪ¤F¦³¥Í¥H¨Ó³Ì¦hªº¤å³¹¡AÀ³¸Ó±Nªñ¨â¦Ê¡A°¾°¾PD-1/PD-L1ªº¤å³¹¤£¤Ó¥h¬Ý¡Aì¦]«Ü²³æ¡A¦]¬°¬Ý¨ì°Æ§@¥Î¨º»ò¦h¡]Grade III¡BIV¡K¡^¡A¸ò822«ç»òÄvª§©O¡H©Ò¥H«ª©ó¤@¶¨¤§¨£ªº¥N»ù¡A´N¬O¿ù¹L¤F·s¿³§K¬ÌÀøªk·sÃĪº¯S©Ê¤w¦³·sªºµo²{»Pµoªí¡Aµ¥¸Ñª¼«á¤Î¦Ñ¥v¥Sªº¬ã¨s¤~Ååı¡A¤w¸gºC¤F¤@¤j¨B¡C ¹ï¤½¥q¦Ó¨¥¸Ñª¼¤é¬O2/21¡F¦ý¹ï§ë¸ê¤H¨Ó»¡¸Ñª¼¤é¬O6/4¡A¯u¬O§é·Ù¤H¡A§Ú·Q¤½¥q¤]¬O©l®Æ¥¼¤Î¡A¤]Åý¨rÆN¦³ª®À»¤§¾÷¡C ´n¼Û¤O¤§¤£¶e¡A¦A¦¸´°½Ðª©¤W¥Í²Î°ª¤âÌ¡A²q·Q¤j¤j¡B¤p©_¤j¡B¦Ñ¥v¤j¡B¹Ç¤j¡B«ù¤[ªº¯E§J¤j¡B¥xÁÞ¤j¡B¤Ñ©R¤j¡KÁÙ¦³³\¦hº|¦Cªº¤j¤jÌ¡A±Ð±Ð§Ú̧a¡I Tai-Tsang Chen. (2013). Statistical Issues and Challenges in Immuno-Oncology. ¡]link.springer.com/article/10.1186%2F2051-1426-1-18 ¡^ Journal for Immunotherapy of Cancer, 1:18. ¨ºÓFig.1¡]§ãµÃ¡I§ãµÃ¡I¡^ Uno, H, Claggett, B, Tian, L, et al. (2014). Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis.¡]www.ncbi.nlm.nih.gov/pubmed/24982461 ¡^³o¤@½gn®³¨ìÅv¤~¯àŪ¥þ¤å JCO, 32(22): 2380-2386. Tai-Tsang Chen. (2015). Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.¡]jnci.oxfordjournals.org/content/107/9/djv156.abstract ¡^¥i±¤¤F¡A³o¤@½g¤]¬O¡A¦U¦ì¬Ý¤£¨ì¥þ¤å¡A½Ð¦Ñ´¤jÀ°¦£§a¡C Journal of the National Cancer Institute, 107(9): djv156. Rosemarie Mick and Tai-Tsang Chen. (2015). Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.¡]cancerimmunolres.aacrjournals.org/content/3/12/1292.abstract ¡^ Cancer Immu |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/5/3 ¤W¤È 07:31:17²Ä 1456 ½g¦^À³
|
¤j®a¦¦w ³o½g¬ã¨s¬O±q"°ò¦]"¥Xµo,¤j®a°Ñ¦Ò~ ¨ÅÀù¦¨¦]¬ã¨s¦³¬ð¯}©Êµo²{ ¤¤¼s·s»Dºô ¡V 2016¦~5¤ë3¤é ¤W¤È6:34.. ¨ÅÀù¦¨¦]¬ã¨s¦³¬ð¯}©Êµo²{ ¨ÅÀùªº¬ã¨sÀò±o«¤j¬ð¯}¡I¬ì¾Ç®a»¡¡A¥L̹ï¨ÅÀù§Î¦¨ªºì¦]¡A´X¥G¤w¸g¦³±µªñ¥þ±©Êªº¤F¸Ñ¡A³o¶µ¥Zµn¦b¦ÛµM´Á¥Z¤Wªº¬ã¨s¡A³Q§Î®e¬O¨ÅÀù¬ã¨s¤Wªº¤@Ó¨½µ{¸O¡A¥¦¦³¾÷·|¹ï¨ÅÀùªº¹w¨¾©MªvÀø¡A±a¨Ó¬ð¯}©Ê¶i®i¡C¡]®L©ú¯]³ø¾É¡^ °·±dªº¨Å©Ð²ÓM¡A¬°¤°»ò·|ÅÜÃa¡A³o¶µ³W¼ÒªÅ«eªº¬ã¨s¡A°ò¥»¤W¥i¥H»¡¸Ñ¶}¤F©Ò¦³Á¼¹Î¡C^°êÀù¯g¾Ç·|»¡¡A¬ã¨sµo²{¹ï©ó¨ÅÀù·sÃĪº¬ãµo¡A¦ÜÃö«n¡C n¤F¸ÑÀù¯gªºì¦]¡A¥²¶·¥ý¤F¸Ñ°ò¦]¨s³º¥X¤F¤°»ò°ÝÃD¡A¤~·|Åý°·±dªº²ÓMÀù¤Æ¡C°ê»Ú¬ã¨s¹Î¶¤À˵ø¤F560Ó¨ÅÀù¯f±wªº¿ò¶Ç±K½X¡A¤HÃþªº°ò¦]¹ÏÃЦ@¦³¤T¤Q»õ²Õ°ò¦]±K½X¡A»¡©ú¤F³o¶µ¬ã¨s¤uµ{¤§¯E¤j¡C¬ã¨sµo²{¦³93¹ï°ò¦]¦pªG¬ðÅÜ¡A´N¦³¥i¯à²£¥Í´c©Ê¸~½F¡C³o¤¤¶¡¦³¤@¨Ç¬O¹L¥h´N¤w¸gª¾¹Dªº¡A¤£¹L³o¤@¦¸ªºµo²{³Ì¬°¥þ±¡C¥¦¥i¥H¬°¨ÅÀù·sÃĬãµo¡A´£¨Ñ§ó©ú½Tªº¤è¦V¡A¹L¥h¤Q¤¦~¨Ó¡A¨ÅÀùªºÃð¹vªvÀø¡A¦¨®Ä¤w¸gÀò±oÃÒ©ú¡A¤£¹L¬ì¾Ç®aĵ§i¡AÀù¯g¬O¤dÅܸU¤ÆªºÅ]°¡A¥¦Ì·|²£¥Í§ÜÃÄ©Ê¡A¥t¤@ÓÃa®ø®§¬O¡A¬ã¨sµo²{¡A¦Ê¤À¤§¤»¤Qªº¨ÅÀù¡A³£¶°¤¤¦b¤QºØ°ò¦]¬ðÅÜ¡A³oªí¥Ü¡A¨ä¾l¦û¤ñ¤£¨ì¤@¥bªº¨ÅÀù¡A¬O¨ä¥L¤K¤Q¦hºØ°ò¦]¬ðÅܳy¦¨¡A³oÃþ¤ñ¸û¨u¨£ªº¨ÅÀù¡A¦]¬°¥«³õ¤Ó¤p¡A¯à§_¹ïÃļt²£¥Í»¤¦]¡A±oµe¤W¤@Ó¤j°Ý¸¹¡C ¨ú¦Ûhttps://tw.news.yahoo.com/%E4%B9%B3%E7%99%8C%E6%88%90%E5%9B%A0%E7%A0%94%E7%A9%B6%E6%9C%89%E7%AA%81%E7%A0%B4%E6%80%A7%E7%99%BC%E7%8F%BE-223432211.html |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/5/2 ¤U¤È 11:51:49²Ä 1455 ½g¦^À³
|
ÁÂÁÂCliff¤jªº¸ÑÄÀ©M¹x¥Û¤jªº¸É¥R»¡©ú¡A¬Ý¤FHope Rugoªº½Í¸Ü¡A§Ú¹ï¨ä¤¤¤G¬q¸Ü¤ñ¸û¦³·P·Q¡A¨ä¤¤¡A²Ä¤@¬q¸Ü¬OI think the whole idea that if you don¡¦t block the immune response¡Xand maybe that¡¦s expressed by TILs, these tumor-infiltrating lymphocytes¡Xthat maybe that makes a big difference, particularly in the more aggressive phenotypes of breast cancer where TILs have correlated with better outcome in patients.¦pªG§A¤£ªýÂ_§K¬Ì¤ÏÀ³¡]¿E¬¡§K¬Ì¤ÏÀ³¡^¡A¤]³\±N¥Ñ¸~½F®û¼í²O¤Ú²ÓM¡]tumor-infiltrating lymphocytes, TILs¡^¨Óªí²{¡A¥i¯à²£¥Í«Ü¤jªº¤£¦P¡A¯S§O¬O¦bTILs¦³¥¿¬ÛÃö¨ÅÀù§ó¿n·¥ªí«¬¡Aµ¹¤©¯f±w±a¨Ó§ó¦nªº®ÄªG¡C ²Ä¤G¬q¬q¸Ü¬OI think the complexities of this is whether the TILs are in the stroma or in the tumor, or where they are. But it does seem like no matter where the TILs are, it does make a difference in prognosis. Adam M. Brufsky, MD: If you have them, maybe they¡¦re indicative of an active immune response. Hope S. Rugo, MD: That¡¦s one of the things.§Ú·Q½ÆÂø©Ê¬OTILs¬O§_¦b°ò½è©Î¸~½F¡A©ÎªÌ¦b¦ó³B¡ATILs¦ü¥G¤£ºÞ¦b¨º¸Ì¡A¥¦³£¨Ï¹w«á¤£¦P¡CAdamªí¥Ü¡A¦³¤FTILs¡A´N´£¥Ü¦³¿n·¥ªº§K¬Ì¤ÏÀ³¡AHope»{¬°¡A³o´N¬O¨Æ¹ê¤§¤@¡C¡]¸~½F®û¼í¤ÏÀ³´N¬O¿n·¥ªº§K¬Ì¤ÏÀ³¡^ ¨â¬q½Í¸Ü¡A§Ú·|·Q¨ì¨ÅÀùTILs¼Æ¥Ø¹ï¹w«á¡]¬O«ü®Ú¾Ú¸gÅç¹w´úªº¯e¯fµo®i±¡ªp¡^¦³¨ä¬ÛÃö©Ê¡A¦P®É³o¤]¬O¿n·¥ªº§K¬Ì©Ê¤ÏÀ³¡C Hope Rugo½Í¸Ü¤¤¦h¥bÀô¶PD-1 inhibitor¤ÎPD-L1 inhibitor§K¬ÌÀˬdÂI¡A¥¼¤½¶}´£¥ÜGlobo HÁÞ¤À¤l¦bªvÀø¨ÅÀù¤¤§êºtªº¨¤¦â¡A¤]³\°ò©óASSOªº«O±K¨ó©w¡C¤£¹L¡AÂǥѰ»´ú¨ÅÀùªºTILs¼Æ¥Ø¹ï©ó¯f±w¹w«á³£¬O¬ÛÃö¨Ó¬Ý¡A¦o´Á«Ý§K¬ÌÀøªk¤]¯à¤ñ·Ó¿ì²z¡AHope Rugo¨ä¤¤ªº»y®ð¦ü¥G§ó¥[°í©w¡A·íµM¡A¦³¤@ºØ¥i¯à¬O¦o¬Ý¤F822¼Æ¾Ú«á²£¥Í«H¤ßªºµ²ªG¡A¤£¹L¡A§ó¤jªº¥i¯à¬O¡A¦o¬Ý¤F¤£¤Ö§K¬ÌÀøªk©MÁ{§É¼Æ¾Ú©Ò±o¥X¨Óªº¼È®É©Êµ²½×¡C ©Î³\¦³¤H»¡¡A±q¤W±¨º¨Ç½Í¸Ü¡A¬Ý¤£¥X©M822¦³¥ô¦óªºÁpµ²¡A¤Å°µ²o±jªº¸ÑÄÀ¡Aªº½T¤]¬O¨Æ¹ê¡A¦ý§Ú¨p¤ß»{¬°¡A¤£ºÞ¬O¨º¤@ºØ±¡§Î¡A822ªº§K¬ÌÀøªkÃø¹D¬O¦o»y®ð°í©w¤¤ªº¨Ò¥~¡H ¹ï·Ó¦o¦b¯E¹©¸Ñª¼«áªº·s»D½Z¡AWhile the study did not meet its originally designed primary endpoint, the encouraging efficacy seen in patients who demonstrated an immune response to the vaccine support the validity of an immunological approach to treating breast cancer and these data will help us develop a global phase 3 study that will provide the data to further elucidate the value of OBI-822 and support the registration of this promising new product. ¦pªG822¬O¨Ò¥~¡A¦o»Ýn¿Ë¦ÛI®Ñ¨Ã¦bASCO¤W¥x¾á¥ô¥DÁ¿¤H¡H |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/5/2 ¤W¤È 12:20:35²Ä 1454 ½g¦^À³
|
ÁÂÁÂCliff¤j¤Î¹x¥Û¤jªº»¡©ú,Åý§Ú̧ó²M·¡¤F¸Ñ822ªº¥«³õ©w¦ì¤Î¥¼¨Óµo®i¤è¦V,·P®¦! |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/5/1 ¤U¤È 07:54:08²Ä 1453 ½g¦^À³
|
Cliff¤j¤¶²Ðªº®y½Í¤¤´£¨ì¡A¨ÅÀùªº§K¬ÌªvÀø¶i®i½wºC¡A¥Dn¦b©ó¨ÅÀù¨S¦³µo²{·s§Üì (neoantigen)¡A¦Ó¶Â¦â¯À½F»PªÍÀù¦b³o¤è±ªºµo²{¸û¦h¡C³o¨âӮרҡA¦³¥t¤@½g¤å³¹¦³¤ñ¸û©ú½Tªº¼Æ¦r¡G global.onclive.com/web-exclusives/hope-rugo-on-pembrolizumabs-potential-in-erher2-breast-cancer ¨âÓ·sÃĹïPD-1/PD-L1ªºORR³£¦b20%¥ª¥k¡A¯E¹©822ªºORR¼Æ¦rÁÙ¤£ª¾¹D¡A©Ò¥H¨Sªk¤ñ¸û¡C ¦³¤@ÂI¥i¥H¤ñ¸ûªº¡A¬OÁ{§É¸ÕÅç¹ï©óPD-L1 over-expression (>=1%) ªº¯f¤H¿z¿ï¼Æ¦r¡C240¦hÓ ER positive/HER-2 negative ªº¯f¤H¤¤¡A¿z¥XªºPD-L1 positive ¯f¤H¥u¦³48¤H (19%)¡C¨ä¤¤¥u¦³25¤H¨Å骬ªp¾A¦X°Ñ¥[¨ü´ú¡C ¶ÀÁ`»P±i¸³³£»¡¡A©¹«á 822 §ä¯f¤HµL¶·°µ GH ¿z¿ï¡A¥un¬Ý§K¬Ì¤ÏÀ³¡C¦pªG¦³¥|¿§K¬Ì¤ÏÀ³ªº¯f¤H¨ì¹FÁ`¯f¤H¼Æªº¥|¦¨©Î¤»¦¨¡A´Nªí¥Ü 822 ªº¼ç¦b¥«³õ¬O©Ò¦³ PD-L1 ªv¨ÅÀùÃĪ«ªº¨â¿©Î¤T¿¡C ¥t¥~¦b°Æ§@¥Î¤è±¡A¨ü´úªº25Ó¯f¤H¤¤¡A¦³¤@Ó¤T¯Åªº¦ÛÅé§K¬Ì¨xª¢¤ÏÀ³(«á¨Óresolved)¡BÁÙ¦³¥Òª¬¸¢¥\¯à¤®¶i¡B¥Òª¬¸¢¥\¯à°I´î¡B»P¤@Ӫͪ¢¤ÏÀ³¡CDr. Rugo»{¬°³o¼Ëªº°Æ§@¥Î¬O¥i±µ¨üªº¡Cµ¥¨ì 822 ¼Æ¦r¥X¨Ó¡A¤]¥i¥H¤@°_¤ñ¸û¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/4/30 ¤U¤È 11:52:14²Ä 1452 ½g¦^À³
|
822ªº¤fÀY³ø§i³Q½s¤JTriple-Negative/Cytotoxics/Local Therapy³o¤@²Õ¡A³o¤@²Õ¦³8½gn³ø§i¡A±qÃD¥Ø§PÂ_¤£¥þµM³£¸ò¤T³±¨ÅÀù¦³Ãö¡F¦pªG822¬O¦]¬°»P¤T³±¨ÅÀù¦³Ãö¦Ó³Q½s¤J³o¤@²Õ¡A¨º¦X²zªº±À´ú¬O¸Ñª¼ªº¼Æ¾Ú¦b¤T³±¨ÅÀù¤è±¥i¯à¦³¤ñ¸û¥iÆ[ªºªí²{¡CÓ¤Hı±o¤£¬OÃa¨Æ¡C Y¯à¦]¦¹¡]¹ï¤T³±Àù¦³¨ô¶Vªí²{¡^¥ý¨ú±oFDA«C·ý¡AÀò±o¦³±ø¥óªºÃÄÃÒ³\¥i¡A¨º·íµM¬O§ó¦n¡A¦¨¥\¾÷·|¦³¦h°ª¡H¨S¬Ý¨ì¼Æ¾Ú·Q²q¤]²q¤£¨ì¡C ¤T³±¨ÅÀù¾ãÅé¡]¤£¤À´Á¡^ªvÀøªº¤¦~¦s¬¡²v¬ù¬°77¢H¡]¨ä¥L«¬93¢H¡^¡]µù¤@¡^¡F¥½´ÁÂಾ©Ê¤T³±ÀùªvÀøªºmedian OS¬°13Ó¤ë(range 1¡V100 months)¡]¦³¦s¬¡100Ӥ몺³á¡I¡^¡A¬Û¸û©ó¾ãÅéÂಾ©Ê¨ÅÀùªºmedian OS¬O2.0¡V3.5¦~¡Aªº½T¬O»¹¤F³\¦h¡]µù¤G¡^¡C §K¬ÌÀøªk¥Î©ó¤T³±¨ÅÀù©|¦bµÞªÞ¡A®Ú¾Ú¦Ñ¥v¤jªº¬ã¨s¡AKeytruda¡]Merck¡FPD-1¡^¡FAtezolizumab (Roche¡FPD-L1)¡FAvelumab (Pfizer¡FPD-L1)¦ü¥G¦¨ÁZ³£¤£«ç»ò¼Ë¡Aµ¥ASCOªº¼Æ¾Ú´¦¾å´Nª¾¹D822¦æ¤£¦æ¡C ¬Q©]è¥XÄlªº¡ADr. Rugo½Í¤T³±¨ÅÀùªº·s¿³ªvÀø¡A«üªº¬OPD-1/PD-L1¡A¦o¤w¸g¬Ý¹L822¼Æ¾Ú¤F¡A¦³¿³½ìªº¤H¤£§«¥J²Ó¬Ý¬Ý¦oªº¡u»y®ð¡v¡A¦³¨S¦³³zÅS¥XGH seriesªº¥i¯à°T®§¡C¡]¦b¨¥½Í¤¤·íµM¨S´£¨ìGH series¥Î©ó¤T³±Àù·|¦p¦ó¡A¦ý¬O½Í¨ì·s¿³ªvÀø¤èªk¡A¦o¹ï822¤ßùØÀ³¤w¦³¼Æ¡A«o¤S¤£¯à²{¦b»¡¥X¨Ó°Q½×¡A¬O¤ß¸Ì«ÜåxÁÙ¤£¯à»¡©O¡HÁÙ¬O¼Æ¾Úso so¤£È±o¤@ÅU¡H¬Ý¦U¦ìªº¥\¤O¯à¤£¯àÅ¥¨ä¨¥¦Óª½Æ[¨ä¤ß¡H¡^¡]global.onclive.com/peer-exchange/advanced-breast-cancer-update/immunotherapy-in-breast-cancer ¡^ Ó¤H¤£¾á¤ßY¹ï¤T³±¨ÅÀùªºÀø®Ä¬ð¥X·|ÁY822ªº¾AÀ³¯g¡A¤Ï¥¿GH¦b¨ÅÀù¡A¬Æ¦Ü¦b¨ä¥LªºÀù¯gªºªí²{²v¤j®a¤ßùئ³¼Æ¡AÁöµM53¥÷¼Ë¥»¬O¤Ö¤F¨Ç¡CY¹ï¤T³±¨ÅÀù¦³®Ä¡A¹ï¥I¨ä¥L«¬§Oªº¨ÅÀù¡Aµ¥·s¤T´Á¸ÕÅç«á¦A¨Ó¦¬ÂÐ¥¢¤g¤S¦ó§«¡C¥un¯à®³¨ì²Ä¤@±iÃÄÃÒ¡A´Nªí¥ÜGH seriesÀù¯gªvÀø¾Ç¬O¥i¦æªº¡A¨ä¥¦ªº«¬§O¡AºØÃþ§OªºÀù¯g¤]´N§ó¨ã§Æ±æ¡A·íµM½Í§P±ÂÅv®É¤]·|§ó¦³§Q¡C µù¤@¡G 1.2014-¡uA 2007 study of more than 50,000 women with all stages of breast cancer found that 77% of women with triple-negative breast cancer survived at least 5 years, versus 93% of women with other types of breast cancer.¡v¡]www.breastcancer.org/symptoms/diagnosis/trip_neg/behavior¡^ 2. 2012-¡uMedian overall survival (OS) for patients with metastatic TNBC was 13 months (range 1¡V100 months), which compares unfavourably with median OS for the general metastatic breast cancer population (median OS 2.0¡V3.5 years)¡v¡]annonc.oxfordjournals.org/content/23/suppl_6/vi46.full¡^³o¬O¤ÆÀøÃĪ«ªº¦¨ÁZ¡C. |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/30 ¤W¤È 02:38:32²Ä 1451 ½g¦^À³
|
¦Ñ´¤j¡A ¤p§Ì»¡±z¡y¦³½Õ¬d¤~¦³µo¨¥Åv¡z¡A¤£¥u¸Ø±z¨¥¤§¦³ª«¦³¾Ú¡AÀ³¸Ó¦h¦hµo¨¥¡A¤@¤è±¤]¬O¦Û¸ØÃѳf¡C ÁÙ¦³¡A³o¥y¸Üªº¥X³B¡A·í¦~¬O¤ò¦Ñ·Ý¤l»¡ªº¡C |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/29 ¤U¤È 11:27:42²Ä 1450 ½g¦^À³
|
»P¦¹¦P®É¡A¥ç¦³¤H¥H«Dªk¤è¦¡¡AÅý§ó¦h¤H±µÄ²¨ìÀ³ÄÝ©ó¥þ¤HÃþªº¾Ç³N¦¨ªG¡C ¾Ç³N¬É®üµsÆW 2011¦~¦¨¥ßªºSci-Hub¡A¥i¿×¾Ç³N¬ÉªºNapster¡B®üµsÆW¡X¡X¥ô¦ó¤H³£¯à¦bºô¯¸¤W§K¶O¤U¸ü¾Ç³N½×¤å¡C¨Ï¥Î¤èªk«D±`²³æ¡A¥un¶i¤Jºô¯¸¡A¿é¤J·j´MÃöÁä¦r¡A«K·|¥X²{»ª¦üGoogle¾Ç³N·j´Mªºª©±¡A¥un«ö¤U¬ÛÃö³sµ²¡ASci-Hubªº¨t²Î«K·|¦Û°ÊÂà¥h½×¤åªºpdfÀɮסC ¹ï©ó¸g±`n§ä½×¤å¡A«o³Q¥I¶OÀð¾Ý¦íªº¤H¦Ó¨¥¡ASci-Hubªº¥X²{²@µLºÃ°Ý¬Oӳ߰T¡C¹ï©ó¾Ç³N¥Xª©°Ó¦Ó¨¥¡A´N¹³«Dªk¤U¸ü¹q¼v¹ï©ó²ü¨½¬¡¤@¼Ë°Q¹½¡C ¥h¦~6¤ë¡A·R«ä°ßº¸¦b¬ü°ê¤J¸[±±§iSci-Hub¡An¨D³Ð¿ì¤HAlexandra ElbakyanÃö³¬¸Óºô¯¸¨Ã½ßÀv·l¥¢¡C¦P¦~10¤ëªk°|¦P·N·R«ä°ßº¸ªºn¨D¡A¥ý¸T¤îSci-Hub·í®Éªººô§}¡]www.sci-hub.org¡^Ä~Äò¹B§@¡C ¤£¹L¦b¬ù¥bÓ¤ë«á¡ASci-Hub¤w¸g¥H¥t¤@Óºô§}¡]www.sci-hub.io¡^«·s¯B²{¡A¨Ã¼W¥[¤F·tºô¡]dark net¡^ºô§}¡]scihub22266oqcxt.onion¡^¡A¤]µù¥U¤F¦n´XÓºô§}³Æ¥Î¡Cªñ¤é·sºô§}¤]µLªk³s¤W«á¡ASc-Hub¦b¨ä©x¤èTwitter¤W¦VŪªÌ¤½§G¨ä¥Lºô§}¡C ¦b³Ì·s¤@´Áªº¡m¬ì¾Ç¡n´Á¥Z¡A¥Íª«¾Ç®a¤Î¬ì¾Ç°OªÌJohn Bohannon±qSci-Hub³Ð¿ì¤HElbakyan¤â¤W¡A¨ú±oºô¯¸¥Ñ¥h¦~9¤ë¦Ü¤µ¦~2¤ëªº¼Æ¾Ú¡A¥]¬A¤U¸ü½×¤åªº¼Æ½X¹ï¶H¼ÐÃÑ¡]digital object identifier, DOI¡^¥H¤Î¤U¸üªÌ³Ì±µªñªº«°¥«¡X¡X¬°«O»Ù¨Ï¥ÎªÌ¨pÁô¡AElbakyan¨S¦³¥æ¥X¥ô¦óIP¦a§}¡C ¤U¸ü¼Æ¾Ú ¥Ø«eSci-Hub¤w¸gÀx¦s¤F5000¸U¥÷½×¤å¡A¾î¸ó¦UÓ¬ì¾Ç»â°ì¡C§Y¨Ï¦b¥h¦~11¤ëºô§}³Q«Ê¡ASci-Hub¦bÂà´«ºô§}«á¤TÓ¤ë¡A¤w¸g¶W¶V³Q«Ê«eªº¤U¸ü¶q¡A2¤ëªº¤U¸ü¦¸¼Æ¶W¹L621¸U¡C³o¬q´Á¶¡¤¤°ê¦³440´Á¦¸¤U¸ü¡A¦L«×¦³340¸U¦¸¡A¥ì®Ô«h¦³260¸U¦¸¡C Bohannon¤ÀªR¤FSci-Hubªº¤U¸ü¼Æ¾Ú¡A¾ã²z¤U¸ü½×¤å©ÒÄݪº¾Ç³N¥Xª©ªÀ¥H¤ÎÁ`¤U¸ü¦¸¼Æ¡C¦bªñ2800¸U¦¸¤U¸ü¤¤¡A¦³ªñ930¸U¦¸¤U¸üªº½×¤åÄÝ©ó·R«ä°ßº¸¡A¬I´¶ªL®æ¡]Springer¡^¥H263¸U©~¦¸¡C¦Ó®Ú¾Ú·R«ä°ßº¸¥À¤½¥qRELX¶°¹Îªº³ø§i¡A2015¦~·R«ä°ßº¸¦b¨äºô¯¸¤W¿ý±oªº½×¤å¤U¸ü¦¸¼Æ±µªñ9»õ¡C ®Ú¾Ú°O¿ý¡A´X¥G¥þ²y¦U¦a³£¦³¤H±qSci-Hub¤U¸ü½×¤å¡A¥Ñ²Ä¤T¥@¬É¦Ü²{®Éªº¬ì¾Ç¤j°ê¬ü°ê¡C¨Æ¹ê¤W¡A¬ü°êªº¤U¸ü¶q¦ì©ó«Xù´µ¤§«á¡A¦W¦C¥þ²y²Ä5¡A¦³¤£¤Ö¤H§Y¨Ï¦³¤j¾Çªº±b¤á¡A¤´µM¨Ï¥ÎSci-Hub§ä½×¤å¡C ¤è«K©Î¬O¨ä¤¤¤@Óì¦]¡C¦õªvµØ²±¹y¤j¾Çªºª«²z³Õ¤h¥ÍGil Forsyth¸ÑÄÀ¡AÁöµM¤j¾Ç©Î¦³q¾\³¡¥÷´Á¥Z¡A¦ý·í¥L¦bGoogle¾Ç³N·j´M§ä½×¤å®É¡A»Ýn¥H¤j¾Ç±b¤áµn¤J¡A¦A¬Ý¬Ý¯à§_¤U¸ü½×¤å¡C¬Û¤Ï¡A¨Ï¥ÎSci-Hubªº¸Ü¡A¥u»Ýn¿é¤J½×¤å¼ÐÃD¡A´N·|¥X²{½×¤å¡C ¥t¤@³Õ¤h¥ÍNatalia Clementi«hªí¥Ü¡A¤j¾Ç¥¼¥²¦³q¾\¤@¨Ç¸û±Mªùªº´Á¥Z¡A§Y¨Ï¹ï¨ä¬ã¨s»â°ì«D±`«n¡C³o¨Ç±¡ªp¤U¡A¦oµLªk¤£¨Ï¥ÎSci-Hub¡C «á³Æ¤è®× ·R«ä°ßº¸¸òSci-Hubªº¶D³^¤´¥¼¦³µ²ªG¡AElbakyanªí¥Ü·R«ä°ßº¸¤£³æ±±§i¦o«IÅv¡A§ó«ü±±¦oIJ¥Ç¡m¬ü°ê¹q¸£´Û¶B¤ÎÀݥΪk¡n¡A»{¬°¦o³z¹L¤J«I·R«ä°ßº¸ªº¹q¸£¨ú±o½×¤å¡C ÁöµMElbakyan©Úµ´³zÅS¦o¦p¦ó¨ú±o½×¤å¡A¦ý¦o½T»{¦³¤£¤Ö¾Ç¬É¤¤¤H¬°¦o´£¨Ñ¨ó§U¡A¦ÛÄ@¥æ¥X¨ä¥Î§@¡]¦Xªk¡^¤U¸ü½×¤åªºµn¤J±b¤á©M±K½X¡C¦³¥Xª©°Ó«ü³dElbakyan¥H³¨³½¹q¶lÄF¨ú¦³Ãö¸ê®Æ¡A¦oªí¥Üµ´µL¦¹¨Æ¡C ¥Ñ©ó¤J«I¹q¸£ªº«ü±±ÄY«¡AElbakyan¥i¯à·|¬ðµM³Q®·¡A³Ì·¥ºÝ±¡ªp¤U¬Æ¦Ü·|³Q¤Þ´ç¬ü°ê¨ü¼f¡C¤£¹L¦o¤w°µ¦n·Ç³Æ¡A§Y¨Ï³Q®·Sci-Hub¤´·|Ä~Äò¹B§@¡A®½´Ú¤w¯àÀ³¥I¦øªA¾¹¶O¥Î¡A¦Ó¦s®w¤¤ªº5000¸U¥÷½×¤å¤w¦³¦hӳƥ÷¡C ¯¬¦U¦ì¤j¤j±ß¦w. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/29 ¤U¤È 11:25:17²Ä 1449 ½g¦^À³
|
¥Í©R»ùȬO¬ü°ê¬F©²³ÌÀu¥ýªº¿ï¾Ü ¬ü°êFDA·|n¨DOBI822¶i¦æ¤T´ÁÁ{§É¸ÕÅç¶Ü? ¤@¦~¬ü°ê°ü¤k¦]¨ÅÀù¦º¤`¤H¼Æ¬ù¹F¥|¸U¤H¡A¤T¦~´N¬O¤Q¤G¸U¤H¡A°²³]¦³¤@ÁûÃĦw¥þ©Ê«Ü°ª¡A¥Í¬¡«~½è«Ü¦n¡A³æÃÄÀø®Ä¤ñ²{¦³ªº¶PÀù¥ÁÙ¦n 50%¥H¤W¡A¤£»ÝÀù¨ÅÀù¨È«¬¡A¤£»ÝÅç§Üì¡A®aÄÝ·ÓÅU¤è«K¡AÃĪ«¬I¥´¤è«K¡A³oÓ¥þ²y¤T´ÁÁ{§É¸ÕÅç°£¤F¬ü°ê71¤H¥~¥]§tÁ{§É¸ÕÅç¬ã¨s¨ü¥þ²y¤jÃļt«H¥ôªº¥xÆW»P»´ä¡AÁú°ê¡A²³¤j¤j»{¬°¬ü°êFDA·|¦Aªá®É¶¡n¨D822°µ¤T´ÁÁ{§É¸ÕÅç¶Ü? |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/29 ¤U¤È 11:23:06²Ä 1448 ½g¦^À³
|
¹x¥Û¤j,¤p¥Ê¥N»x,¦ó»Ý¹Dºp. ¦Ñ´½T¹ê¨S¦³ªþ¤W°Ñ¦Ò¨Ó·½,¤£´L«ìµÛ,¦b°Q½×«Ç¸Ì¥u¦³¯u²z,¦Ñ´¬O¤£¹ïªº. ¦Ñ´¦b¹Î¶¤·|ij³Ì±`»¡ªº¤@¥y¸Ü´N¬O:¦pªG»¡ªº¤£¹ïªº,½Ðì½Ì§ÚªºµLª¾.©Ò¥H§Ú̬ì«Ç¸Ìªº°Q½×³£«Ü¼ö¯P. èè¤~¨ì®a,¸É¬d¤F¤@¤U¨Ó·½¦p¤U: J Invest Dermatol. 2013 Jun;133(6):1462-5. doi: 10.1038/jid.2013.67. The dark side of cyclophosphamide: cyclophosphamide-mediated ablation of regulatory T cells. Becker JC1, Schrama D. ³o¤@½g¬Ofree open access,¤Wºô´N¥i¥H§ì¨ì,¶¶«K³¥¤HÄmÃn©M¤j®a¤À¨É¤@°¦¥\¯à¶W±j¤jªº¯Q¾~! 5000¸U¥÷SCIÂå¾Ç¤åÄm³£¥i¥H¤â¨ì´N¨Ó,±Û«a¤j´N¦A¤]¤£¥Î¥h¤¤°êÂåÃľǰ|¹Ï®ÑÀ]¤F! 1.¥unµn¤J¤U±ªººô¶ sci-hub.cc/ ¦A¶K¤W±z¦bpubmed§äªº½×¤å¼ÐÃDªºdoi¸¹½X,¦p¤W¤@½gªº¬O10.1038/jid.2013.67 ¤@ÁäopenÂê,¤å¥ó§ì¤U¨Ó!§Æ±æ¹ï±z¦³À°§U! SCI-hubªº¥Ñ¨Ó ¤HÃþ³Ì³»¦y«eªuªºª¾ÃÑ¡A²@µLºÃ°Ý¦³¤£¤Ö¦b¾Ç³N¬É¤§¤¤¡A¯d«Ý«á¨ÓªÌµo±¸¡B§ï¨}¡B×¥¿¬Æ¦ÜÂà¤Æ¬°§ïÅÜ¥@¬ÉªºÀ³¥Î¡C¥i¬O¡A¤j¶q´Á¥Z½×¤å³£§x¦b¾Ç³N¥Xª©°Óªº¥I¶OÀð¡]pay wall¡^¤§¤º¡A¤@½g½×¤å¦¬¶O°Ê»³30¬ü¤¸¡C ·íµM¡A¥Xª©°Ó·|«ØijŪªÌq¾\´Á¥Z¡A´NµL¶·³v¦¸¥I¶O¡A»ù¿ú¬Û¹ïn§C±o¦h¡C°ÝÃD¦b©ó¡A¥ô¦ó´¿±µÄ²¹L¾Ç³N½×¤åªº¤H³£ª¾¹D¡A¤@½g¤å³¹I«á¬O¤j¶qªº¾Ç³N¤åÄm¡A¤£·|¥u¨Ó¦Û¤@¨â¥»´Á¥Z¡C §â¤j²³¾×¦b¥~ªº¥I¶OÀð ¦b°ªµ¥±Ð¨|Åé¨î¤ºªº¾ÇªÌ¡A°_½X¥i¥H±q¤j¾Ç¹Ï®ÑÀ]q¾\ªº´Á¥Z¤¤¡A§K¶O¾\Ū½×¤å¡CµM¦Ó§Y¨Ï¬O«¢¦ò¤j¾Çªº¹Ï®ÑÀ]¡A¥ç´¿¸gªí¥Ü¡u¾Ç³N´Á¥Zªºq¾\¶O¤Ó°ª¡v¡A¹N½×¨ä¥L¸ê·½¸û¤Öªº¤j¾Ç¡C¦AªÌ¡A²{®É¤£¤Ö¹ï¾Ç³Nª¾ÃѦ³¿³½ìªº¤H¥¼¥²¯d¦b¤j¾Ç¤§¤º¡A«K·|¦]¬°µLªk¤ä¥I°ª©ù¶O¥Î¦Ó³Q±Æ©Ú¦b¥I¶OÀ𤧥~¡C ¥¿¦p¤£¤Ö¤H«ü¥X¡A¾Ç³N½×¤å§@ªÌ¤j¦h¼Æ¨Ó¦Û¤½©®¸ê§Uªº¤j¾Ç¡A¶i¦æ¥Ñ¤½©®¸ê§Uªº¬ã¨s¡A¦Ó¼f®Ö½×¤åªº¾ÇªÌ¦P¼Ë§K¶O©Î¥H§C»ù¬°´Á¥ZªA°È¡A¥u¬°«P¶i¾Ç³N¬Éµo®i¡Cµ²ªG´N¬O¤£¤Ö¥Ñ¤½²³¸ê§Uªº¬ã¨s¦¨ªG¡A³Q¾Ç³N¥Xª©°Ó¥H°ª»ù½æ¥X¹Ï§Q¡C ¥H¥þ²y³Ì¤j¾Ç³N¥Xª©°Ó·R«ä°ßº¸¡]Elsevier¡^¬°¨Ò¡A¸Ó¤½¥q2015¦~¦¬¤J¶W¹L20»õ^Âé¡A½Õ¾ã«á¸gÀç·¸§Q7.6»õ^Âé¡X¡X¬ùµ¥¦p¹O86»õ´ä¤¸¡A©Î·s¥x¹ôªñ360»õ¤¸¡C §ï²¤è®× ªñ¦~¾Ç³N¬É³vº¥·NÃѨì³oÓ°ÝÃD¡A¹Á¸Õ¥H¦UºØ¤è¦¡ª§¨ú§ïÅܨî«×¡C¨Ò¦p³Ð¿ì¡u¶}©ñÀò¨ú¡v¼Ò¦¡ªº´Á¥Z¡X¡X©Ò¦³½×¤å¥ô¦ó¤H§¡¥i§K¶O¾\Ū¡C¤S©Î¬O¥Ñ¦h®a¤j¾ÇÁp¦X¸ò¥Xª©°Ó¨óij¡A¥H«K¾ÇªÌ¥i¥H§K¥I¥Zµn¶O¥Î§ë½Z¨ì¥Xª©°ÓºX¤Uªº¶}©ñ¦¡´Á¥Z¡C ²üÄõ¬F©²¤µ¥ó¦¨¬°¼Ú·ù²z¨Æ·|¥D®u°ê«á¡A¤]ª§¨ú©ó2020¦~«e¼Ú·ù½d³ò¤ºªº©Ò¦³·s½×¤å¡A§¡¥H¶}©ñÀò¨ú¼Ò¦¡µo®i¡A¥H±À°Ê¬ì¬ã¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/29 ¤U¤È 10:50:45²Ä 1447 ½g¦^À³
|
¥DnÀø®Ä«ü¼Ð¥¼¹F¼Ð¬OºÖ¤£¬Oº× §Ú³ßÅw¤Ï¦V«ä¦Ò¡A°²¦p³o¦¸Á{§Éªì¨B¤½§i¥DnÀø®Ä«ü¼Ð¹F¼Ð¡A¥N»x´N¤j±ø¤F¡A²z¥Ñ«Ü²³æ¡A¥þ²yÀù¯g§K¬ÌÀøªk³]©wPFS³£¨S¹F¼Ð¡A¯E¹©ªºOBI822«o¹F¼Ð¡A³o·|¤Þ°_¬ü°êFDA¤£¬Û«H³oÓ»P²{ªp¤£²Åªºµ²ªG¡A¦]¦¹¨S¦³¹F¼Ð¤Ï¦Ó¬O¹F¼Ð¡A³o±N¦³§Q©ó¥¼¨Ó»P¬ü°êFDA°Q½×¤è¦V®É ªº¦³§Q±¡¶Õ¡A¯à¿Eµo§K¬Ì¤ÏÀ³²£¥Í¨¬°÷§ÜÅ骺 ¦¸±Ú¸s¦bMPFS,MOS¹F¼Ð´N«Ü¦n¡C ¨ä¥L¦pORR,HR¤]«ÜÀu²§ªº¸Ü¡A±¡¶Õ§ó³B©ó¦³§Q¦a¦ì¡A¶ë¯Î¥¢°¨¡AX¤§«DºÖ |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/4/29 ¤W¤È 10:37:36²Ä 1446 ½g¦^À³
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/27 ¤U¤È 11:20:15²Ä 1424 ½g¦^À³ ¦V«e¤j Cancer immune escape is frequently associated with the induction of an inappropriate immune response, i.e., a response that does not inhibit but perhaps even promotes the tumor. Indeed, increased frequencies of tumor-infiltrating regulatory T cells (Tregs) are associated with an impaired prognosis in several cancers. Thus, depletion of Tregs, e.g., by cyclophosphamide, was proposed as a means to boost immune responses to cancer. ¦Ñ´¬O³o¼Ë·Qªº, ¤HÃþ¥v¤W³o¬O²Ä¤@¦¸¬Ý¨ìcyclo©M822¤@°_¥Î,¨âÓÃĪ«´Nºâ¨S¦³¥æ¤¬§@¥Î,À³¸Ó¤]·|¤¬¬Û¼vÅT «ç»ò¥i¯à§A¤ÏÀ³§Aªº,§Ú¤ÏÀ³§Úªº?¤S¤£¬O¸ÕºÞ¹êÅç! ¤]¦³¥i¯à822ªº®û¼í²{¶H(¬Ý°_¨Ó¸~½FÅܤj)¤j¤j¶W¹Lcycloªº§@¥Î©O? |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/29 ¤W¤È 10:25:41²Ä 1445 ½g¦^À³
|
¦³«í¤j¡A ¦hÁÂÀ°¦£¡I |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/4/29 ¤W¤È 09:50:41²Ä 1444 ½g¦^À³
|
¹x¥Û¤j ¤p§Ì¦³¦sÀÉ,»Ýn¦A¶K¤W¥h? |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/4/29 ¤W¤È 09:38:30²Ä 1443 ½g¦^À³
|
¥xÁÞ¤j¤Î²³¤j¦w ¥xÁÞ¤j¦A¦¸ÁÂÁ±zªº»¡©ú! ¤p§Ì¦APO¤W¤½¥q¦^À³ªº¨â¬q¸Ü,¦]¬°¤p§Ì¤]¤£¤Ó²M·¡¤½¥q°w¹ïMOSªí¹Fªº¬Oþ¤@ºØ¤ñ¸û?¨Ñ¤j®a°Ñ¦Ò! 1¡B3/31ªk»¡,¶ÀÁ`»¡ ¯u¥¿ì¦]¬O¥un²£¥Í¦³®Äªº§K¬Ì§ÜÅé¡A¤w¸gÃÒ¹ê³o¸s¯f¤H¹ï©ó¨S¦³¥ÎÃĩΨS¦³¤ÏÀ³ªº¯f¤H¡A³£¦³«D±`¤jªºÁ{§É·N¸q¸ò¦n³B¡A¦Ó¥B§Ú̪¾¹D§K¬ÌÀøªk²{¦b¡A¤j®a²{¦b¦b¬ÝPrimary endpoint ¬O¬ÝPFS¡A¬Ý´_µo®t²§¦bþ¸Ì¡A´_µoÆ[©À¬O¦b¤Æ¾ÇÀøªk©Î¼Ð¹vªvÀø¤º¸û²M·¡¡A¥i¬O§K¬ÌÀøªk¥L¬O¹ï¯f¤Hªºªø´Á¦s¬¡ªºimpact¸û¤j¡A´N¬O»¡¥undata¦¨¼ô¡AÀ³¸Ó¥i¥H¬Ý¨ì¥L¹ï¯f¤Hªºos¡A¯f¤Hªºªø´Á¦s¬¡¤@¼Ë¥i¥H¬°¯f¤H±a¨Ó¦n³B¡A©Ò¥H³oÓstudy Åã¥Ü©Ò¦³§K¬ÌÀøªkªº¯S¼x¡A¦Ó¥B¤]ÃÒ¹ê¦o¥i¥Hµ¹Àù¯g¯f¤H±a¨Ó¦n³B¡A§ó¬Ã¶Qªº¬O¦]¬°³o§K¬ÌÀøªk¤£¹³¤ÆÀø¡B¼Ð¹vªvÀø¡A¹ï¯f¤H¥Í¬¡«~½è¼vÅT«D±`¤j¡A©Ò¥H¬Û«H³o¦¸¦basco°Q½×·|¤Þ°_«Ü¦hªº°jÅT¡A¹ï©ó³oÓ·sªº¡A´N¬O¥H«e§ÚÌ»¡first in class¡A¥H«e§¹¥þ¨S¦³ÃÒ¹ê¹L³o¼Ëªº§K¬ÌÀøªk¡A¦Ó¥B¬O¥D°Êªº§K¬ÌÀøªk¡A¦]¬°³Qapproveªº§K¬ÌÀøªk³q±`³£¬O³Q°Ê§K¬ÌÀøªk¡A²³æ¸ÑÄÀ§Æ±æ¤j®a¥i¥H§ó²M·¡¡C 2¤½¥q2/21^¤å·s»D½Z TAIPEI, TAIWAN, February 21, 2016 ¡X OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced the topline results of the Phase 2/3 study of OBI-822/821 (formerly OPT‐822/OPT‐821), which evaluated the clinical benefit and immunogenicity of the investigational immunotherapy in patients with metastatic breast cancer. Based on the data available to date, the study (Protocol Number OPT-822-001) did not meet the primary efficacy end point of progression-free survival. However, patients who demonstrated an immune response (IgG or IgM) showed highly significant improvement in progression-free survival and the secondary endpoint of overall survival is trending towards statistical significance. OBI-822/821 was generally well tolerated with no major safety concerns. Full results will be presented at an upcoming international scientific conference. |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/29 ¤W¤È 08:53:05²Ä 1442 ½g¦^À³
|
ª©¥D¤j¡A ¦Ñ´¤j¨º½g¶K¤å¯à±Ï¦^¨Ó¶Ü¡H³Â·Ð¤F¡I ÁV¿|~~¤w¸g¥Ã¤[§R°£¤F¡A¯u¬O©êºp¡A¦ý§Ú·Q¸g¹L±zªº¸ÑÄÀ¡A¦Ñ´¤jÀ³¯à½Ì¸Ñ~BYª©¥D |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/29 ¤W¤È 07:55:44²Ä 1441 ½g¦^À³
|
¦Ñ´¤j¡A ±z»~·|¤F¡C¤p§ÌªºÅå¹Ä¸¹¬O«öÆgªº·N«ä¡A§¹¥þ»{¦P±zµo¨¥¦³®Ú¾Ú¡C±z¤d¸U§O§R¤F³o¬q¡C ¬Ý¨Ó¤p§Ìªºªí¹F¯à¤O¦³°ÝÃD¡C¦b¦¹¹Dºp¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/4/29 ¤W¤È 12:21:41²Ä 1440 ½g¦^À³
|
»aÃǤj: ·PÁ±zªº¸Ñ»¡, ³Ò¾r±z^¤å±Ð¾Ç, ¯u¤£¦n·N«ä., ¤F¸Ñ¤F, ÁÂÁ±z ! |
|
|
·|û¡G»aÃÇ10141976 µoªí®É¶¡:2016/4/29 ¤W¤È 12:11:12²Ä 1439 ½g¦^À³
|
QQ¤j, An exception to the rule is simply something which goes against the norm (rule). ©Ò¥H The following abstracts have received formal Exceptions to ASCO¡¦s Confidentiality Policy for the 2016 Annual Meeting. ¥y¤l¸ÌªºExceptions«áªºto¥un·Q¦¨against¡A«üªº¬O°w¹ïASCO¡¦s Confidentiality Policyªº¨Ò¥~¡A³o¼Ë´N¤£ÃøÁA¸Ñ¤F¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/4/28 ¤U¤È 11:20:59²Ä 1438 ½g¦^À³
|
Pie¤j: Æg!! ·PÁ±zªº¸ê°T. ¯à§_¸ò±z½Ð±Ð¦³Ãö¤U¦C³o¥y: The following abstracts have received formal Exceptions to ASCO¡¦s Confidentiality Policy for the 2016 Annual Meeting ¬O«ü³o¨Çasbtracts¤w¸g³QASCO®Ö㬰exceptions ¶Ü ? (§Ú¤£¬O«Ü¯à½T©w¦]¬°¥Î¤F to ¦Ó¤£¬Ofrom) ., ÁÙ¬O¥u¬O»¼¥ó¥Ó½Ð¤F ? ¥t¥~¦bASCOªºconfidentiality policy exceptions¤U, ¯à±µ¨üÀ³¸Ó¬O¦b¨u¨£±¡¦³¥i쪺ª¬ªp¤U¼Æ¾Ú¥~¬y¦Vªk³W³æ¦ìµ¥µ¥¦Ó«D¤½¥¬©Î¤½§i. ³oÂI¬O§_¯à½Ð±z¶i¤@¨BÄÄÄÀ? ³Â·Ð±z¤F !! |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/28 ¤U¤È 10:10:25²Ä 1437 ½g¦^À³
|
·PÁ¹x¥Û¤jªº±Ð»£,{¦³½Õ¬d¤~¦³µo¨¥Åv¡I} ¦Ñ´¯Â¾ÌÓ¤H¸gÅç·QªkJ»¡¤K¹D,¨S¦³¥ô¦óevidence-based´N¶Ãµo¨¥®ö¶O¦U¦ì¤j¤jªº®É¶¡,½T¹ê¤£¸Ó,¦b¦¹P ¤W12¸U¤Àªººp·N. Àµ½ÐªO¥D§â³o½gµo¨¥§R°£,·P®¦. {¦Ñ´10141055 µoªí®É¶¡:2016/4/27 ¤U¤È 11:20:15²Ä 1424 ½g¦^À³ } |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/4/28 ¤U¤È 06:53:18²Ä 1436 ½g¦^À³
|
¤»¤ëÁ{§É¼Æ¾Ú¥x¬ü¦P¨B¤½§i¥i¦h¤@¨Ç¤H¦V¤½¥q«Øij: 1·í¤Ñ¦³±M·~½Ķ¤Hû¸Ñ»¡ 2·í¤Ñ·|«á³X°Ý´X¦ì¥þ²y¨ÅÀùÅv«Â»P¿Õ¨©º¸¼ú±o¥D¹ïÁ{§É¼Æ¾Úµoªí½×z¡A³z¹L°ê»Ú«n·s»D´CÅé¸ê°T¶Ç¼½¥þ²y¡A¥H¨D¤½¥¿«ÈÆ[¡C 3·í¤Ñ¤W¤È¶}¤@Óªk»¡·|¡A²`¤J±´°Q°Ýµª¡C ~~~ ¥xÁÞ¤j¡A¦n·N¨£..§Æ±æ¦h¤@ÂI¤H¸ò¤½¥q¤ÏÀ³«Øij.. ³o¤£¶È¥i¥HÁÙ¤½¥q²M¥Õ¡A¤]¥i¥HÃÒ©ú¯Î°|ªøªº¦¨´N¡A»P¹ï¥xÆWªº°^Äm¡A©Ô¦^³oÓ¦¨¬°¥«³õ»PªÀ·|ªºµJÂI.. ·PÁÂ.. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/28 ¤U¤È 06:45:37²Ä 1435 ½g¦^À³
|
²³¤j¤j ¤»¤ëÁ{§É¼Æ¾Ú¥x¬ü¦P¨B¤½§i¥i¦h¤@¨Ç¤H¦V¤½¥q«Øij: 1·í¤Ñ¦³±M·~½Ķ¤Hû¸Ñ»¡ 2·í¤Ñ·|«á³X°Ý´X¦ì¥þ²y¨ÅÀùÅv«Â»P¿Õ¨©º¸¼ú±o¥D¹ïÁ{§É¼Æ¾Úµoªí½×z¡A³z¹L°ê»Ú«n·s»D´CÅé¸ê°T¶Ç¼½¥þ²y¡A¥H¨D¤½¥¿«ÈÆ[¡C 3·í¤Ñ¤W¤È¶}¤@Óªk»¡·|¡A²`¤J±´°Q°Ýµª¡C ¹x¥Û¤j ¦UºØ¥i¯à±¡ªp³£¥i´£¥X¤À¨É»P±´°Q¡AÁÂÁ¹x¥Û ¤j ¦³«í¤j ¦³Ãö¥Ø«eMOS±À¦ô¡AÓ¤H²q´ú¤p©_¤j»P¤Ñ©R¤j¬ÝªkÀ³»P¦³«í¤j¦³«Ü¤j¸¨®t¡AMOSÀ³¤À¨âºØ ¡A ¹êÅç²Õ»P¹ï·Ó²Õ¤ñ¸û¡A¹êÅç²Õ¤º¦³²£¥Í¨¬°÷§ÜÅé»P¨S²£¥Í¨¬°÷§ÜÅ餧¤ñ¸û¡C |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/4/28 ¤U¤È 06:25:29²Ä 1434 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤j¤ÎPie¤j¤À¨É |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/4/28 ¤U¤È 05:59:38²Ä 1433 ½g¦^À³
|
ÁÂÁÂpie¤j¤À¨É |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/4/28 ¤U¤È 05:52:53²Ä 1432 ½g¦^À³
|
Pie¤j ·PÁ±zªº¤À¨É Åwªï¦h¤W¨Ó |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2016/4/28 ¤U¤È 05:22:40²Ä 1431 ½g¦^À³
|
¥¤ß¦Ó½×¡A¤½¥q°£¤F¦M¾÷³B²z¯à¤O«Ü®t¤§¥~ ¨Ò¦p¸Ñª¼«á¤@ª½³Q®Á¥´¤]¨S¦³¤j°}¥MÅGÅ@ ÁÙ³Q·j¯Á½Õ¬d«o¥u¯à°×¤Ú¦Y¶À³s ¦ý¹ï©ó¥»·~ªº±M·~ÁÙ¬O¥i°é¥iÂI §Ú¦³«H¤ß822¤µ¦~·|¨ì¤d¨½¸ô¡A ¯E¹©¬O¤d¨½°¨¡A§B¼Ö´N¬O¯E¤Í ´CÅéÁý¥L¦Y¤Ú¨§¡A©Ô¨{¤l¥Í¯f«á ´N·|ªø¥X¯Í»H¦¨¬°¸¤Ñ°¨¡A¿W¨¤Ã~ Unicorn,¦n¦nµ¥µÛ |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/28 ¤U¤È 05:12:34²Ä 1430 ½g¦^À³
|
¥xÁÞ¤j¡A §Æ±æ¤p§Ì¬O¥Õ¾Þ¤ß¤F¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/28 ¤U¤È 05:11:11²Ä 1429 ½g¦^À³
|
Pie¤j¡A ·PÁÂPie¤j´£¨Ñ¬Û·íÄ_¶Qªº¸ê°T¡A§Ú¬Ý¨ì¥Ó½Ð¤w®Öã¤F¡A¬ü°ê¤§©Ò¥H°¶¤j¨Ó¦Û©ó¹ï¦UºØ¨Æ°È¥i¯àªº±¡ªpµ¹¤©¬Û·í©P©µ¤S¦³¼u©Êªº¦Ò¶q¡C |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/4/28 ¤U¤È 04:59:34²Ä 1428 ½g¦^À³
|
¦³ª×ªêÂÃÀsªº¤H¸ò§Ú̦b¤@°_ |
|
|
·|û¡G¤p¹xµ£10141398 µoªí®É¶¡:2016/4/28 ¤U¤È 04:39:46²Ä 1427 ½g¦^À³
|
Pie¤j: §Ú¨Ì±z´£¨Ñªº³sµ²,µM«á¿ïexceptions to dates, ¨ä¤º¤å¥Ñ¤W©¹¤U¼Æ²Ä¤TÓ´N¥i¬Ý¨ì¯E¹©ªº¥Ó½Ð¤F ±z¯uªº¦n²Ó¤ß ! ÁÂÁ ! ¯E¤Íª©¤W¯u¬O¯à¤H²§¤h¦n¦h§r |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/4/28 ¤U¤È 04:27:06²Ä 1426 ½g¦^À³
|
ASCO ¨ÅÀù¦³¨âÓ¤l¶µ Breast Cancer¡XHER2/ER Breast Cancer¡XTriple-Negative/Cytotoxics/Local Therapy ¥u¬O¤G¿ï¤@ªº±¡ªp, ¥i¯à©M¥Ó½ÐFDAÃÄÃÒ¨SÃö«Y OBI-822ªº®É¬q, Á`¦@¦³¨â½gabstract³ø§i, µM«á¬O°Q½×Á¿µû, ±µµÛQ&A¤¬°Ê °Q½×®É¬q¥DÃD¬OEngineering New Therapies for Metastatic Breast Cancer OBI-822ÄÝ©ó·sÀøªk, ÁÙÆZ¶K¤Áªº ¥t¥~, ASCO¦³³W©w¦pªG¬O¯S®í±¡ªp, ¦b¦V¥D¿ì³æ¦ì³ø³Æªº«e´£¤U, ¥i¥H®e³\¼Æ¾Ú¤½¥¬ ¤½¥q¤w¸g¦³¦VASCO¥Ó½Ð³o¶µ¯S¨Ò, ¼È®É¤£¥Î¾á¤ß¼Æ¾Ú¥~¬y, ¦Ó³Q¨ú®ø¸ê®æ¤F (am.asco.org/policies-and-exceptions) The following abstracts have received formal Exceptions to ASCO¡¦s Confidentiality Policy for the 2016 Annual Meeting: Abstract 1003: Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/28 ¤U¤È 03:06:08²Ä 1425 ½g¦^À³
|
4¦pªG¨S°O¿ùªº¸Ü¥Ø«eÂಾ©Ê¨ÅÀù[¾A¥Î¶P¯e§´ªº¯f±w°£¥~¡AMOS 56.5Ó¤ë]MOS¤£¬O30Ó ¤ë¡AÀ³¸Ó¬O¤w¶W¹L¤F¡C¤T³±©ÊÂಾ©Ê¨ÅÀùÃĪ«¤]¶V¨Ó¶V¦n¡A¯f±wÀ³¿n·¥±µ¨ü¥¿³WªvÀø¡A¼ÖÆ[µ¥«Ý¨ÅÀùOBI822ªº¤W¥«¡AÀù¯gªvÀøªº²z·Q:¥Í¬¡«~½è¡A¦w¥þ¡Aªø´Á¦s¬¡»P°ª¶Q¤£¶QªºÃÄ»ù¡AOBI822¦³¹F¼Ðªº¼ç¤O¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/28 ¤U¤È 02:25:24²Ä 1424 ½g¦^À³
|
¦³«í¤j 1¥Ñ©óÂå¾Çªº¶i¨BÂಾ©Ê¨ÅÀùÃĪ«·|¶V¨Ó¶V¦n ¥i·j´M°Ñ¦Ò¡GÂಾ©Ê¨ÅÀùªvÀø ³o¬O¥x¤jªº¸ê°T¡C 2 ¨ÅÀùOBI822¤»¤ë¤½§iªº¼Æ¾Ú¤j®an¯S§Oª`·N¡A³oÁûÃĬO³æÃĪºÀø®Ä¡A¤ÆÀøÃÄ°^Äm¦³¡A¥Dn¥Øªº¦b©ó¼W±j§K¬Ì¤O¡A¦]¦¹¥Î¤£¯à¥Î³æÃÄ ªºÀø®Ä¥h»P¶P¯e§´©Î¨ä¥LÁp¦X¥ÎÃĬۤñ¸û¡C 3n¤@¸û°ª¤Uªº¶µ¥Ø¬O: ¦w¥þ©Ê»PÀø®Ä¡A¥Í¬¡«~½è¡A¨Ï¥Î¤è«K©Ê¡AÃÄ»ù¡A822¤£¥²´ú¨ÅÀù¨È«¬»P§Üì¡A¥u»Ý¥ý´ú¬O§_·|²£¥Í¨¬°÷§ÜÅé¡A¬Û·í¤è«K¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/28 ¤U¤È 01:36:48²Ä 1423 ½g¦^À³
|
5 ¤½¥q¥i»P¬ü°êFDA°Q½×¥ý·Ç¤©¨Ï¥Î¦b¥½´Á ¨ÅÀù¯f±w¤W¡A¨Ï¥Îªº¶¶§Ç¨Ì§Ç¬O¤T³±©Ê¡A¶Pº¸»X¶§©Ê¡AHer-2¶§©Ê (¦]¤¤¦ì¼ÆÁ`¦s¬¡´Á©|¦bÆ[¹î¤¤¡A¥un¶W¶V²{¦³Àø®Ä´N㤩¨Ï¥Î¡A¤@ª½¨ì¦UºØ¨È«¬³£¯à¨Ï¥Î¬°¥D) 6¥þ²yÁ{§É¤£¦A¥HStage4¬°¹ï¶H,¦Ó¬O¥HStage2,Stage3¯f±w¬°¦¬®×¹ï¶H¡AÄ~Äò©¹«e±À¶i¡AÂX¤j¨Ï¥Î¤H¤f¡C ¥H¤W¤»ÂI¶È¨Ñ¤À¨É°Ñ¦Ò¡A¤@¤Á¥H¤»¤ë¤½§i¬°·Ç |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/28 ¤U¤È 12:59:49²Ä 1422 ½g¦^À³
|
¸É¥¿ ¤½¥q·|¤£·|©ñ±óHer-2¶§©Ê¨ÅÀù¡AÂ੹¶}©Ý¨ä¥L¨È«¬¨ÅÀù¥«³õ¡A¤½¥q¦^µª:¤£·|¡A¥t¥~¤G¤ë¸Ñª¼«á..... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/28 ¤U¤È 12:50:09²Ä 1421 ½g¦^À³
|
¹x¥Û¤j 1ì¨Ó¬O¹x¥Û¤jªº¾á¼~¡A°O±o¬Ý¨ì³oÓ¤À¨É¡A ³QÁY«áªºªº¨Ï¥Î¤ñ²vÁöµM¤]¤£¤p¡AÄvª§ªÌ¤Ö¡A·m§ð¦Ê¤À¤§15%¤T³±©Ê¨ÅÀù¥«³õ¨ä¹ê¤]¬Û·í¥iÆ[¡C 2®ÖãÃĪ«·|¬Ý¬O§_¤ñ²{¦³¤w¤W¥«ªºÃĦU¤è¦V¤ñ¸û¡A³oÓ°ÝÃD¥u¯àµ¥¼Æ¾Ú¥X¨Ó¦Aµû½×·|§ó«ÈÆ[¡A¹x¥Û¤j¥u¬O²q´ú¦Ó¤w 3 2014¦~ªÑªF·|¦³ªÑªF°Ý¨ì¬ÛÃö°ÝÃD¡A¤½¥q·|¹F¤£·|©ñ±ó¥ô¦ó¤@ºØ¨È«¬ªº¨ÅÀù¡A¥[¤W¥¼¨Ó¥HÁ`¦s¬¡´Á¬°¶D¨D¡AÀ³¸Ó¤£·|¿éµ¹¶Pº¸»X¶§©Ê¨ÅÀù¡C 4¥»¦¸Á{§ÉÃÒ©ú¦UºØ¨È«¬³£¦³®Ä¡AÓ¤H»{¬°³QÁYªº¥i¯à©Ê§C¡A°£«Dµ¦²¤©Ê¦Ò¶q¡C |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/4/28 ¤U¤È 12:42:28²Ä 1420 ½g¦^À³
|
¹x¥Û¤j ¤p§Ì¦³¤@Ó¸û¼ÖÆ[ªº·Qªk,¤£ª¾¬O§_¦³¹D²z,½Ð±z«ü¥¿! ¦]¬°¶ÀÁ`3/31ªk»¡¦³»¡mos¸ê®Æ©|¥¼¦¨¼ô,¦ý´N²{¦³¸Ñª¼¸ê®ÆÆ[¹î,³Ì®tªº±¡§Îmos¦³20¤ë,Àu©ó¤T³±©ÊÀù¥½¯f¤H©Ò¦³ÃĪ«ªvÀømos,¦ý¬O§_¸ûER+,PR+,¬Æ©Î¸ûHER+Áp¦X¥ÎÃÄMOS56.5¤ë¬°¨Î,¥Ñ©ó¸ê®Æ©|¥¼¦¨¼ô,µL±q¤ñ¸û,¬G¥H³Ì«O¦u𷪺ì«h,¥ý°Ñ¥[¤T³±©Ê¨ÅÀù³o¤@²Õ§O¡C ¥t¥~¤p§Ì·QASCO°Ñ¥[þ¤@²Õ§O,À³»P«áÄò¥Ó½Ð¦óºØ¨ÅÀù¾AÀ³¯gµLµ´¹ïÃö«Y,YÀHµÛ®É¶¡¶i®i,822MOS¸ê®Æ¤@ª½¥¼¦¨¼ô,¤]¥Nªíªø§À®ÄÀ³¶V©ú½T,¦b»P¦U°ê·¾³qÃÄÃÒªº¹Lµ{¤¤,¤@¥¹¼Æ¾Ú¦¨¼ô,Y¤]¸û¨ä¥L¨ÅÀù¨È«¬¾AÀ³¯gMOS¼Æ¾Ú¨Î,¤£ª¾¬O§_¥i¥H·s¼W¾AÀ³¯g¤è¦¡³w¦æ°µ·¾³q¨Ã¥Ó½Ð¾A¥Î¡C¥H¤W¤p§Ì©å¨£,·q½Ð«ü¥¿¡I ¥xÁÞ¤j ¤p§Ì¦³¤@°ÝÃD½Ð±Ð¡A¥ý«e±z¦³´£¨ì,¨ÅÀù¥½´Á¯f¤H³Ì·s¸ê®ÆMOS30¤ë,¶P¯e§´Áp¦X¥ÎÃÄ°w¹ïHER+ MOS¥i¹F56.5¤ë,¤£ª¾¬O§_¦³¦UºØ¨ÅÀù¨È«¬ªº²Ó³¡MOS¸ê®Æ¡A¤p§Ì³£·j´M¤£¨ì,¥uª¾¥Ø«e¤T³±©ÊÀù¥½¯f¤HµL¦³®ÄªºªvÀø¤è®×,©Ò¥H±Àª¾MOSÀ³¸Ó«Üµu,¤£ª¾¦û60%¶Pº¸»X«¬Àù¥½¤§¯f±wMOS¤j¬ù¬O¦h¤Ö? |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/28 ¤W¤È 11:05:59²Ä 1419 ½g¦^À³
|
¥xÁÞ¤j¡A ¤£½T©w±zªºµo¨¥¬O§_°w¹ï¤p§Ìªº¤Uz²q´ú¡G ¡y¤½¥q°ª¼h¦h¦¸ªí¥Ü¡A¯E¹©ªº822¦b©Û¶Ò¯f¤H¤§«e¨ä¹ê¤£»Ýn¥ý°µ¿z¿ï¡A¥un¥´¥|°w¬Ý§ÜÅéªí²{´N¦n¤F¡C©Ò¥H¡A³oÓÃįu¥¿±¹ïªº¥«³õ¬O©Ò¦³¨ÅÀù¯f¤H¡C¦ý¬O¦bASCOªº³ø§i¼ÐÃD«o¬O°w¹ï¡©¤T³±©Ê/²ÓM¬r¯À/local treatment¡ª¡A°µ¤FÁY¡C(¤p§Ì»{¬° local treatment À³¸Ó½Ķ¦¨§½³¡ªvÀø¡A¦Ó«D·í¦aªvÀø¡C) Àù¯g·sÃĦb¥Ó½ÐFDA³\¥i®É¡A»Ýn¸ò²{¦æªº¡©¥ý¶iªvÀø¤è¦¡¡ª°µ¤ñ¸û¡A¦pªGPK³Ó§Q´N¥i¥H¥[³t¨úÃÒ¡C ¤p§Ì±À·Q¡A¤½¥qªº³ø§i·|°µ³oÓÁY©Î³\¬O¦]¬°¡G¹ï©óHER-2+©Î¬OER+ªº¯f¤H¡A¥i¯à822ªºÀø®Ä¸ò¨ä¥Lªº¥ý¶iÃĪ«¬Û¤ñµLªk§¹³Ó©Î¤£°÷«G²´¡A©Ò¥H¦pªG§â¾AÀ³¯g³]©w¦b©Ò¦³¥|´Á¨ÅÀù¯f±w¡A¥i¯à¤S¬Ý¤£¥X©úÅãÀu¶Õ¦ÓµLªkª½§ðÃÄÃÒ¡A¨º´N¥²¶·¦A°µ¤T´Á¡C¦ý¬O¦]¬°¤T³±©Ê¨ÅÀù¥Ø«e¨S¦³¦nªºÃĪ«¡A©Ò¥Hn¥ý¥´¥|°wµ¥§K¬Ì¤ÏÀ³ªº¡©¯ÊÂI¡ª´N¤£¬O°ÝÃD¤F¡A822¥i¥H»´©ö§¹³Ó¡C¦pªG³oÓ¾AÀ³¯gªºÁY¯à°÷±a¨Ó©úÅ㪺¬Û¹ïÀu¶Õ¡A³o¬O¤£¬O´N¬O±i¸³©Ònª§¨úªº conditional approval¡H [¤T³±©Ê¯f±w¦û¨ÅÀù¤H¤fªº15%¡A¥«³õ¨ä¹ê¤£ºâ¤p¤F¡C] ¤½¥q¦b2/22¥H¤Î3/31ªº¨â¦¸°OªÌ·|·í¤¤³£´£¨ì¡AÁöµM´N¾ãÅé¹êÅç²Õ»P±±¨î²Õªº¼Æ¾Ú°µªº¹ï¤ñ¤£¨ã²ÎpÅãµÛ©Ê¡A¦ý¬O¤½¥qÁÙ¬O·|±N©Ò¦³¹êÅç²Õªº¼Æ¾Ú¦A°µ°Ï¤À [sub-division] ¡A§ä¥X¹ï©ó822¨ã¦³©úÅãÀø®Äªº¯f¤H±Ú¸s¡C¬O§_¤w¸g§ä¨ì¤F¡H¡z ¤p§Ì»{¬°¯E¹©¥Ø«eªº²Ä¤@¥Ø¼Ð´N¬O¦b³Ìµu®É¶¡¸Ì®³¨ì²Ä¤@±iÃÄÃÒ¡A¦Ü©ó¾AÀ³¯g©Ò²[»\ªº½d³ò¨Ã¤£¬O³Ì¤j¦Ò¶q¡C¦pªG¯à°÷²[»\©Ò¦³¨ÅÀù¯f±w¡A·íµM³Ì¦n¡C¦ý¦p¹LFDA¿Å¶q²{¦³¼Æ¾ÚªºÅãµÛ©Ê¡A¥H¤Î»Ýn¥ý¥´¥|°w¤~¯à½T»{§K¬Ì®ÄªGªº¨î¡A¥ý±NÃÄÃÒ¨î¦b¤T³±©Ê¡A¤½¥q¤]À³¸Ó¥ý®³ÃÄÃÒ¦A»¡¡CµM«á¦A°µ¥þ±¤T´Á¡A¸Õ¹Ï¤T¦Ü¤¦~«á®³¨ì©Ò¦³¨ÅÀù¥|´Áªº¾AÀ³¯g(¤]³\¥]¬AÁp¦X¥ÎÃĤè®×)¡C¤½¥q¥Ø«e¤´µM¦b³]p¥þ²y¤T´Á¡A¬O§_¤]¬O¦p¦¹¦Ò¶q¡H |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/4/28 ¤W¤È 10:18:53²Ä 1418 ½g¦^À³
|
·PÁÂ¥xÁÞ¤j´£¨Ñ³o»òÆgªº°T®§¡I¡I¡I |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/4/28 ¤W¤È 09:56:56²Ä 1417 ½g¦^À³
|
Cyclophosphamide ¸ò OBI-822 ©Ò¤Þ°_ªºªº¤ÏÀ³ ¬O¤£¦Pªº ¤ñ¸û¤£®e©ö²£¥Í¥æ¤e¤ÏÀ³ ì¦]¦p¤U¡G 1.Cyclophosphamide¡G«D±M¤@©ÊÃľ¯ ¨«ªº¬O°w¹ïCANCER CELL ¦bCELL CYCLE ªº¨BÆJ¥h¬r±þ CANCEE CELL ²³æ¨Ó»¡ ´N¬O ÅýCANCER CELLµLªk²ÓM¤Àµõ ¦ý¤HÅé¥un·|¤@ª½¤ÀµõªºCELL ´N·|¼vÅT ³o´N¬O©Ò¿×¤ÆÀøªº«á¿ò¯g 2.OBI-822 ¡G¾÷¨î«Y¤Þ°_±M¤@©Ê¦ÛÅé§K¬Ì¤ÏÀ³¡A¹ïIgMªº²£¥Í ¤£·|¼vÅT ¤ñ¸û¦³¥i¯àªº¬O¼vÅTIgG ¦]¬°¥¼§K¬ÌB CELL¤@¹J¨ì822§Üì ´N¶i¦æ¤Àµõ ²£¥Í¤j¶q¥i¥H¤Àªc¿ëÃÑCANCER CELL IgG ªºB CELL¡C¦ý¥unCyclophosphamideÃĪ«¤£n¶]¨ì²O¤Úµ² ¼vÅT´N·|«Ü¤p¡C 3.¥t¥~¡APD-1µ¥§K¬ÌÃĪ« ÄݳQ°Ê§K¬Ì¤ÏÀ³ «Y°w¹ïCELL MAKER ¥h±Ò°ÊCELL ¦Û±þ©Î¤Þ°_¬r±þ¤ÏÀ³ ±M¤@©Ê¸û¤@¯ë¼Ð¹vªº¤ÆÀøÃĪ«§ó°ª¡A¯ÊÂI¬OÀøµ{¤ñ´N¤[¡C833´N¬OÃþ¦üPD-1ªº¤è¦¡¡ã ¤p§Ì²L¨£¨Ñ参 ¦³¿ù»~½Ð«ü¥¿ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/28 ¤W¤È 09:23:17²Ä 1416 ½g¦^À³
|
°e³ø¤j¡A²³¤j¤j ¬ü°êCancer Moonshot ¤»¤j¤è¦V¤¤¯E¹©¬ãµoªº²£«~¤¤¦³¤Ó¤è¦V²Å¦X¡A¥xÆW¯E¹©ªº²£«~¯uªº¬O¯¸¦b¥@¬É»â¥ý¦a¦ì¡A¯¸¦bÀù¯g§K¬ÌÀøªkªº¾ú¥v®ö¼é¤W¡C ¥t¥~¸É¥RÓ¤H¬Ýªk: ½×¤åµoªí»P±N¨ÓÃĪ«¨Ï¥Î½d³ò¬O¨â¦^¨Æ¡A¨ÅÀùOBI822¤£»ÝÅç¨ÅÀù¨È«¬»P§Üì¡A¥u»ÝÅç§ÜÅé¬O§_¨¬°÷¡AÓ¤H²q´úÀ³¸Ó©Ò¦³¨ÅÀù¨È«¬³£¥i¨Ï¥Î¡A¤£·|¥u¨î¦b¤T³±©Ê¨ÅÀù¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/27 ¤U¤È 11:31:36²Ä 1415 ½g¦^À³
|
¦Ñ´¤j¡A ¦³½Õ¬d¤~¦³µo¨¥Åv¡I¦hÁ¡I |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/4/27 ¤U¤È 09:54:38²Ä 1414 ½g¦^À³
|
¬Oªº Cliff¤j ±z¬O¹ïªº Àù¼w¬P¨â²Õ¿@«×¤@¼Ë ½Ð¤j®a°Ñ¾\ clinicaltrials.gov/ct2/show/NCT01516307 |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/4/27 ¤U¤È 09:36:09²Ä 1413 ½g¦^À³
|
«ù¤[ªº¯E§J¤j ±z´£¨ì¡u¹êÅç²Õ¥´Àù¼w¬P¾¯¶q¤ñ±±¨î²Õ¤Ö ¤Þ°_µu´Á§ÜÅé¤ÏÀ³¤Ö¡v¡A ¦ý¤p§Ì°O±o¬O¡A¨â²Õªº¨ü¸ÕªÌ©Ò±µ¨üªºCyclophosphamide¾¯¶q¡]300mg/m2¡^»P¬I¥´ªº®É¶¡ÂI³£¬O¬Û¦Pªº¡A´N¬O¬G·N³o¼Ë³]p¤~¯à®ø°£¨â²Õ¦]¤£µ¥¾¯¶q©Ò³y¦¨ªºÀø®Ä®t²§¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/4/27 ¤U¤È 05:33:40²Ä 1412 ½g¦^À³
|
¦V«e¤j ±zªº°ÝÃD Åý¤p§Ì«ä¦Ò¨ì Y¥H«á822Áp¦X¥ÎÃÄ n±K¤Áª`·N¨âÃĦX¤@ ¦]¬°¾ÉP§K¬Ì¨t²ÎªºÄvª§¤ÏÀ³ ¦Ó©µ¿ð822ªºµu´Á§K¬Ì¤ÏÀ³ ¤£¹L³o»Ýn¹êÅç©Î¬ã¨s¨ÓÀËÅç §K¬ÌÃĸò¨ä¥LÃÄ ¨âºØ¥´¤U¥h ¬O§_Ävª§§K¬Ì¤ÏÀ³ §Ú¥u¬OªÅ·Q ½Ð¤j®a§O·í¯u Y¦Ñ¥v¤jÄ@·N¤W¨ÓÁ¿¸Ñ ´N§ó¦n¤F |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2016/4/27 ¤U¤È 02:25:01²Ä 1411 ½g¦^À³
|
OBI-822 ¤Î OBI-833ªº¾÷·|.. ¬ü国Àù¯g¡§µn¤ë计¦E¡¨ªº¥D§ð¤è¦V¤§¤@..Àù¯g¬Ì] 4¤ë4¤é¡A¬ü国Àù¯g¡§µn¤ë计¦E¡¨发¥¬¤»¤j¥D§ð¤è¦V¡A¥]¬AÀù¯g¬Ì]¡B°ª灵±Ó«×Àù¯g¦´Á检测¡B§K¬Ì疗ªk¤Î组¦X疗ªk¡BÀù细M©M肿½F·L环¹Ò细Mªº单细M°ò¦]组¤ÀªR¡B¤Iµ£Àù¯gªº·sªv疗¤èªk¡B¥[强数Õu¦@¨É.........(http://health.sohu.com/20160421/n445359764.shtml) According to the NCI, the panel will consider how to best advance the themes proposed for the National Moonshot Initiative, including the development of: •cancer vaccines •highly sensitive approaches to early detection •advances in immunotherapy and combination therapies •single cell genomic profiling of cancer cells and cells in the tumor microenvironment •enhanced data sharing •new approaches to the treatment of pediatric cancers (https://www.mdanderson.org/newsroom/2016/04/2-md-anderson-expert.html) ¦^¨Ó¬Ý¤@¨Ç°|ªø¦b¥ß°|ªº¤ù¬q....ü °|ªø¥[ªo..¦U¦ì¤j¥[ªo... |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2016/4/26 ¤U¤È 09:59:07²Ä 1410 ½g¦^À³
|
·PÁ¦³«í¤j¤Î¯E§J¤j ³o¤]¬O¸ê°T¤£¹ïµ¥ªº±¡ªp ¤½¥q«Ü¦h¸ê°T³£¬O¿ï¾Ü©Ê,À½¤ú»I¦¡Åý¤H½M²q |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/4/26 ¤U¤È 05:32:16²Ä 1409 ½g¦^À³
|
¦V«e¤j Ãö©ó¦¹ÂI ¤p§Ì¤]¬O¦³¬Û¦PºÃ´b ¥H¤U¥u¬OÓ¤H²q´ú 1.¹êÅç²Õ¥´Àù¼w¬P¾¯¶q¤ñ±±¨î²Õ¤Ö ¤Þ°_µu´Á§ÜÅé¤ÏÀ³¤Ö 2.822»PÀù¼w¬P¥´¤J¨Åé ¤À§O³y¦¨§ÜÅé²£¥Í ¦ý¬O¤S¦]¬°¨Åé§K¬Ì¤ÏÀ³¶q¦³«× ¨Ï±o¨âºØÃĪº§K¬Ì¤ÏÀ³¶q³Q¤À´²¤F ¨S¦³±M¤@¥B¨¬°÷¿@«× ©Ò¥H10©P©µ¿ð¤ÏÀ³ ¤SÀù¼w¬P§K¬Ì¿@«×¤£¨¬ Åܦ¨¨âÃ䤣°Q¦n |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/4/26 ¤U¤È 05:06:10²Ä 1408 ½g¦^À³
|
¦V«e¤j ¤p§Ì¬O¸ÕµÛ¦^µª±zªº°ÝÃD,¤£ª¾¬O§_¦]¬°¹êÅç²Õ¤Ö³¡¤À§K¬Ì¤ÏÀ³¸û±jªº¯f±w©Ò²£¥Íªº¸~½F®û¼í±¡§Î,¤£¦ý©è¾P¤F¥´¤Ö¾¯¶qCyclophosphamideªºÁYÀù®ÄªG,¥B¾ÉP·¥¤Ö¼Æ¤H´£¦³Q§PPD,©Ò¥H§Î¦¨PFS¥¼¹F¼Ðªºì¦]¤§¤@,¥H¤W¤p§Ì©å¨£¨Ñ°Ñ |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2016/4/26 ¤U¤È 02:30:47²Ä 1407 ½g¦^À³
|
¦U¦ì¤j¤j Ãö©ó¯Eô¸Ñª¼¥¼¹F¼Ð¡A±Ð¥Dªk»¡¦ü¥G¥H§K¬Ì©µ¿ð¬°³Ì¥Dn¤§¼vÅTì¦]¡C ¤S¥H¹ï·Ó²Õ¬I¥HCyclophosphamide«á²£¥Í¤FÀø®Ä¡A¨Ï±oI´º¤ñ¸ûÈ´£°ª¡A¶i¦Ó¼vÅTPFS¥¼¹F¼Ð¡C ¤p§Ì«D±`¯Ç´e¡HCyclophosphamide¬°¤w¤W¥«ªv¨ÅÀù¤§¥ÎÃÄ¡A¨ã¦³§í¨îÀù²ÓM¥Íªø¤§¥\®Ä¡C ¹êÅç²Õ¤]¦³Áp¦X¥ÎÃÄCyclophosphamide¡A¬°¦ó¨S¦³¹³¹ï·Ó²Õ¤@¼Ë§í¨îÀù²ÓM¥Íªø¡H Y¦³§í¨î·í¥i´ç¹L§K¬Ì©µ¿ð¤§´Á¶¡¡Aµ¥¨ì822²£¥Í§ÜÅé¡A±µÄòªvÀø¡A¦ü¥i¹LÃö¹F¼Ð¡C ¦³¤j¤j¥i¸Ñ¶Ü¡H |
|
|
·|û¡GÀ³³\¤§¦a10141362 µoªí®É¶¡:2016/4/25 ¤W¤È 06:48:58²Ä 1406 ½g¦^À³
|
chen6053¤j ©ñ¤ß¡A¨ºÓ¬O¦Ñ¹«·|¶BÄF®×+1¡A¯E¹©¥u¬O¨ä¤¤¤@ÓÄF¤Hªº¼Ðªº¦Ó¤w¡C ¦Ó¥B§ÚÁÙ¸ò¹L¨â¦¸³æ¡A¤âªk¤ñ¤@¯ëªº¶BÄF±M·~¡C ¥LÌ·|»¡¦Û¤v¦ÑÁó¦h¦æ¦h¦æ¡A¦ý¬O·ín¨D´£¨Ñ¤½¥qt³d¤H¨¥÷ÃÒ¡A«oµ¹§Ú¤@Ó¤C¤Q¤¦~¦¸ªº¤HÀY... ¦ý¬O¥LÌ´£¥X¨Ó´X¥G¨C¤@Àɳ£¥i¥H°é¡B¦Ó¥BÂê¶W¤[ªº¡ã ©Ò¥H¸ò¹L¨â¦¸¸Õ³æ¡BÁÈ´X¤d¤¸¤§«á§Ú´N°h¥X¤F¡C ¹ê¦b¬O¤ÓªêÄê ³oºØ¦Ñ¹«·|®Ú¥»´N¤£·|¶R¤JªÑ²¼¡A¦ÛµM»P¤½¥qµL¯A... |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/4/25 ¤W¤È 01:16:00²Ä 1405 ½g¦^À³
|
ªF´Ë°]¸g·s»D 1ÂI10¤À«e ¤U¤è ¶]°¨¿O·s»D ...µJÂI:¦Ê¤H±±°éÁʯE¹©ªÑ²¼ÁÈ9%§Q®§ ¥D¶û±²120»õ¼ç°k..... |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/4/25 ¤W¤È 12:00:12²Ä 1404 ½g¦^À³
|
²q·Q¤j.. §Ú¤]¤@¼Ë¡A³o»ò±M·~ªº¬ã¨s»P¤ÀªR¡A§Ú¥u¦³ÀY¸~ªº¥÷¡A¦ý¾ãÅéÁÙ¬O¬Ý±oÀ´nªí¹Fªº·N«ä.. §Ú¥u¦³´L·q.´L·q.¦A´L·q.. ~~~ µLªº·P¿E ²³¤j¤jªº¤À¨É ¤×¨ä ¦Ñ¥v¤j Cliff ¤j®¦®v ¦Ñ´¤j±Ð±Â ¯E§J¤j ±a»â¤j¹Ù»{ÃÑFDAÃÄÃÒì«h ¹ê¨Ò©M¸É¥R ÁÂÁ¦AÁÂÁÂ! ·P®¦¦A·P®¦! |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/4/24 ¤U¤È 11:38:57²Ä 1403 ½g¦^À³
|
«Ó¥v¤j³o»òºë±mªº¤å³¹¡A¤@©wn¨ì³B¶K¡I·PÁ«ӥv¤j¡I10000ÓÆg¡I ·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/4/24 ¤U¤È 11:28:11²Ä 11453 ½g¦^À³ µo¦¨ÁZ³æ«e¡A¥ý¬Ý¬Ý§O®a§K¬ÌÃĪ«ªº¦¨ÁZ¦p¦ó¡H ½÷·çPD-L1(Avelumab)¨ÅÀùªºÁ{§É³ø§i¡Aµoªí©ó2015¦~12¤ëSABCS¸t¦wªF¥§¶ø¨ÅÀù¤j·|¡AThe JAVELIN trial¬OÓ¤j«¬¤@´ÁÁ{§É¡A¹wp¦¬¦hºØ¸~½F¯f±w1670¤H¡A¨ä¤¤¨ÅÀù¦¬¤F168¤H¡A¨S¦³¿z¿ïPD-L1ªí²{²v¡C168¦ì¯f±w¤¤¡AHer2¦³26¤H¡B¤T³±©Ê¨ÅÀù58¤H¡B¶Pº¸»X«¬¦³72¤H¡AµLªkµû¦ô¨ÅÀùÃþ«¬ªº12¤H¡CÁ{§Éµo²{¡AOR¤H¼Æ¶È8¤H¡A¥]¬A¤@¦ìCR¤C¦ìPR¡AORR=8/168=4.8%¡ASD¦³39¤H=23.2%¡C¦pªG±Ä¥Î§K¬Ì¸~½Fµû¦ôirRC·Ç«h¡A¦³2¦ìPDÀ³¸Óµø¬°PR¡C¦pªG±NORR¤À¬°§K¬Ì²ÓMPD-L1¶§©Ê»PPD-L1³±©Ê¡A´N¦³©úÅã²Îp®t²§¡Athe different was statistically significant (33.3% vs 2.4%; P =0.001)¡K¡K¡AÅ¥»¡¥xÆW¦³®a¤½¥q»¡¡A¦pªG±NPFS¤À¬°¦³§K¬Ì¤ÏÀ³¡BµL§K¬Ì¤ÏÀ³¨â²Õ¡K¡K 2015¦~SABCS¨ÅÀù¤j·|¡ARugo¬OKeytruda ER+¨ÅÀù³ø§iKeynote028ªºlead author ¡A¦¬®×261¤H¡A¨ä¤¤18.4%¡B48¤HÄÝ©óPD-L1¶§©Ê¡A³o48¤H¤¤¦³25¤H¥i¥Hµû¦ô¡AORR=12%(3PRs)¡C¿z¹L¯f¤H¤§«áORR¤~12%¡A±zı±o¦n¤£¦n¡H 2014¦~SABCS¡AKeytruda¤T³±©Ê¨ÅÀù³ø§iKeynote012¡A111¤H¿z¿ï¥XPD-L1¶§©Ê65¤H¡A¨ä¤¤32¤H¯Ç¤JÁ{§É¡A27¤H¥i¥HCRµû¦ô¡AOR¦³5¤H¡ASD¦³7¤H¡APD¦³12¤H¡A1¤H¥X²{ªvÀø¬ÛÃöÄjº©©Ê¦åºÞ¤º¾®¦å¦Ó¦º¤`¡APFS=1.9Ó¤ë¡C PFS=1.9Ó¤ë PFS=1.9Ó¤ë PFS=1.9Ó¤ë PFS=1.9Ó¤ë ¡§Everyone continues to be quite excited about immunotherapy in breast cancer,¡¨ said Jennifer Litton, MD, of the University of Texas MD Anderson Cancer Center¡C¦¹¥~¡AªÛ¥[ô¤j¾Ç¸~½FpµeRita Nanda³Õ¤h¹ï©óPFSªí¥Ü¡¨ quite impressive¡¨¥xÆW´CÅé±M®a¦W¼L¤j·§¥Ã»·µLªkÅé·|Jennifer Litton¦b¿³¾Ä¤°»ò¡A¤]µLªk²z¸Ñ1.9Ӥ몺PFS¦³¤°»òȱoquite impressive¡C¥Ø«e¶i¤J¤T´ÁÁ{§É¤F¡AKeynote-119 ù¤óPD-L1(atezolizumab)¤T³±©Ê¨ÅÀù¡A¸g¿z¿ï«á¡A21ÓPD-L1¶§©Ê¯f±w¤¤¡A2ÓCR¡B2ÓPR¡A©Ò¥HORR¬O19% ¤T³±©Ê¨ÅÀù¥u¥e¨ÅÀù¤H¼Æ15%¡A±q³o15%ÁÙn¥h¿zPD-L1ªí²{²v¡AÁa¨Ï¿z¥XPD-L1¶§©Ê¡A¨ä¸~½F¤ÏÀ³²v¤j·§20%¡A¦pªG¤£¿z¿ïPD-L1¡A´N·|¹³½÷·çAvelumab¤@¼Ë¡A¾ãÅéORR¤~4.8%¡CÅ¥»¡¥xÆW¦³®a¤½¥qªº¨ÅÀùÁ{§É¤£¥Î¿z¿ï¯f¤H¡A¦Ó¥BÅ¥»¡§K¬Ì¤ÏÀ³¤ñ¨Ò«D±`°ª¡A¥i¬O³Ìªñ«ÜË·°¡AË·°¨ìnaturalÂø»x«D±`¦n©_¡A¡u¥xÆWÁ{§É¸ÕÅçµ²ªG³o»òpostive¡A¬°¦óªÑ²¼¤@ª½¶^¡H¡v |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/4/24 ¤W¤È 11:44:55²Ä 1402 ½g¦^À³
|
ÁÂÁ¤p©_¤j¡ACliff¤j¤jǦì«e½ú«ü¾É¡C Cliff¤j¤j«e½ú...³\¤[¥H¨Ó¡A¤º¤ß¤p§Ì¹ï±z«D±`·q«... ¥u¬O¤p§Ì³o¤è±¬O¥Õè¡A^¤åµ{«×«Ü®t¡A©Ò¥H«ôŪ±zªº«ü¾ÉÁö«Ü»{¯u¤]ºâ¶Ô¡A¥i¬O«Ü¦Y¤O¡A©Ò¥H¤@ª½¤£´±½Ð±Ð±z°ÝÃD¡C ¦³®É³s°ÝªºÁx³£¨S¦³¡C ¦ý¯uªº«ÜÁÂÁ±z¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/4/24 ¤W¤È 07:47:37²Ä 1401 ½g¦^À³
|
Cliff¤j ÁÂÁ±z¡I ¥t¡A¥H¤U±z¬Ý´N¦n¡A¤Å¦bª©±¤W¦^µª¡IÁÂÁ¡I ´N±M§Q³¡¥÷¡A±z»P´X¦ì¯E¤Í̬O§_¦³¬ã¨s©Î°Q½×¹L¡H ¬O§_¦³¬Ý¥X»Ýnª`·N¤§³B¡H¦pªG¦³¥ô¦ó«Øij¡A¦A³Â·Ð¨p¤UÁpµ¸¤½¥q¡I ÁÂÁ±z»P³o¨Ç¯E¤Í̤F¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/4/24 ¤W¤È 12:19:25²Ä 1400 ½g¦^À³
|
¥Xª©¤j¡B¤p´²¤á¤j¡G¨º¥÷MSKCCªº³ø§i¦b¡u2015/7/20 ¤U¤È 05:28:52 ¥»ª©¡v´¿¸g¶K¹L¡A¦A§â¥¦ºK¿ý¹L¨Ó«¶K¤@¦¸¡CÄÝ©óMSKCC³]pªº¡u¦hªG¾ð¡vªº¦h«ÁÞ§Üì²Õ¦X·§©À¡C ¡y±µ¤U¨Ó¦³¤F³oÓPhase IªvÀø§Z±_Àù¡B¿é§ZºÞÀù¡B¸¡µÄÀù¯g, ¤£¬OªvÀø¨ÅÀùªº¡A¨S§ä¨ì°w¹ï¨ÅÀùªº¡C ¡uUnimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission¡v Phase I¡]clinicaltrials.gov/ct2/results?term=Unimolecular+Pentavalent&Search=Search¡^ ³oºØ¤»ù¦hªG¾ðªº¤@´Á³ø§i¡G²³æ§ãn±Æª©²M´·¡G ¡]www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0CCUQFjABahUKEwiPyImzmunGAhVCFJQKHbBxBqE&url=http%3A%2F%2Fwww.poster-submission.com%2Fcdrom%2Fdownload_poster%2F37%2F27248%2F890P&ei=5aWsVc_BI8Ko0ASw45mICg&usg=AFQjCNGCjn1aKkwodGjUUJjUhfxHuWkJGg&bvm=bv.98197061,d.dGo ¡^¡z ¤W±ªº³oÓ±m¦â³ø§i¥i¯à¬O¥h¦~¦b¬YÂå¾Ç·|§e²{¡A·í®É§Ú¨S¦³¯S§O¸ÑÄÀ¤º®e¡C¨ì¤F2016/03³Q§ë½Z¦ÜCancers´Á¥Z¡A©ó2016/04/22¥Z¥X¡F¤µ¤Ñ¤U¤È³Q¥Xª©¤j§ì¨ì¡C¤p§Ì¤µ±á¤]µo²{¤F¡Aªñ¤EÂI»P´X¦ì¤j¤j°Q½×µÛ¡A¤]³£§Ñ¤F¨ä¹ê¥h¦~¶K¹L¤å¡A¤Ó¦h¸ê®Æ¤F¡AµLªk¥þ³¡°O¦í¡K¡K ¥Ļ⤺ؤH¤u¦X¦¨ªºÁÞ§Üì(GH,GM2,STn,TF,Tn)µ²¦X¦¨¤@Ó³æ¤@ºc³y¡A±µ¤WKLH, ¦A¥HQS-21¬°¦õ¾¯¡C2011-2013¦~¶¡¡A¦@¦¬®×24¦ì¡A¥´¤T¾¯¡A°lÂܤF19Ó¤ë¡A20¦ì´_µo¡A6¦ì¥P³u¡CµL«¤j°Æ§@¥Î¡C Ó¤Hı±o¯à»¤µo²£¥Í¹ï§ÜGH,SSEA-3,SSEA-4ªºIgG§ÜÅ骺ÃÄ´N«Ü¦n¥Î¤F¡A¦n¥Î¤S³æ¯Â¡A¤]´N¬O¹Ú¤Ûª©ªº833¡]GH-DT/C34¡^¡A¤£¥²§Ë¨ì¤¡B¤»ºØªºÁÞ§Üì¡C³oºØ¤»ù¡A¤»»ùÁÞ§Ü쪺§@¥Îì²z¤Ó½ÆÂø¡A¦X¦¨¦¨¥»¤S°ª¡A´Nºâ¦³®Ä¡A·Q¶q²£®É¤S¬O¤@¤j³Â·Ð¡C 822¥Î©ó§Z±_Àù ¤]¬OºK¿ý¡B«¶K(¤¤¤åĶ¤å)¡G¡u2015/04/02 ¤U¤È10:02:02 ¥xÆWn¦¨¬°¥@¬É¤§¥ú¥þ¾a¯E¹©³o¤ä¤F¡v822¥Î©ó§Z±_Àùªº¤G´Á¸ÕÅ窺ªì´Á³ø¾É¡C ¡u2014¦~11¤ë8-11¤é¡A²Ä15©¡°ê»Ú°üÀù¾Ç·|¡]International Gynecologic Cancer Society¡^Âù¦~·|¡]biennial meeting¡^¦b¿D¬w¾¥º¸¥»¥l¶}¡A¥H¥x¥_°¨°ºÂå°|¸¡²£³¡±i§Ó¶©¥D¥ô¬°²Ä¤@§@ªÌªº®ü³ø®i¥Ü¡]Poster presentation¡^©ó11¤ë10¤é¦b·|³õ®i¥X¡C¡v ¡u¥Øªº¡G ¥Dn¥Ø¼Ð¬O¨M©wGlobo H-KLH¬Ì]¥Î©ó§Z±_¤W¥ÖÀù¡B¿é§ZºÞÀù©Îìµo¸¡½¤Àù±wªÌ¦b¯S©wªvÀø«áªº§K¬Ì®ÄªG¡]immunogenicity¡^¡C¡v ¡u¤èªk¡G ³o¬O¤@¶µ¥HGlobo H-KLH ¥[¤W QS21 (OPT-822/821)§@¬°¥D°Ê§K¬ÌªvÀøªº¶}©ñ¦¡²Ä¤G´ÁÁ{§É¸ÕÅç¡A¥Î©ó¤wµL¯e¯f¶i®i¡]non-progressive¡^ªº§Z±_¤W¥ÖÀù¡B¿é§ZºÞÀù©Îìµo¸¡½¤Àù±wªÌªº¬ã¨s¡C©ó²Ä1¡B 2¡B 3¡B 4¡B 12¡B 20¶g¬I¥´§K¬Ì»s¾¯¡A¦b¥´«e¡B¥´«á²Ä¥|¶g»P²Ä¤Q¤G¶g©â¨ú¦å²M¤ÀªR¡C§ÜGlobo HªºIgG ¤ÎIgM«h³z¹L·L¯]¦¡§K¬Ì¤ÀªR¦Ó±o¡]bead-based immunoassay¡^¡C¡v ¡uµ²ªG¡G 33¦ì§Z±_Àù¡B¿é§ZºÞÀù©Î¸¡½¤Àù±wªÌ±µ¨ü´î¿n¤â³N¡]debulking operation¡^¤Î¹`°ò¤ÆÀø«á¡]platinum-based chemotherapy¡^¦¬®×¦Ü¤µ¡A¥]§t22¦ììµo¡]22 primary¡^»P11¦ì´_µoӮס]11 recurrent diseases¡^¡C°lÂܤ¤¦ì¼Æ¡]median follow-up¡^¬°4 (2-5.5)Ó¤ë¡C±µ¨ü¦Ü¤Ö¥|¾¯ªº±wªÌ¤¤¦³88¢MIgM¿@«×¤W¤É¡A43¢MIgG¿@«×¤W¤É¡C°£¤F¦³¤@¨Ç§C·Åµo¿N¤Î§½³¡¥Ö½§¤ÏÀ³¤§¥~¡A¨S¦³«¤jªº°Æ§@¥Î¡]severe adverse side effect¡^¡C¡v ¡uµ²½×¡G ¥Ø«eªº¼Æ¾ÚÅã¥ÜGlobo H-KLH¬Ì]¦³®Ä¦a»¤µo¥i¿ëÃѪº¡]recognizable¡^§ÜGlobo HªºIgM »PIgG¡A¥i¾Ú¦¹±À½×¥¦¯àÄÀ¥X«áÄòªº§K¬Ì¦ê¬y¤ÏÀ³¡]Immune cascades¡^¡A¥H¤Î§ÜÀù®ÄªG¡]anti-tumor effect¡^¡C³o¨Ç¼Æ¾Ú¤]Åã¥Ü³o¶µ¬Ì]¬O¦w¥þ¥B@¨ü©Ê¨}¦n¡C¡v ¥t¥~¡A999¤j¡A¤p§Ì¬Ýªk»P¤p©_¤j¬Û¦P¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/4/23 ¤U¤È 10:11:15²Ä 1399 ½g¦^À³
|
999¤j¡A ³¯¹a¬z¦Ñ®v»¡ªº³o¬q¸ÜÁö¬O¦b¸Ñª¼«áªº¤½¶}µo¨¥ ¦ýÀ³¸Ó¤£¬O¬Ý¤F¸Ñª¼«áªº³ø§i©Ò°µªºµ²½× ¦n¤[¥H«e¥i¯à¬OCliff¤j©Î¥xÁÞ¤j©Î°e³ø¤j´¿¤À¨É¹L¬ÛÃöªº½×¤å GH¨ã¦³§K¬Ì§í¨î¤Î«P¶i¦åºÞ¼W¥Íªº¥\¯à ·í®É¤£ª¾¬O«ç»ò¹B§@ªº ±q³o¬q¸Ü¤F¸Ñ¨ìì¨Ó¬O¡u·P¬V¡v©P¾Dªº²ÓM¡A ±Ò°Ê¤F¸~½F©P¾D²ÓM¦b¤HÃþFL®É´Á¹B§@ªº°ò¦] ¡uÀu¤Æ¡v¤F¸~½FÂX¤j¼W¥ÍªºÀô¹Ò¡C |
|
|
·|û¡G¤p´²¤á10134411 µoªí®É¶¡:2016/4/23 ¤U¤È 06:39:55²Ä 1398 ½g¦^À³
|
§Ú¥u¤j·§¬Ý¬Ý¥Xª©¤j§ä¨ìªº³o¤@½gªº¼ÐÃD¡A¥H¤ÎºKnºË¤@¤U¡A ¬Ý°_¨Ó¦n¹³¬OCliff¤j(?)¤§«e©Ò¤À¨Éªº¦hªG¾ð¡C ¦L¶H¤¤¨º®ÉCliff¤j¦³´£¥X¥Lªº¤ß±o¡A ¦n¹³¬O»¡¦pªGÀù²ÓM¤W¦³¦UºØ¤£¦PªºÁÞ¤À¤l¡A¦ý¦Ê¤À¤ñ¤£¤@©w¡A¥B¨CÓ¤H¦³¤°»ò¤]¤£¤@©w¡A¨º»ò¦hªG¾ð´N¦³¥¦ªºÀuÂI¡A ¦ýGlobo-H series¬O¤Q¦hºØÀù²ÓM¬Ò¦³¡A¥B¥H¨ÅÀù¨Ó»¡¡A´X¥G¦Ê¤À¦Ê¦³¡A¨º»ò¡A¥ÎGlobo-H´N¥i¥H¤F¡C ¦pªG¦³¬Ý¿ùªº¸Ü¡A©Î¦³°O¿ùªº¸Ü¡A©Î²z¸Ñ¿ù»~ªº¸Ü¡A½Ð¦h¥]²[¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/4/23 ¤U¤È 06:00:05²Ä 1397 ½g¦^À³
|
°e³ø¤j ¬Ý¤F¤@¤U ³o½g¨Ã«D822¡I ¦Ó¬O¨ä¥L¬ã¨s²Ä¤@´ÁªºÁ{§É¡ã µM«á¡A¤p§Ì¤]¾á¤ß±z»¡ªº... ÁÙ¦n¦³¥Ó½Ð±M§Q¤F |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/4/23 ¤U¤È 05:26:42²Ä 1396 ½g¦^À³
|
³oӯΰ|ªø¦b¬YÓºtÁ¿¦³´£¨ì,GHªº¥Í¦¨¥i¯à¸ò²ÓMªº§Ö³t¥Íªø¦³Ãö¡C |
|
|
·|û¡G¤p²ø10140417 µoªí®É¶¡:2016/4/23 ¤U¤È 05:10:21²Ä 1395 ½g¦^À³
|
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission www.mdpi.com/2072-6694/8/4/46/htm ¬Ý§@ªÌ¸s¦³¤@Ó¬O¤j³°´ò¥_¬ÙµØ¤¤¬ì§Þ¤j¾ÇªºQian Wan¡I¨S¬Ý¨ì¥xÆW¤H¡H©Ò¥H³o½g¸ò¯E¹©¦b°¨°ºÂå°|ªº¦X§@§Z±_Àù¥D°Ê§K¬ÌÀøªkÁ{§É¸ÕÅç¨S¦³Ãö«Y¤F¡H |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/4/23 ¤U¤È 03:45:04²Ä 1394 ½g¦^À³
|
¥xÁÞ¤j¤j¡A¤p©_¤j«e½ú¡G ³¯¹a¬z¦Ñ®v»¡ªº³o¬q¸Ü¬O¦b¸Ñª¼«áªº¤½¶}µo¨¥... ³o¬q¸Ü¬O§_¬O¥i¥H¸ÑÄÀ¬°822Á{§Éµo²{ªºµ²ªG¡C ³¯¹a¬z¦Ñ®v»¡¡G GH°£¤F¦b¸~½F²ÓMµo²{¤§¥~¡Atumor©P³òªº²O¤Ú²ÓM¤Î¦åºÞ²ÓM¤]·|¦³GH-positiveªºªí²{¡A§Ï©»¬O¡y·P¬V¡zªº²{¶H(·íµM¤£¬O·P¬V)¡A²O¤Ú¨t²Î³Q§í¨î¡AT-cell¡AB-cellªº§K¬Ì¥\¯à·|¤U°¡AGH-positive«h³y¦¨¤F¦åºÞªº¹L«×¼W¥Í¡A¦]¦¹YGH³Q±±¨î¦í¡A¦åºÞ¹L«×¼W¥Í©M²O¤Ú¨t²Î¤]·|«ì´_¥¿±`¡C ÁÙ¦³¦pªG³o¦¸ASCO¤fÀY³ø§i¡A¯uªº¬O±q¤T³±©Ê/²ÓM¬r¯À/·í¦aªvÀø...¶}©l°µ¬°³ø§i«ÂI... ³oÀ³¸Ó°µ¦ó¸ÑŪ822/821ªºÁ{§É®ÄªG......¦p¦ó¬Ý«Ý822/821...¡H¡H¡H ·q½Ð½Ñ¦ì«e½ú±M·~¤j¤j«ü¾É¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2016/4/23 ¤U¤È 02:52:12²Ä 1393 ½g¦^À³
|
¤pªº·QOBI¨t¦C³Ìªñ¶i®iÅýMSKCC§â³o¬ã¨s«¦B½c¸Ì§ä¥X¨Ó¤F.. ¤Ö¤F¯Î°|ªøªº·Ò¤¦Äl.¥P¤¦´N¨ì¤£¤F¤H¶¡.. ¯Î°|ªø³Ìªñ¨üªº§é¿i©M¥L¾Ö¦³ªº§Þ³N¦³Ãö???(¢®`¦k·Q¯g¤Sµo§@¤F) |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/4/23 ¤U¤È 02:23:24²Ä 1392 ½g¦^À³
|
¯«°¯S»`°e³ø¤j §Z±_¯g¡ã ±z¤]¤Ó±j¤F§a¡I ¬Q¤Ñ¤~published,±z¤µ¤Ñ´N§ä¨ì¤F¡I ¡m®³¡n»ò¼F®`¡IÆg¡I ÁÂÁÂÅo¡I |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2016/4/23 ¤U¤È 02:08:05²Ä 1391 ½g¦^À³
|
¤£¦n·N«ä.¤S·Q³Â·Ð¦U¦ì±M·~¤j¤jÌ..ÁÂÁ A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission http://www.mdpi.com/2072-6694/8/4/46/htm |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/4/22 ¤U¤È 06:04:20²Ä 1390 ½g¦^À³
|
¹x¥Û¤j¡A ¤p§Ì¨S¦³¥´ºâ§ä±z¡A ¥u¬O¸ò±z¤À¨É¤@½gµ§°O ±zÀ³¸Ó¤£·|¤Ï¹ï§a¡I ¹x¥Û¤j¡A¦U¦ì¤j¡A ¥x¤jÂå°|§K¬Ì·Àã¬ì³\ªÃ¹çÂå®v»¡¡G 1.2016¦~ASCO¡A§K¬ÌÀøªk¤´±N¤j©ñ²§ªö¡C 2.¨CÓ¤ë¬Æ¦Ü¨CÓ¬P´Á³£¦³°ê»ÚÃļtµoªíªºÃö©ó§K¬ÌÀøªkªº´Á¥Z½×¤å¥X¨Ó¡C 3.°ê»Ú¤jÃļt¯{¤F¼Æ¦Ê»õªº¿ú¦b§K¬ÌÀøªkªºPD-1¡BPDL-1¡BCTLA-4¡B TIM-3¡BLAG-3¡BCD28µ¥T cellªºInhibitory receptors©ÎActivating receptors¤W±¡A¥u®`©È¦Û¤v¦b¥¼¨ÓªºÀù¯gªvÀøªº¥D¬y§K¬ÌÀøªk¤À¤£¨ì¤@ªMü¡A°ê¤º·sÃĬÛÃö¤½¥q¦pªG·Q§ë¸ê¬ãµo¦bPD-1¡BPDL-1¡BCTLA-4µ¥³o¨Ç¤jÃļt¤w¸g¯{¤j¿úªº¶µ¥Ø¤W¡A³Ì¦nªº§@ªk¬O¤£n¦A°µ¤U¥h¡A§â¿ú¬Ù¤U¨Ó¡A°µ¨ä¥¦ªºµo®i¡C 4.¤p¤À¤lÃĪ«©Î¼Ð¹vÃĪ«¦pªGM PFS¤£¯à¤ñ²{¦³¼Ð·ÇÀøªkÃĪ«´£°ª¨ì50%¡A¬Æ¦Ü100%¡A´N¤£·|¨ü¨ì¤Ó¤jªºÆf¥Ø¡C ¥x¤jÂå°|¸~½FÂå¾Ç³¡ªL®a»ôÂå®v»¡¡G(¸~½FªºÀù¯g) 1.§K¬ÌÀøªkPD-1¡BPDL-1¡BCTLA-4µ¥ÃĪ«¡A¤jÃļt¤£¥u³æÃĪvÀø«ùÄò¶i¦æ¡A¨â¨â¤¬¬Û²Õ¦XªºÁp¦X¥ÎÃĤ]¦bÁ{§É¹êÅ礤¡A¦]¬°¥Ø«e¤w®³¨ìÃÄÃÒªºªº§K¬ÌÀøªkÃĪ«¡AOSªø§Àªº¤j¬ù¥u¦³¨â¦¨(¥H¶Â¦â¯À½F¤ÎNSCLC¬°¨Ò¤j¬ù¬O¨â¦~¥H¤Wªºªø§À)¡A¬ì¾Ç®a¸Õ¹Ï³z¹L¨â¨â²Õ¦Xªº§K¬ÌÀøªkÃĪ«¼W¥[ªø§Àªº¤ñ¨Ò¡A¦ý°Æ§@¥Î¼W¥[ªº·ÀI¤]¤j´T´£°ª¡C 2.¤wª¾ªº§K¬ÌÀøªkÁ{§É¹êÅç´X¥G³£·|¦³delay response(2Ó¤ë~3Ó¤ë)¤Î®û¼í²{¶H¡A¦³§K¬Ì¤ÏÀ³ªº±wªÌ¡A¦³ªº¸~½F·|ª½±µÁY¤p¡A¦³ªº¸~½FµyÅܤj¦AÅܤp©ÎªÌStable disease¡A¦³ªº´Nª½±µÅܤj¨ì¶W¹L25%¦Ó¦¨¬°PD¡C 3.¦³§K¬Ì¤ÏÀ³ªº±wªÌ¡AÆ[¹î¸~½Fª½±µÁY¤p©Î¸~½F¥ýÅܤj¦AÁY¤p¡A»P±wªÌ¥¼¨ÓªºOSªí²{¥¼¥²¦³©úÅ㪺Ãö«Y¡C 4.¤@¯ëªº¤ÆÀø©Î¼Ð¹vªvÀø¡A¸~½FY¦³mutation·|¤ñ¸ûÃøªvÀø¡A¦ý§K¬ÌÀøªk¹ï©ó¦³mutationªº±wªÌ¤ÏÀ³¤Ï¦Ó¤ñ¸û¦n 5.¬ì¾Ç®a¸Õ¹Ï³z¹Lbiomaker¡A¨Ó§ä¥X¬Ýþ¤@ºØ¯f¤H¾A¦Xþ¤@ºØÃÄ¡A¥Ø«eªº§K¬ÌÀøªk¤´µM¤£°÷ºë·Ç¡A¤£ª¾¹Dþ¨Ç±wªÌ·|¦¨¬°OSªºªø§ÀªÌ¡A¤]¤£ª¾¹Dþ¨Ç±wªÌªºÀø®Ä¤£¨Î¡C ³¯¹a¬z¦Ñ®v»¡¡G GH°£¤F¦b¸~½F²ÓMµo²{¤§¥~¡Atumor©P³òªº²O¤Ú²Ó¥]¤Î¦åºÞ²ÓM¤]·|¦³ GH-positiveªºªí²{¡A§Ï©»¬O¡y·P¬V¡zªº²{¶H(·íµM¤£¬O·P¬V)¡A²O¤Ú¨t²Î³Q§í¨î¡AT-cell¡AB-cellªº§K¬Ì¥\¯à·|¤U°¡AGH-positive«h³y¦¨¤F¦åºÞªº¹L«×¼W¥Í¡A¦]¦¹YGH³Q±±¨î¦í¡A¦åºÞ¹L«×¼W¥Í©M²O¤Ú¨t²Î¤]·|«ì´_¥¿±`¡C ¥H¤W¬O¤@ÓªB¤Í¦b2016/3/30¡ASI2C©Ò¿ìªº¡uÀù¯g§K¬ÌªvÀø¦b¥xÆW¡v©Ò°µªºµ§°O¡A¤p§Ì±N¬Ý±oÀ´ªº³¡¤À¾ã²z¦p¤W¡Aµ¹¥Ø«e¤´¦³¯E¹©ªÑ²¼ªº¯E¤Í¡A·Q·Q¬Ý822±N¦b°ê»Ú¤j¼tªº§K¬ÌÀøªkª§¹Ü¾Ô¤¤¦û¦³¦óºØ¦a¦ì¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/4/18 ¤U¤È 09:27:17²Ä 1389 ½g¦^À³
|
§ó¥¿~´N¤p§Ì©Òª¾ Cox model ¬O¥Î¨ÓÀËÅçeffect side ´N¤p§Ì©Òª¾ Cox model ¬O¥Î¨ÓÀËÅçeffect size ¬Û«H½×¾Â¤W ³\¦h«e½ú³£ª¾¹D§Ú¤§«e©«¤å¦³»~ ¥t¥~ ¤p§Ì¤´µM°í«ù ¦]¬°±±¨î²Õ¥´Àù¼w¬P ¥B¹êÅç²Õ¦³©µ¿ð¤ÏÀ³ ©Ò¥H¨Ï±o±±¨î²Õ¤¤¦ì¼Æªº«e¬qKM¦±½u¤ñ¸û¹êÅç²ÕLM¦±½u¥k²¾ ¥t¥~ ¤p§Ì¬O¤£ª¾¹D¨ä¥¦Àù¯gÃĪºHR¦h¤p ¦ý¬O822YÅý¦³¥|¿§ÜÅé¿@«×ªº¦¸±Ú¸s¦³0.2©Î§ó¤pªºHRÈ ´Nªí¥Ü80%¥|¿§ÜÅé¿@«×ªº¦¸±Ú¸sn¤ñ±±¨î²Õ¦³©úÅ㪺Á{§ÉÀø®Ä 0.2¬OÓ¤H¹w´Á ¤£ª¾¨ä¥L«e½ú¥H¬°¦h¤Ö¬°¦X¥G¹w´Á? |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/4/18 ¤U¤È 01:16:15²Ä 1388 ½g¦^À³
|
·PÁÂCliff¤j´£¨Ñªº¤åÄm¡A¦Ñ¥v¤jªº¤À¨É ¡u¡§Statistically Significant¡¨Results¡GÅãµÛªº²Îp®t²§ •Response rates ¡Vproportions -Chi square test ¥HChi square test pºâRR •Survival curves ¡VKM -time to event (OS, PFS) ¥HK-M¹Ï¨Ó¬ÝOS¡BPFS ¡VMedian survival ¡Vmidpoint on KM curves ¡VP value -logrank test comparing the survival distributions (curves) ¥Hlogrank testpºâPÈ ¡VHazard ratio ¡VCox model assumptions ¥HCox model assumptionspºâHazard ratio¡]HR¡^ ¡VConfidence intervals (not overlap 1) •Clinically significant ? ÅãµÛªºÁ{§É·N¸q¡H¡v ¥H¤p§Ì±q2/21¡A2/22¡A3/31ªº°OªÌ·|»Pªk»¡·|¤º®e±À½× 822ªºÁ{§Éµ²ªG¤£·|¥X²{Theratope 2003¦~¤T´ÁªºÃþ¦ü¹Ï«¬(¨â±ø¦±½u±qÀY¨ì§À©Ô¤£¶})¡APFSªºKM¹Ï«¬¤ñ¸û®t¡A«e¥b¬q¤£¥u¬O¤À¤£¶}¡AÁÙ¥²¶·§e²{¬YºØµ{«×ªº³Âªá(¤¬¦³¿éĹ)¡A«á¥b¬q¨â²Õ´N©úÅã©Ô¶}®t¶Z¡COSªºKM¹Ï«¬¡A¦]Æ[¹î®É¶¡¤£¨¬¡A³]¸ê®ÆÁ٫ܦh(³\¦h¤HÁÙ¬¡±o¦n¦nªº)¡A¦]¦¹¤½¥q»¡§e¥¿±ªºÁͶաA¦ý¹Ï«¬¤ñPFS¦n¬Ý¡A¨â±ø¦±½u±q«e¥b¬q´N¤w¸g³vº¥¤À¶}¡A¹ï·Ó²ÕªºM OS¥i¯à¤w¥X²{¡A¹êÅç²ÕªºM OSÀ³¸ÓÁÙ¨S¥X²{(¦pªG¨â²Õ³£¤w¥X²{¡A¤½¥qÀ³¸Ó·|Á¿OSªºPȬO§_¹F²ÎpªºÅãµÛ)¡C YASCO¤½¥¬ªºKM¹Ï»P¥H¤Wªº®t²§¤£¤j¡A±q¤WzªºFDA¼f®Ö¼Ð·Ç Response rates¡X¥un¤£¿éµ¹¦Ñ¥v¤j«e´X½g¦³ÃöYervoy¡BOpdivo¡BKeytrudaµ¥§K¬ÌÃĪ«´N¦æ¤F¡A¦]¬°²¦³ºÁÙ¬O¸ò¸~½FªºÅܤjÁY¤p¦³Ãö¡A´N¸ò¤WzªºÃĨӤñ¸û¡C Survival curves¡V¬ÝPFS¡A¤]¬ÝOS¡C¤£¥u¬Ý²ÎpPÈ¡Amidpoint¡BHazard ratio¡BConfidence intervals³£¬Ý¡CPFSªºKM curve¡A¦]¬°«e¥b¬q§e³Âªá¡A©Ò¥H¦bmidpoint©MPȤ£º}«G¡AConfidence interval¤]¥¼¥²¦³©úÅã®t¶Z¡A¦ý¦]curve«á¥b¬q¨â²Õ©úÅã©Ô¶}¡AHazard ratioÀ³¸Ó·|©úÅã¤p©ó1¡COSªºKM curve«e¥b¬q´N©Ô¶}¡A©Ò¥H¦bPÈ¡Bmidpoint¡BHazard ratio¡BConfidence intervals¤W³£·|¦³²ÎpªºÅãµÛ®t²§¡C Clinically significant ?M PFS ¨S¦³ÅãµÛ¡A¦ýM OS¦³ÅãµÛ¡AM OSªº«n©Ê»·¤j©óM PFS¡A ¦ÓClinically significantµû¦ô¥HM OS¬°¥D¡A¦]¦¹822¬OClinically significant¡C ¥H¤W¬O¤p§Ì¥Ø«eªº·Qªk¡AASCO¤½¥¬¼Æ¾Ú®É¦A¨Ó¤ñ¹ï¬Ý¬Ý¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/4/18 ¤W¤È 08:07:28²Ä 1387 ½g¦^À³
|
µLªº·P¿E ²³¤j¤jªº¤À¨É ¤×¨ä ¦Ñ¥v¤j Cliff ¤j®¦®v ¦Ñ´¤j±Ð±Â ¯E§J¤j ±a»â¤j¹Ù»{ÃÑFDAÃÄÃÒì«h ¹ê¨Ò©M¸É¥R ÁÂÁ¦AÁÂÁÂ! ·P®¦¦A·P®¦! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/4/18 ¤W¤È 07:19:20²Ä 1386 ½g¦^À³
|
ÁÂÁÂCliff¤j ¦Ñ´¤j ´N¤p§Ì©Òª¾ Cox model ¬O¥Î¨ÓÀËÅçeffect side ²ÎpÅãµÛ ±`±`¦]¬°¼Ë¥»¼Æ°÷¤j ²Ö¿n°_¨Ó ¥d¤è¦ÒÅç´N·|ÅãµÛ ©Ò¥Hcox ´£¥X®ÄªGȪºÀËÅç¼Ò¦¡ ¤@¯ë¨Ó»¡ HR ·ÀI¤ñ¶V§C ¥Nªí¹êÅç²Õ¥ÎÃĶV¦³®Ä ASCO ¤½§G®É ¤j®aÀ³ª`·N¦¹¼ÆÈ |
|
|
·|û¡G°Ñ¤@©@10141487 µoªí®É¶¡:2016/4/18 ¤W¤È 01:26:14²Ä 1385 ½g¦^À³
|
·PÁ¦ѥv¤j©MCliff¤jªº¤À¨É¡A¥u¯à·PÁ¡B·PÁ¡B¦A·PÁ¤F!! ¤p§Ì¶È¯à¸òÀH¤j¤j̪º¸}¨B«e¶i¡A¦b³oÃä³¥¤HÄmÃn¤@¤U¡CY¯E¤Í̹ï^¤å¦³¬ÈÄß·P¡A©Î³\¹Á¸Õ³oÓºô¯¸(¦L¶H¤¤¤§«e¦³þ¦ì¤j¤j¤w¸g´£¹L¤F): www.bioon.com/ ¸Ì±¦³«Ü¦hªF¦è¥i¥H¬Ý¡C¨Ò¦p¦Ñ¥v¤j¦b¹j¾ÀªOPOªºKeytruda¡A¤j¤jÌ¥i¥H¸Õ¬Ý¬Ý¦bºô¯¸¥k¤W¤è¶ñ¤J«á¬d¬Ý¬Ý¡A¦³«Ü¦h¬ÛÃöªºªF¦è¥i¥H¬Ý¡A¬Û«H¤j®a¬Ý¹L«á¡A¥i¥H·§²¤ª¾¹D°ê»Ú¤j¼t¦b·F¹À¡A¯E¹©¦³¬Æ»òÀu¶Õ¡A¨ì©³¬O¨ìþÓLEVEL¡C ³oÃä²³æÁ|¤@¤Uèè¤p§ÌºË¨ìªºªF¦è:¥|Ó¤u§@¤é¡I¬I¶QÄ_¤½¥q¸~½F·sÃÄOpdivoÀò§å³t«×³Ð¬ö¿ý--¦]¬°Opdivo¯à°÷ÅãµÛ´£°ª±wªÌªºÁ`Åé¥Í¦s²v¡C(¯E¹©ªºOS¦³¾÷·|¶Ü?) ¥t¤@Ó¨Ò¤l: Àq¨FªFPD-1§K¬ÌÀøªkKeytruda®i²{¤T³±¨Å¸¢Àù¡]TNBC¡^ªvÀø¼ç¤O--Á`½w¸Ñ²v¹F¨ì¤F18.5%(¤T³±©Ê¨ÅÀù¤w¸g¦³§K¬Ì©ÊÀøªkn·m¤F?) ³Ì«á¡A¸òÀH¨â¦ì¤j¤jªº»¡ªk¡A¯E¤ÍÌÅý§Ṳ́j®a¤@°_¶i¨B§a¡A¥´°ê»ÚÁɪº¯E¹©¡A®É¶¡¨ì¤F»ùȦ۵M·|¹üÅã¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/4/17 ¤U¤È 11:33:09²Ä 1384 ½g¦^À³
|
¦Ñ¥v¤j Cliff ¤j: ¨â¦ì¤j¤j¨C¤@¥X¤â³£Åý¤HÅåÆA Æg¹Ä¤£¤w. ·PÁÂ. «ùÄòN¹M«ôŪ¤¤. |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/17 ¤U¤È 10:58:27²Ä 1383 ½g¦^À³
|
Cliff¤j,·PÁ¤À¨É. PDF Page.47¡G³o¤@¬q½Ð²q·Q¤j¡B¤p©_¤j¡B¯E§J¤j¡BÅó±ø±ø¤j¡B¤Ñ©R¤j¡Kµ¥¤j¤j̬ã¨s¡C ¡u¡§Statistically Significant¡¨Results¡GÅãµÛªº²Îp®t²§ •Response rates ¡Vproportions -Chi square test ¥HChi square test pºâRR ^^^^^^^^^^^proprotion=category variable---¤]´N¬OÃþ§OÅܶµ, ¦³¤ÏÀ³(Åܤp)©ÎµL¤ÏÀ³(¨S¦³Åܤp) •Survival curves ¡VKM -time to event (OS, PFS) ¥HK-M¹Ï¨Ó¬ÝOS¡BPFS ¡VMedian survival ¡Vmidpoint on KM curves ¡VP value -logrank test comparing the survival distributions (curves) ¥Hlogrank testpºâPÈ ¡VHazard ratio ¡VCox model assumptions ¥HCox model assumptionspºâHazard ratio¡]HR¡^ ¡VConfidence intervals (not overlap 1) ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^95% CI¨S¦³¸I¨ì1=²Îp¤W¦³ÅãµÛªº·N¸q,¦]¬°¥H¤WªºÅܶµ:RR, PFS,OS,MPFSµ¥³£¬OÃþ§OÅܶµ,¨â²Õ¤§¶¡ªº¦MÀI¤ñHR´N¬O¨â²Õ¬Û°£(ratio)ªº·§©À,¸I¨ì1´N¥Nªí²Îp¤W¨S¦³ ÅãµÛªº·N¸q;Yn¬Ýªºendpoint¬°³sÄòÅܶµ®É,´N¬O¬Ýmean difference,¨º´Nn¬Ý¦³¨S¦³overlap 0, ¬O¨â²Õ¬Û´î(difference)ªº·§©À •Clinically significant ? ÅãµÛªºÁ{§É·N¸q¡H ±z¦bP-48¤w¸ÑÄÀ,¦pªG¥u¦³¤@Ó,¨º»òÁ{§É¦³·N¸q¤ñ²Îp¦³·N¸q§ó«n!!! ¦Ñ´¯Zªù§Ë©ò,¨£¯º~~ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/4/17 ¤U¤È 10:13:48²Ä 1382 ½g¦^À³
|
Cliff¤j ·PÁ¡I 10000ÓÆg¡I ºÎ«e«ôŪ¤@¤U!¥[ªo¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/4/17 ¤U¤È 10:05:36²Ä 1381 ½g¦^À³
|
©IÀ³¦Ñ¥v¤j´¿»¡¹Lªº¡A§Ṳ́£¯àµ¥«Ý©Î¾¬±æ´CÅé©Î¦W¼L¸ò¤W§Ú̪ºµ{«×¡A¦pªG¥L/¦o̤@ª½¤£Ä@¥Î¥\ªº¸Ü©O¡H§ÚÌÁÙ¬On«ùÄò¶i¨B¡C §ä¨ì¤@¥÷¤åÄm¡A¥i¥HÅý§Ú̧ó¤F¸ÑFDAªºview¡C¡]ÁöµMº¶Án©ú¨ä¤º®e¤£¥NªíFDAªº¬Fµ¦¡^ ¡uFDA Oncology Drug Approval-- Endpoints, Effectiveness, and Approval¡vFDA¼f®Ö¸~½F¥ÎÃÄ¡XÀø®Ä«ü¼Ð¡B¦³®Ä©Ê¤Î®Öã¡A¦@72±iSlide¡C¡]www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm103366.pdf ¡^ ¨ú´X±i¨Ó¬Ý¬ÝPDF Page.14 ¡uSome trial considerations¡G¤@¨ÇÁ{§É¸ÕÅ窺¦Ò¼{¦]¯À¡G •Usual situation for many FDA drug approvals ¤@¯ëFDAÃÄÃÒ®Ö㪺±¡§Î ¡VMultiple studies ¦hÓ¬ã¨sµ²ªG ¡VStudies are large 1,000 ¡V5,000 patients ¦¬®×¼Æ1,000 ¡V5,000¦ì ¡VPlacebo control group ¦³¹ï·Ó²Õ ¡VDouble Blinded or a blinded independent assessmentÂùª¼©Î¦³¤Jª¼¿W¥ßµû¦ô³æ¦ì ¡VHighly significant p values (0.001) ¦³«D±`ÅãµÛªºpÈ •Oncology drug data submitted for approval ´£¥æÃÄÃҥӽЪº¸~½F¥ÎÃÄ ¡VOne study, 100 ¡V800 patients ³æ¤@¸ÕÅç¡A¦¬®×¼Æ100 ¡V800¦ì ¡VNo blinding, no placebo control ¶}ª¼¡BµL¹ï·Ó²Õ ¡VHeterogeneous patient group ¦¬®×±Ú¸s¦h¼Ë¤Æ ¡VStatistical evidence ~ 0.03 ¡V0.05 pÈ0.03 ¡V0.05 *Concern ¡Vhow confident can we be that results are real *ª`«ªº¬O¡X¯àµ¹FDA¦h¤Öªº«H¤ß¡A¬Û«H³o¼Ëªº¸ÕÅçµ²ªG¬O¯uªº¡H¡v PDF Page.47¡G³o¤@¬q½Ð²q·Q¤j¡B¤p©_¤j¡B¯E§J¤j¡BÅó±ø±ø¤j¡B¤Ñ©R¤j¡Kµ¥¤j¤j̬ã¨s¡C ¡u¡§Statistically Significant¡¨Results¡GÅãµÛªº²Îp®t²§ •Response rates ¡Vproportions -Chi square test ¥HChi square test pºâRR •Survival curves ¡VKM -time to event (OS, PFS) ¥HK-M¹Ï¨Ó¬ÝOS¡BPFS ¡VMedian survival ¡Vmidpoint on KM curves ¡VP value -logrank test comparing the survival distributions (curves) ¥Hlogrank testpºâPÈ ¡VHazard ratio ¡VCox model assumptions ¥HCox model assumptionspºâHazard ratio¡]HR¡^ ¡VConfidence intervals (not overlap 1) •Clinically significant ? ÅãµÛªºÁ{§É·N¸q¡H¡v ¤U¤@¬q¦³·N«ä PDF Page.48¡G ¡uStatistical / Clinical Significance ? ²Îpªº/Á{§ÉªºÅãµÛ·N¸q •Best case ¡Vhave both ³Ì¦n¬O¥H¤W¨âªÌ¬Ò¨ã •Can you have stat sig. but not clinical ¡Vyes ¦³¨S¦³¥i¯à²Îp¤WÅãµÛ¦ÓÁ{§É¤W¤£ÅãµÛ¡H--¦³¡I ¡VApproval likely ? No ¥i¯à®³ÃÄÃҶܡH¤£¡I •Can you have clinical sig. but not stat ¡Vyes ¦³¨S¦³¥i¯à²Îp¤W¤£ÅãµÛ¦ÓÁ{§É¤WÅãµÛ¡H--¦³¡I ¡VApproval likely ? It depends ¥i¯à®³ÃÄÃҶܡH¬Ý±¡§Î¡I •Phase 2 results ¤G´ÁÁ{§É¸ÕÅçµ²ªG •Statistical design may become inappropriate ²Îp³]p¤£·í •Safety advantage, Other ¦w¥þ©ÊªºÀu¶Õ¤Î¨ä¥L •Clinical benefit is the goal! ¥Øªº¬OÁ{§É®Ä¯q¡I¡v ³o³¡¤À©IÀ³¤F¦Ñ¥v¤j¤j«e´X½g¦³ÃöPD-L1/CTLA-4ªº·sÃļf®Öµ²ªG¬ã¨s¡A¦³§U©ó¤F¸ÑFDA¼f®Ö¸~½F·sÃĪº¨¤«×¡C72¶ªº¤º®e»á¬°Â×´I¡A¦³¿³½ìªº¤H¥i¦Û¦æ¬ã¨s¡C ¤p·s¤j¡G ¤W¦¸±zªº°ÝÃD¡G Q¡G¡uFDAªº°Q½×·|ij,¬O§_¦pT-vec ¯ë¥Ó½ÐÃÄÃÒ«e·|¦³FDAªºCTGTAC¡]²ÓM¡B²Õ´¡B©M°ò¦]Àøªk±M®a©eû·|¡^©MODAC¡]§Ü¸~½FÃĪ«±M®a©eû·|¡^¡H¡v A¡G¡]From FDA¡G¡yMeetings With FDA¡z¡FJudit Milstein¡F2013 Jun 20¡^¡G ¡uPre-NDA/BLA Meeting¡GEarly discussions on priority or standard review, and need for Advisory Committee meetings ¡v ¡uAdvisory Committee meeting is the default for all New Molecular Entities (NMEs)¡v ©Ò¥H±À´úEOP2·|ij¤£»Ýn¥Ó½Ð¥l¶}Advisory Committee meetings¡F¦ý¬OY¤@¥¹±Ò°Ê¥Ó½ÐÃÄÃҮɡA¤£ºÞ¬O®³¤G´Áµ²ªGÁÙ¬O¥¼¨Ó¤T´Áªºµ²ªG¥h¥Ó½Ð¡AÀ³¸Ó³£n¥ý¥Ó½Ð¶}Advisory Committee meetings¡A¦]¬°822ÄÝ¥þ·s¤À¤lµ²ºc¡]NMEs¡^¡C ³\¤j¤j¡G ±zªº°ÝÃD¤p§Ì¤£²M·¡µª®×¡An½Ð±z°Ñ¦Ò¹x¥Û¤j»P«Øcc¤jªº¶K¤å¡C¤p§Ì¥uª¾¹D¹ï©¤¹ï©óGlobo H ªº¬ã¨s¨Ã«D¤@µL©Òª¾¡C ¡u肿½F¿}¬Ì]ªº¬ã¨s进®i. ÀN±`øÊ, 叶·s¤s¡v¡]www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjY1rXevZXMAhWEGpQKHStCBdQQFggaMAA&url=http%3A%2F%2Fwww.yxxb.com.cn%3A8081%2Faps%2FhomeAction!downloadArticleFile.action%3FattachType%3DPDF%26id%3D14145&usg=AFQjCNFms2fcVcC4tKnmnCtF180S0FSKHg ¡^ ¡u细Mªí±¿}链ÉO肿½F¤z细M¡G201509¤¤°ê/¤¤µØ¯f²z¾ÇÂø»x¡v |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/4/16 ¤U¤È 07:24:08²Ä 1380 ½g¦^À³
|
¹x¥Û¤j ¬O¨S¿ù ´Nºâ¸ê®ÆÅuµ¹À´ªº±M®a¬Ý n°µ¥X¨ÓÃø«×¤]«Ü°ª ¦ý<°ÝÃD>¬O²³¤H¤]³\±aÂIµL·N¶¡µo²{ ¦Ó¥X²{ÆF·P¶i¦Ó¸Ñ¨M<°ÝÃD> ³oªÀ·|¬O¼Ò¥é¨Ó¼Ò¥é¥hªº©Ò¥H¤@ª½¥X²{·s²£«~ ´N¹³¤p§Ìè¨ìªF«n¨È¥þ¯¥Íªº¥«³õ ¤p§Ì¾ã¾ã«Ý¤F4Ó¤ë·dÀ´·í¦a¤Hªº¾P°â³f·½ ¤è¦¡¤Î¥«³õ³Ì«á¬O·í¦a¤H©Ê®æ ¾ã²z«á¤p§Ì¦³¼Ò¥é¤]¦³¦Û¤v·sªºµo²{ ³Ì«á¥i¤À¹¨ì¥«³õ ¤×¨ä¬O°ª§Þ³N¶V¶°¤¤ ¶V¤£»ÝÅý¤Hª¾¹D ¥u»ÝÅý¤j®aª¾¹Dµ²ªG ÁÙ¬O»Ý¤p¤ß¤£±o¤£¨¾ ¤p§Ì¦³µoµ¹¦n´Xӥߩe ½Ð¥L̪`·N (¤p§Ì´N¬O©È¤HÁÈ£« «¢«¢) °ß¤jÀ³¸Ó¦³¥LªºÃø³B§a ²¦³ºÁÙ±o±¹ï¥Lªºªø´Á¹Ù¦ñÌ ©Ò¥HÀ³¸Ó¨âÃø |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/16 ¤U¤È 06:44:27²Ä 1379 ½g¦^À³
|
¹ï©¤ªºÃÄ«~¬Fµ¦¥Ø«e«Ü¶Ã¡A¦U¤è»¡ªk³£¦³¡C¯¸¦b¯e±±¤¤¤ß»P°ê®a°]¬F¥ß³õ¡A§Æ±æÃÄ»ù¦X²z¤Æ¡A©Ò¥H§Æ±æ¥D±À°ê²£ÃĪ«¡A¯à°÷¥é»s¶i¤fÃĪ«³Ì¨Î¡C¦ý¬O¥h¦~¥X¤F¤@Ó44¸¹¤å¡A¥H«~½è±±ºÞ¬°¦W±NªùÂe©Ô±o«D±`°ª¡A¦³¥i¯à·|¿W«p¶i¤fÃĪ«¡C ¹ï©¤¹L¥h¦]¬°ÃÄÃҥӽЯBÀÝ¡AÁ{§É¹êÅ礣¶È«~½è¦³°ÝÃD¡A¬Æ¦Ü¦³³y°²¨Æ¥ó¡A©Ò¥H²{¦b·Qn´£°ª«~½è¡C¦ý¬O¤j³°ªºÁ{§É¸ê·½»P«~½è¥ý¤Ñ¤£¨¬¡A©Ò¥H¥Ø«eÃÄÃҥӽЦ³ÂI¥b°±º¢ª¬ºA¡C¦ôp¯E¹©n¥h¥Ó½ÐÁ{§É¤]nªá¨Ç®É¶¡¡C ¦Ü©ó¬O§_¦³¤H¯à§â¾ã®M¸ê®Æ®³¥h¥é»s¡H¨ä¹ê¥ú¦³Á{§É¸ê®Æ¬O¨S¦³¥Îªº¡C«ç»ò§âÃĵ¹°µ¥X¨Ó¤~¬O°ÝÃD¡A¦]¬°¤£¶ÈKLH³oÓ³J¥Õ½è¬O¿W®a¥Í²£¡A¹ï©¤¶R¤£¨ì(«e¨â¤Ñ¤~½Í¹L³oÓ¸ÜÃD)¡A¦Ó¥B¯E¹©ªº±M§Q¤]¤£·|§â©Ò¦³»sµ{¨BÆJ¼g¦b¸Ì±¡A¦pªG³sµ²¶q¤£¨¬¡AÃĮĬO¥X¤£¨Óªº¡C³o¸ò¤p¤À¤lÃĤ£¦P¡A¤£¬O¤@ӤƾǦ¡´N¯à·d©wªº¡C |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2016/4/16 ¤U¤È 01:53:07²Ä 1378 ½g¦^À³
|
Cliff¤j~ «È®ð¤F. §Ú¬OÁy¥Ö¤ñ¸û«p ©Ò¥H¤æÁx¦V§A½Ð¯q §Ú¬Û«H¥H§Aªº±M·~¦^ÂÐ ¥H¸Ó¬O«Ü¦h¤H¥Ø«eµ¥«Ýªº¤[§ò¥ÌÀM ·PÁ±zªº±}°O»P¦^ÂÐ. ·Q¦A½Ð±Ð¤@¨Æ ¦pªG822ªº¼Æ¾Ú»PÀø®Ä¯uªº¦p°|ªø©Î±i¸³»¡ªº¨º»ò¦n ªF¦è®³¨ì¹ï©¤ ¬O¤£¬O¤w¸g¥i¥H®³¨ìÃÄÃÒ ¦Ó¥B¤w¸g¶}©l¦b¦U¤j¹A§ø¬I¥´ªvÀø? ¤p§Ì¦bĬÃh¤¯³Õ¤h¹L¥@«e¤@¦~¦hÅ¥¹L¨äºtÁ¿ ¥L»¡:¤U¤@Ó¥@¥N¤Þ»âªº·sÃĶ}µo¥i¯à¬O®Ö»Ä©ÎÁÞ¤À¤l »¡¯uªº·í®É§Ú®Ú¥»Å¥¤£À´¤]¤£ª¾¹D¬O¤°»ò ²{¦b¦^ÀY¨Ó¬Ý ÁÞ¤À¤l¬O¤@Ó«Ü«nªº¥¼¨Óµo®i«ÂI ¨º¦pªGÁÞ¤À¤lªº§Þ³N¥~¬y¨ì¹ï©¤ ¨º¹ï©¤ªº¥\¤O¬O§_·|¤j¼W ©ÎªÌ822°Ó¾÷¥¿¦¡´£«e®i¶}??? ¥H¤W¬O§Ú²³æªº°ÝÃD ÅwªïCliff¤j¤Î¨ä¥L¤j¤j¤£§[¦^Âнç±Ð ÁÂÁÂ. |
|
|
·|û¡G®È¤H10142235 µoªí®É¶¡:2016/4/16 ¤U¤È 12:25:52²Ä 1377 ½g¦^À³
|
5619¤j¡AÓ¤H¹Á¸Õ¹ïsiRNA°µ¤@¨Ç¨Ç¸ÑÄÀ¡C ¤HÃþ°ò¦]Æ^´OµÛµL¼Æªº¯f¬r°ò¦]»P¸õÅD°ò¦]¡A©Ò¥Hºt¤Æ¤W´N¦³¤º¥Í©Êªº siRNA (small interfering RNA) ¶i¦æ¦Û§Ú°ò¦]±±¨îªº³]p¡C ¤H¤u¦X¦¨³oºØsiRNA¦¨¥»«Ü«K©y¡A®i²{ªº§@¥Î¸ò¤p¤À¤lÃĪ«¾÷¨î¤]«Ü¹³¡A¦ý¤ñ¤p¤À¤lÃĪ«½d³ò§ó¼s¡A§ó®e©ö³]p¡A¤£¹L±Á{ªº°ÝÃD¤]¬OÃþ¦üªº¡C ¯EÃvªº°ò¦]¤§®ü¡AÀôÀô¬Û¦©¡A·Q¥H¤@өμÆÓÃöÁ䪺ªýÂ_¨Óªv¯f¡A·|¤Þ°_¦h¤Ö¤wª¾¤Î¥¼ª¾ªº¤ÏÀ³¡HÁÙ¦³«Ý§ó¦h¬ã¨s¡C OBI822¨«ªº¸ô¼Æ¤£¦P¡A¥L¤ñ¸û¹³¥~¬ì¤â³N¡A¨Dªº¬O°®°®²b²b°£±¼¤£nªº²ÓM¡C¥u¬O¡A³o§â¤â³N¤M¨Ó¦Û§Ú̦ۨªº§K¬Ì¨t²Î¡C©Ò¿×§Ö¤M±Ù¶Ã³Â°Õ¡I ¤£n³´¤J´X¸U¦~¨Óªº°ò¦]ºt¤Æ¹CÀ¸¸Ì¡Aª½±µ¬å±¼Ãaªº¡A¯d¤U¦nªº¡A¦A¾a´X¸U¦~¨Óªº¥Í²zºt¤Æ¡A¦Û§ÚÀø¡¡I§ÚÓ¤H¤ñ¸û³¼¦V³oÓ¸ô¼Æ¡I µ²½×¬O¡A§Æ±æ¯E¹©°ª¼h¡A¤]¦³¾÷·|¦Û§Ú×·Ò¡A¦Û§Ú´_ì¡C©È³o³õ¶Ë²ª¡AÅý¤H¤£¦pÂk¥h¡A§t¹~§Ë®]¥h¡A´N¤£ª¾¯E¹©½Ö¨Ó±µ¤â¤F¡I ¯¬ºÖ¥LÌ ¯¬ºÖ§ÚÌ ¦u±o¶³¶}¨£¤ë©ú¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/15 ¤W¤È 10:10:41²Ä 1376 ½g¦^À³
|
5619¤j ±q°Êª«¹êÅç¨ì§¹¦¨¤HÅé¤T´Á®³¨ìÃÄÃÒ¬O¤@¬qºCºCªø¸ô (10-12¦~) ³Ì«á¬O§_¦³®ÄÁÙ¬O¥¼ª¾ °Êª«¹êÅç»P¯E¹©Á{§É¤T´Á°µ¤ñ¸û¬O«ÜÃø¤ñ,À³®³¨âÓÁ{§É¤T´Áµ²ªG¨Ó¤ñ¸û ¤j®a³£ª¾¹Dªk»¡·|´£¨ìªºÆ[©À: °Êª«¹êÅç¯à²£¥Í§ÜÅé,¤HÅé¹êÅç¬O§_·|²£¥Í§ÜÅé,·|²£¥Í§ÜÅé¬O§_¯à±þÀù²ÓM,¯à±þÀù²ÓM«á¤H¬O§_¯à¦³¸û¨Îªº¦s¬¡´Á ¦U¦ì¤j¤j«ä¦Ò¤@¤U¨ÅÀùOBI822 °µ¨ì¤F¶Ü? |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/4/15 ¤W¤È 09:51:08²Ä 1375 ½g¦^À³
|
www.ted.com/talks/paula_hammond_a_new_superweapon_in_the_fight_against_cancer/transcript?language=en#t-174468 ¦U¦ì«e½ú¤j¤j¡ATED ¦³¤@³õºt説¡A´£¨ì¥Î©`¦Ì²É¤l±N siRNA ª`¤JÀù²ÓMªº³Ð·sÀøªk¡A¹êÅçµ²ªG«Ü¦n¡]°Êª«¹êÅç¤T³±©Ê¨ÅÀù¡^¡C³o·|¬O¯E¹©§K¬ÌÀøªkªºÄvª§¹ï¤â¶Ü¡H ¶¶«K«Øij¯E¹©¡]¤p§Ìª¾¹D¤½¥q¦³¤H¦b¦¹¼ç¤ô¡^¡AASCO¤§«á¬O§_¥i¥H¦w±Æ¦bTEDºtÁ¿¡A¦V¥@¬É¤¶²ÐÀù¯g§K¬ÌÀøªk¡H |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2016/4/15 ¤W¤È 07:31:13²Ä 1374 ½g¦^À³
|
©`¦Ì¤p¤k¤l¤j¡G ¤p§Ì¤W¯ZµLªk©ó¤W¯Z®É¶¡¤º¹ï¥~¥´¹q¸Ü¡AÁÙ¬O¦³¤j¤j¥i¥HÀ°¦£¥´µ¹¤½¥q? §Ú·|¸Õ¸Õ³o«H½cinfo@obipharma.com ¥u¬O¤£ª¾¦³¨S¦³¤H¬Ý¡C ¥t¥~¡A¥i¥H¬Ý¤@¤U¤U±ªººô§}(«Øij¥Íª«§Þ³N²Ä¤@¦ì) www.ptt.cc/bbs/Patent/M.1335540812.A.BDF.html |
|
|
·|û¡GHumble10141629 µoªí®É¶¡:2016/4/15 ¤W¤È 01:17:47²Ä 1373 ½g¦^À³
|
Cliff¤j... «D±`ºë±mªº¤À¨É...¨ü±Ð¤F... ¤p§Ì·M¨£...¥H¤½¥qªk»¡ºA«×+¤w¸g±Ò°Êªº¤T´Áplan·|ij+ASCO... °t¦X¶ÀÁ`©Ò¨¥£¸¤Á±N·|¥[³t... «D±`¦³¥i¯à¨«¬ð¯}©ÊÀøªkª§¨ú¤p¤T´Á...¦p¦¹½Í±ÂÅv¤]¤ñ¸û¯¸¤W·... ³æ¯Â²q´ú...«¢... |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/4/15 ¤W¤È 01:13:32²Ä 1372 ½g¦^À³
|
¤p·s¤j¡G EOP2 meeting¤§«e·|¤£·|¦³±M®a¿Ô¸ß·|ij¡H¤p§Ì©|¥¼§ä¨ìµª®×¡A©Ò¥Hµª¤£¤W¨Ó¡C ¦Ñ¥v¤j¤j¡G ±z¤ÓÁ¾µê¤F¡I¨S¦³±z¡A´N¨S¦³³o¬q¶K¤å¡A·PÁ±z¡I ²³¤jÌ¡G §ó¥¿¤@³B«e±ªº¶K¤å¡G²Ä¤T¬q ì¤å¡G¡u¡KFDAªº¡uBreakthrough therapy¡v»{ÃÒ¬O¦b2012/07/09³q¹L¹ê¬Iªº¡A¡K¡v §ó¥¿¡G¡u¡KFDAªº¡uBreakthrough therapy¡v»{ÃÒ¬O¦b2012/07/09³q¹L¹ê¬Iªº¡]µù¤T¡^¡A¡K¡v |
|
|
·|û¡GSu10142295 µoªí®É¶¡:2016/4/15 ¤W¤È 01:01:41²Ä 1371 ½g¦^À³
|
|
|
|
·|û¡G¦ÌÄ_10132489 µoªí®É¶¡:2016/4/14 ¤U¤È 09:54:59²Ä 1370 ½g¦^À³
|
¤p§Ì¶È¬O¤@¯ë§ë¸ê¤H,Ãö©óÁxºÞÀù¥H¤U¸`¿ý¦Û¦]µØ¥Í§Þ105¦~4¤ë¥÷¤½¶}»¡©ú®ÑP32: doc.twse.com.tw/pdf/201604_4172_B04_20160414_214431.pdf ÁxºÞÀù¦³¤TºØ¥Íªøªº§ÎºA¡G(1)ÁxºÞ©P³ò®û¼í«¬¡F(2)ÁxºÞ¤º¾À¸~½F¡F(3)¸~ª¬¸~½F¡C¨x¤ºÁxºÞÀù (IH-CCA)ªº§ÎºA§Y¬°ÁxºÞ¤º¸~¶ô«¬¡C°ß¤@¦³ªvÀø®ÄªGªº¤èªk¬°¥~¬ì¤Á°£©Î¨xŦ²¾´Ó¤â³N¡A ¦ý¬O«Ü¥i±¤ªº¬O¸Ó¯e¯f³Qµo²{®É¤j¦h¤w¸g¬°±ß´ÁÀù¡A¶È¦³30%¥ª¥k¥i¨Ï¥Î¥~¬ì¤â³NªvÀø¡C ÁxºÞÀù¤§¤Æ¾ÇªvÀøªº¦¨®Ä¬Û·í¤£¨Î¡A¥Ø«e¼Ú¬ü¥Dn¥«³õ¤]©|¥¼¦³ÃĪ«³q¹LÁ{§É¸ÕÅç¨Ã¥¿¦¡¨ú±oªvÀø¦¹¯e¯f¡C5- FU¬O³Ì¥ý¨Ï¥Î©ó§ÜÁxºÞÀùªºÃĪ«¡A³æ¿W¨Ï¥Î®É¶È¦³10%ªº®ÄªG¡F¤§«á¦X¨Ö¨Ï¥Îleucovorin ¡Binterferon-£\¡Acisplatin¤Îoxaliplatin«á¥i±o¦³ªº®ÄªG¥Ñ25%¼W¦Ü50%¡A¦Ó¤¤¦ì¼Æ¦s¬¡´Á (median survival)¥Ñ6Ó¤ë¨ì12Ó¤ë¡C¦X¨Ö¨Ï¥Îcapecitabine¤Îcisplatin¥i´î»´¬r©Ê¡A¨Ã¦³ 41%ªº®ÄªG¡A¤¤¦ì¼Æ¦s¬¡´Á¬°12Ó¤ë¡C³Ìªñgemcitabine³æ¤@¨Ï¥Î¦³®Ä¹F30%¡F¦X¨Ögemcitabine ¡Bcisplatin¡Bcapecitabine¤Îoxaliplatin¦³®Ä²v¹F36%¡A¤¤¦ì¼Æ¦s¬¡´Á¬°10¨ì15Ó¤ë¡A ºî¦X¤wµoªíªº½×¤å¡AÁ`µ²¬°gemcitabine¦X¨Öcisplatin©Îoxaliplatin ¥i¥H±o¨ì³Ì¨ÎªºªvÀø®ÄªG¡C ¦]µØ¥Ø«eªºGemcitabine Oral¨ú±o©t¨àÃÄ»{ÃÒ¤µ¦~§Y±N¶i¤J¤G´ÁÁ{§É¥i¥H¸ò¤½¥q°Ý°Ý¬Ý |
|
|
·|û¡GRussell10140734 µoªí®É¶¡:2016/4/14 ¤U¤È 09:19:08²Ä 1369 ½g¦^À³
|
½Ð°Ýª©¤W¦U¦ì¯«¤H¤j¤j ÁxºÞÀù¦pªG¥ÎKeytruda·|¦³®Ä¶Ü??? ÁÙ¬O¦³¨ä¥LÃĪ«¥i¥HªvÀø ÁٽФ£§[§i¤§..ÁÂÁ ¥»¨Ó´Á«Ý822¯à¦¤é¤W¥« ¥Ø«e¬Ý¨Ó§Æ±æ¤£¤j ü....¦pªG¯E¹©ªº822¯à¦³®ÄªvÀøÀù¯g Åý¥¦¦¤é¤W¥«¯uªº¥i¥H±Ï«Ü¦h¤H |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/4/14 ¤U¤È 06:35:29²Ä 1368 ½g¦^À³
|
Cliff¥S ±z¼gªº¤º®e¤ñ¦Ñ¥vºë±m¤Ó¦h¤F^^ Æg |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/4/14 ¤U¤È 02:33:48²Ä 1367 ½g¦^À³
|
¤å: big.sunyet.com/biol/a/n916609.html ¡i·s»D¨Æ¥ó¡j¡G¤µ¤Ñ¬ü°êFDAªºCTGTAC¡]²ÓM¡B²Õ´¡B©M°ò¦]Àøªk±M®a©eû·|¡^©MODAC¡]§Ü¸~½FÃĪ«±M®a©eû·|¡^ ¨âÓ±M®a¤p²Õ¥H22¡G1µ´¹ïÀu¶Õ¤ä«ù¦w¶i§Ü¸~½F¬Ì]talimogene laherparepvec¡]T-Vec¡^¥Î¤_±ß´Á¶Â¦â¯À½FªvÀø ¡CPDUFA¤é´Á©w¦b10¤ë27¤é¡A©¡®ÉFDA±N¨M©w¬O§_§å·ÇT-Vec¦b¬ü°ê¤W¥«¡C ½Ð°Ý Cliff ¤j: FDAªº°Q½×·|ij,¬O§_¦pT-vec ¯ë¥Ó½ÐÃÄÃÒ«e·|¦³FDAªºCTGTAC¡]²ÓM¡B²Õ´¡B©M°ò¦]Àøªk±M®a©eû·|¡^©MODAC¡]§Ü¸~½FÃĪ«±M®a©eû·|¡^ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/4/14 ¤U¤È 01:41:48²Ä 1366 ½g¦^À³
|
¦³ÃöFDAªºconditional approval¡A¤p§Ì»`¶°¨ìªº¸ê®Æ»P§PÂ_¡G¡]¦Ñ¥v¤j¤j¡A©êºp¡In¶K¤å«e¤~¬Ý¨ì±zè¦b¹j¾Àª©ªº¶K¤å¡K¡^ Ó¤H»{¬°¥Ø«e¬°¤î¡A¡uconditional approval¡v¨Ã¥¼¹³¡uFast track¡v¡B¡uAcclerated approval¡v¡B¡uPriority review¡v©Î¡uBreakthrough therapy¡v¨º¼ËÄÝ©óFDA¥¿¦¡ªº»{ÃҦ춥¡F¦ý¬OFDA¥x±¤U¤´¦³conditional approvalªº¹B§@¡]¥Î¡^¡A©Ò¥H¥Ø«e¡uconditional approval¡v¶È¬O¤@ºØ±Ôz©Êªº¦Wµü¡A©|¥¼¦¨¬°FDAªº±M¦³¦Wµü¡C ¥ý¬Ý¤@«h2012/05/04¤@½gForbesªº³ø¾É¡A¤å¤¤§@ªÌ»{¬°·sÃĬãµo¯Ó¿ú¯Ó®É¡A¤O³¯FDAÀ³§ó¦³°µ¬°¡A¦h®Öã¤@¨Ç°µ§¹Phase II«áªº·sÃÄ¡A¡u¡Kencourage the FDA to approve more drugs after mid-stage phase II testing, using a process called¡yconditional approval.¡z¡K¡v¡]µù¤@¡^¡A¨ä¹ê³o¦ì§@ªÌ¦Û2012/04/24´N¤w¸g´£¥X©IÆ~¤F¡]µù¤G¡^¡A¦ý¬O¨´¤µ¨Ã¥¼¬Ý¨ì¡uconditional approval¡v¥¿¦¡¦¨¬°FDAªº¤@¶µ·sªº·sÃĬãµo±MÄÝ»{ÃҦ춥ªº³ø¾É¡C ¤£¹L¡A¦pªG¦U¦ì¤£°·§Ñªº¸Ü¡A¤p§Ì¥H«e¤£¥u¤@¦¸´£¨ì¡AFDAªº¡uBreakthrough therapy¡v»{ÃÒ¬O¦b2012/07/09³q¹L¹ê¬Iªº¡A©Ò¥HFDAÀ³¸Ó¦bµy«áªº¤C¤ë¥HBTD³o¶µ§ó¼s§ó¦³¹ê½è®Ä¯qªº·s»{ÃҦ춥¨Ó¦^À³¦U¤èªº´Á«Ý¡A¹ê¬IBTD¨ì²{¦b¡A¥i¯à©|µL¢¤Á»Ý¨D¦A²K¤J¡uconditional approval¡vªº·s»{ÃҦ춥¡C ¨º¡uconditional approval¡vªººë¯«´N¦¹³Q¿ò§Ñ¡H ¦pªG§Ú̦AÄ~Äò°lÂܤU¥h·|µo²{¡A¿n·¥¥ô¨ÆªºFDA¤´µMÆF¬¡¦³¼u©Ê¦a§â¡uconditional approval¡vªººë¯«¹B¥Î¦b·sÃĪº¼f®Ö¤W¡C2015/12/11FDA®Öã¤FGenentechªº¬ãµo¤¤¤fªA·sÃÄAlecensa (alectinib)¡]µù¥|¡^¡A³o´Ú·sÃijQ¦³±ø¥ó¦aã¥Î©ó¨ã¦³ALK-positiveªºÂಾ©Ê«D¤p²ÓM©ÊªÍÀù¡A¥B¹ïPfizerªºXalkoriµL®Ä©ÎÃø§Ôªº±wªÌ¡CÀò㪺²z¥Ñ¨Ó¦Û©ó¨âÓmidstageªºÁ{§É¸ÕÅçµ²ªG¡A½Ð¦Û¦æÂI¾\¥h¬Ý¡Aȱoª`·Nªº¬O¡A¦bµù¥|ªºFDA·s»D½Z¨Ã¥¼¥X²{conditional approval±Ôz¡A¦ý¦bµù¤ªº´CÅé³ø¾É¤¤´N§â¥¦µø¬°¬Oconditional approval¡C¨ä¹ê³oÓÃĤw¸gÀò±oFDAªº¡uAcclerated approval¡v¡B¡uPriority review¡v¡B¡uBreakthrough therapy¡v¤Î¡uOrphan drug designation¡v»{ÃÒ¡A¥i¿×¤T¤dÃd·R¦b¤@¨¡A»Ý¤£»Ýn¦A¥[¤W¡uconditional approval¡vªº»{ÃÒ¡HÓ¤H»{¬°¡AFDA¥i¯à¤]»{¬°¥Ø«e¤w¸g°÷¥Î¡A©|µL¢¤Á»Ý¨D¦A²K¤J¡uconditional approval¡vªº»{ÃҦ춥¡C§g¤£¨£³oÓÃĨëD§¹¬üµL·å¡A¥¦¬O¦³¤@¨Ç¸ûÄY«ªº°Æ§@¥Îªº¡]µù¥|¡^¡A¡u¡KAlecensa may cause serious side effects, including liver problems, severe or life-threatening inflammation of the lungs, very slow heartbeats and severe muscle problems. Treatment with Alecensa may cause sunburn when patients are exposed to sunlight.¡K¡v¡C¡]¤×¨ä³Ì«á¤@¶µ¡A¦Y¤F³oÓÃÄ«á¬O¨£¤£±o¶§¥úªº¡A¥u¯à¦b®a·d¦Û³¬¡K¡^ ¦^¨ì822¨¤W¡AASCO¤§«á¡A±µ¤U¨ÓªºÃöÁä¬OFDA«ç¼Ë¬Ý«Ý822¤G´Áªº¸Ñª¼µ²ªG¡H ·í«en°È¡A¤½¥q°£¤F·Ç³ÆASCO·í¤Ñ³õ¤º¤W¥xªº¸ê®Æ»P³õ¥~±M®a¿Ô¸ß·|ijªº¸ê®Æ¤§¥~¡AÀ³¸Ó¦Ò¼{¦P®É¶i¦æ¥Ó½Ð»PFDAªº°Q½×·|ij¡]End-of-Phase 2 meeting¡FEOP2¡^¥H¤Î¥Ó½Ð¬ð¯}©ÊªvÀø»{ÃÒ¡C ¬ð¯}©ÊªvÀø»{ÃÒªº¥Ó½Ð¡G¦³¤F¤G´Á¸Ñª¼ªº¼Æ¾Ú¡A¬O¸Ó¥Ó½Ð¬ð¯}©ÊªvÀø»{ÃÒªº®ÉÔ¤F¡A´£¥X¥Ó½Ð«á60¤é¤º·|¦³µ²ªG¡A822¶Õ¦b¥²±o¡C³o¶µ»{ÃÒ¡A·U¦®³¨ì·U¦n¡A³Ì¿ð³Ì¿ð¦b·s¥þ²y¤T´Á¶}©l«e´Nn®³¨ì¡A¦³rolling review¤@¸ô¬Û¦ñ¡A·s¤T´Áªº¸ô¤ñ¸û¦n¨«¡A¥i¥HÁקK¨«ÞªP¸ô¡C³o¶µ¥[«ùªº®Ä²v¡A´N¤¤¸Î¹Î¶¤ªº¸gÅç¡A¥He-mail¸òFDA´£°Ý®É¡A¤@¶g¤º³£¯à±o¨ì¦^ÂÐ¥i¸êÃÒ©ú¡C »PFDAªº°Q½×·|ij¡]End-of-Phase 2 meeting¡FEOP2¡^¡G³oÓ·|ij»Ý¥Ñ¤½¥q´£¥X¥Ó½Ð¡A¤@¥¹´£¥X«á¡AFDA·|¦b21¤é¤º½T»{·|ij±Æ©w¤é´Á¡A¥B³Ì¿ð·|¦b60¤é¤º¥l¶}·|ij¡C¡]FDA type B meeting¡^ ·|ij«ÂI¦b¾ã²z¤@¡B¤G´Á¼Æ¾Ú¡A¬°«áÄò¤T´ÁÁ{§É¸ÕÅç³]p¾Q¸ô¡F¥B¦P®É°Q½×CMC¬ÛÃöªººØºØ²Ó¸`¡A©Ò¥HÁÙn·Ç³ÆCMCªº¸ê®Æ/¶i«×¡C«eªÌ¾ú¸g3/19 late-breaking abstractú¥æ§¹¦¨»P4/2Û´°±M®a·|ijªºµ²½×«á¡A¥i¯à®t¤£¦h¤F§a¡H«áªÌ±i¸³3/31»¡CMC¨S°ÝÃD¡A©Ò¥H¡A±µ¤U¨Ó¬O¦ó®É´£¥XEOP2·|ij¥Ó½Ð¡H ·|ij¤¤FDA±Mû·|¹ïÃļtªº´£°Ý¤©¥H¸Ñµª¡A©Ò¥HFDA§Æ±æÃļtn´£¥X¦Û¤vªººÃ°Ý¡A¤£n°Ý¶}©ñ¦¡ªº°ÝÃD¡A¨º¬O¥HÃļt¬°¥D¦Ó¥l¶}ªº·|ij¡A¤£¬O¥ÑFDA¥D¾É¡C¤]§Æ±æ¤£nÁ{®É´£¥X¤£¦b쥻±Æµ{¤ºªº°ÝÃD¡C©Ò¥H±À´ú822¸Ñª¼ªº³ø§i¯à§_ª½±µ¥Ó½ÐÃÄÃÒ¡A©Î¬O¦A°µÓ¤p¤T´Á´N¦n¡Kµ¥¡A»Ýn¤½¥q¥D°Ê±Æ¤Jijµ{´£°Ý¡C ¤Û·Q¦bBTD¼f®Ö©ÎEOP2·|ij¤W¯à¥X²{¹³¤ß®®½²¸³ªº©_¹J¡A·Q¶R¤@ÓÄ«ªG«o©ê¦^¤@Ó¤j¦è¥Ê¡]µù¤»¡^¡K ¥H¤W¸ê®Æ¤£¬O¨Ó¦Û¤½¥q¡A¶È¤p§ÌÓ¤H»`¶°¬ã§P¡A²³¤j̽ФŻ~¸Ñ¡AÅwªï«ü¥¿¡C ³\¤j¤j¡A¤p§Ì¤@ª½±}°OµÛ¸Ñª¼«á¤í±zªº¤@¥÷¤ÀªR¡A¹ê¦b¬O¤O¤§¥¼¶e¡Aª¯¼L¦R¤£¥X¶H¤ú¡C¤é«e¤~¥¿»P¸ê²`¯E¤Í°Q½×·|¤£·|¥X²{Theratope 2003¦~¤T´ÁªºÃþ¦üµ²ªG¡]µù¤C¡^¡A«á¨Ó¸g¥Ñ«üÂI¡A¥Ø«e¼f·V¼ÖÆ[¡C¦p±i¸³©Ò¨¥¡]2/21¡B2/22¤Î3/31¡^»¡ªk³£¬O¬Û¦Pªº¡B¥¿½Tªº¡F¦Ó¥B¸Ñª¼µ²ªG¤£¬O¥¢±Ñ¡A¥u¬O¥¼º¡¨¬·íªì³]pªº¥DnÀø®Ä«ü¼Ð¡F¥´¨ì¯uÃĪº´N¦³²£¥Í§ÜÅé¡A¦³²£¥Í§ÜÅé |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/13 ¤U¤È 10:33:49²Ä 1365 ½g¦^À³
|
¥NÂà5619¤jªº´£°Ý¡G Ãö©óconditional approvalªº©w¸q¥H¤Î©Mfull approval ªº®t²§,¤p§Ì¦bFDAªºAnimal & Veterinary°Ï¦³§ä¨ì¡A¦bDrugs°Ï«o§ä¤£¨ì¡C ½Ð¦U¦ìÄÀºÃ¡C |
|
|
·|û¡G©`¦Ì¤p¤k¤l10141142 µoªí®É¶¡:2016/4/13 ¤W¤È 10:28:55²Ä 1364 ½g¦^À³
|
§g¤j: ÁöµM¯E¹©¤½¥q¤º³¡¤]¦³¥i¯à·|ÂsÄý¯Eª©,¦ý±z³o¨Ç¹ï±M§Qªº°ª¨£¬O§_¤]¥i ¥H¥D°Êªº¤è¦¡¹ï¤½¥q«Ø¨¥? |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2016/4/13 ¤W¤È 07:43:50²Ä 1363 ½g¦^À³
|
°e³ø¤j¡G ¦³°}¤l¨S¬Ý±M§Q¤F¡A¤§«e¤Ñ¤Ñ¬Ý¡A¥u¬O³£¬Ý¹q¤lªº¡A¤@¯ë²Ä¤@¨B·|¥ý¬d¼Ú¬w±M§Q§½¡A¦]¬°¥L·|§â¬ÛÃöªº±M§Q®a±Ú¸j¦b¤@°_¡A ¥H±z»¡ªº³o½g¨Ó¬Ý¡A¤U±¬°§ä¨ìªººô§}¡G worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20160324&CC=WO&NR=2016044326A1&KC=A1 §A¥i¥H¬Ý¨ì Priority number(s): US201462050567P 20140915 ªí¥Ü³o½g¬O¥H¬ü°ê¬°Àu¥ýÅv¤é°e¶i¼Ú·ùªº ¥H¼Ú·ù³o½g¤W±ªº¤½¶}¤é2016-03-24©¹«e±À18Ó¤ë´N¬O°e¥ó¤é¡Aªí¥Ü³o¤G½g®tªº«e«á¨S¦³¦h¤[¡A¦]¬°³£¦³1¦~¥b«á¦Û°Ê¤½¶}ªº§@ªk¡A¦ýY¬O§Ú³B²z¡A§Ú¤£·|¦P®É°e¡A§Ú·|¦b°e¤J¬ü°ê±M§Q§½«á¡An¨ì1¦~ªº«Å§i´Á«e¦A°e¤J¼Ú·ù¡A³o¼Ë¦b¼Ú·ù¨ºªº¥i¥H±ßªñ1¦~¤~¤½§i¡A¥B¤G¦a±M§Qªº¼f¬dû¤£·|¤@¼Ë¡A¼Ú·ù¼f¥X¨Ó¸ò¬ü°ê¼f¥X¨Ó¡A¥i¯à¥Ó½Ð¶µ·|¤£¦P¡A©Ò¥H¡A§Q¥Î¤W±ªº¦n³B¬O¥i¥H¤£¦P®ÉÀ³¥I¤GÓ±M§Q§½¡A¥t¥~¡A¼Ú·ù¼fªº·|¤ñ¸û²Ó¦ý®É¶¡¤ñ¸û¤[¡A¥ý¦³¤@½g¬ü°êªº§@°Ñ¦Ò¡A·|¨î¼f¬dûªºµø³¥¡A¼f¬dûY¦³¥i¥H°Ñ¦Òªº±M§QÀ˯Á³ø§i¡A·|¬Ù¥h¤£¤Ö®É¶¡¡A¦ý¤]¦P®É·|¦³°½Ãiªº¤ßºA¡A¼f¬dû¤]¬O¦³·~ÁZÀ£¤Oªº¡A¦ÛµM¦³ªº°Ñ¦Òªº·|¤ñ¸û§Ö¥B¤ñ¸û¦n¼f¡C |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/4/13 ¤W¤È 03:01:16²Ä 1362 ½g¦^À³
|
¤s¤¤¤j ¨º¨S¤°»ò¦nºâªº¡A´N¡u§¹³Ó¡v°Ú¡I ´N¥Ø«e©Ò±oªº¸ê®Æ¨Ó¬Ý¡A¦³¨º¤@ÂI¤£¬Oº¡¤À¶Ü¡H ¥t¡A¦^¹x¥Û¤j¡G ¥unÃÄ«~®ÄªG¦n¡A¾P°â¤]¤£¬O¤°»ò°ÝÃD¡I ºô¸ô¨º»òµo¹F¡Aµæ¥«³õ½æµæªºªü«¼¡A¦pªG¦³»Ýn¡A¤]·|¤Wºô¬d¡A¤]ª¾¹Dn¥Î¤°»òÃÄ°Ú¡I ®ÄªG®t¤£¦hªºÃÄ¡A¤~n¥h±À¾P¡A¤~¦³¡u¾P°â¡v¤Î¡u«~µP¡v°ÝÃD¡A¦b¡u®ÄªG®t¤£¦h¡vªºª¬ªp¤U¡A¤j¤½¥qªºÃÄ¡A¦ûÀu¶Õ¡I ¨S¦³¹ªÀy¤j®a¶RªÑ²¼ªº·N«ä¡A¯Â¬ì¾Ç°Q½×¡AÅwªï´£¥X¤£¦P¬Ýªk¡I§ë¸ê»Ý¦Ût¬ÕÁ«¡I |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2016/4/12 ¤U¤È 10:58:11²Ä 1361 ½g¦^À³
|
ÁÂÁ Cliff¤j Ãö©ó¤º¤åªº¸Ñ»¡.¤Î §g¤j ªº±M§Q»¡©ú... ¤¤¥¡¬ã¨s°|ªº±M§Q..·s©_ÁÞ¦@³mª«¤Î¨äÀ³¥Î(http://otl.sinica.edu.tw/index.php?t=9&group_id=22&article_id=1457) ÁÙ½ö¦b¨º..³o±M§Q¬OOBI¦Û¤vªº ¤pªºµL²á¹ï³o½s½X."WO"2016/044326"A1".¥Nªí·N¸q¬d¤F¤@¤U.. (WO) PCT A1 ¡X ±a¦³À˯Á³ø§iªº±M§Q¥Ó½Ð»¡©ú®Ñ A2 ¡X ¤£±aÀ˯Á³ø§iªº±M§Q¥Ó½Ð»¡©ú®Ñ A3 ¡X À˯Á³ø§i https://images.webofknowledge.com/WOK46/help/zh_CN/DII/hcodes_wipo.html PCT¡X¡X°ê»Ú±M§QÅé¨t ±M§Q¦X§@±ø¬ù(PCT)¤è«K¥Ó½Ð¤H¦b°ê»Ú¤W´M¨D¹ï¨äµo©úªº°ê»Ú±M§Q«OÅ@¡A説©ú±M§Q§½§@¥X±M§Q±Â¤©¨M©w¡A«K§Q¤½²³¬d¾\³o¨Çµo©ú¤¤¯A¤ÎªºÂ×´I§Þ³N¸ê°T¡C ®Ú¾ÚPCT´£¥æ¤@¥ó°ê»Ú±M§Q¥Ó½Ð¡A¥Ó½Ð¤H¥i¥H¦P®É¦b¥þ¥@¬É148Ó°ê®a´M¨D¹ï¨äµo©úªº«OÅ@¡C ¤F¸Ñ§ó¦hPCTª¾识 http://www.wipo.int/export/sites/www/pct/zh/basic_facts/faqs_about_the_pct.pdf ¯E¹©¥[ªo..... |
|
|
·|û¡G¤s¤¤10141474 µoªí®É¶¡:2016/4/12 ¤W¤È 09:23:27²Ä 1360 ½g¦^À³
|
²³¤j¦w ¤U¤åÂà¶K¦ÛCLIFF¤j©ó2015/8/8 10:49:55µo¤å¡A¤£ª¾¹D¬O§_¦³¯«¤H¥i¥H¥H²{¦b¤j¹Ù¤ÀªRªº¸ê®Æ±N822»PIBRANCE¤ÎHERCEPTIN°µ¤ñ¸û¡A¥H¤F¸Ñ822»PÄvª§¹ï¤âªº°ò¥»®t¶Z¡C ****************************************************************** ·|û¡GCliff10135274 µoªí®É¶¡:2015/8/8 ¤U¤È 10:49:55²Ä 370 ½g¦^À³ ¸¨¸¨ªøªº¤º®e¡A¬Ý¤F¨S¥´¬ÚÁÙ¯uÃø¡C ASCO¡]¬ü°êÁ{§É¸~½F¾Ç·|¡^¦b6¤ë22¤é©ó½u¤W¥Z¸ü¤@½g¤å³¹¡A§Æ±æ§â§ÜÀù·sÃĪº»ùÈ¥H¶q¤Æ¤ñ¸ûªº¤è¦¡§e²{¥X¨Ó¡A§@¬°¸~½F¬ìÁ{§ÉÂå®vªº°Ñ¦Ò¡C³o¤£¬OASCO²Ä¤@¦¸³o¼Ë°µ¡A¦¦b´X¦~«e´N¶}©l©IÆ~¾ã¦X¡A¨ä¥L¦U°ê¦p^ªk¼w¥[¿D¤]³£¦³Ãþ¦üªº·§©À®Ø¬[¡A°ò¥»¤W³£¬O¥H²{¦³ªºÁ{§É§ÜÀùÃĪ«ªºÁ{§É¸ÕÅç¼Æ¾Ú¨Ó¤ÀªR«Øºc¡A¸¨¹ê¡u¹êÃÒÂå¾Ç¡vªº²z©À¡A¦]¬°¬ì¾Çª`«ÃÒ¾Ú¡A¤@Ó·sªº§ÜÀùÃĪ«½Ï¥Í¡A¥i¥H±aµ¹±wªÌ¦h¤jªº§U¯q¡A¤£¬O¬Ý¬ÝFPS¦³¦h°ª¦Ó¤w¡A¤]¤£¬O¥u¬Ý°Æ§@¥Î¤j¤£¤j¡A§ó¤£¥i¯à¾Ì·Pı·Q¹³©Î¥u¾ÌÃļt®ï¶Ôº}«Gªº·~°È¥Nªíªº¤@±¤§Ãã¡A¤@¤Á³£¬Ý¬ì¾ÇÃÒ¾Ú¡A¦³´X¤ÀÃÒ¾Ú»¡´X¤À¸Ü¡C¯u¦³¤H¬°¥i¥H¥DÆ[¾Þ±±ªº¬OÃÄ»ù¡A¦Ó³o¶µ¤]³Q¦C¤J·sÃÄ»ùȵû¦ô¤¤ªº¤@¶µ¡C ASCO¦b¦¹Ä³ÃD¤WªºÃöª`¡A¸g¹L¦h¦~ªººtÅܨì¤F2013¦~¡A¥ÑASCOq¥X¡uÀù¯g·ÓÅ@¤u§@ªº®Ö¤ß»ùÈ¡v¡]ASCO Value in Cancer Care Task Force¡^¡AÂê©w¡u¦³»ùÈ¡vªº§ÜÀù·sÃÄ¥²¶·¥[±jª`«Àø®Ä¡]Clinical Benefit¡^¡B°Æ§@¥Î¡]Toxicity¡^¡B¶O¥Î¡]Cost¡^µ¥±¦V¡C³o¬O±q°ê®aÂå¾Ç¬ã¨s°|¡]The Institute of Medicine¡FIOM¡^©Ò´¿´¦òUªº¤»¶µ«~½è«ü¼Ð¤¤¬D¿ï¥X¨Óªº¡]¦w¥þ©Ê¡B¦³®Ä©Ê¡B¥H±wªÌ¬°¤¤¤ß¡B¾A®É©Ê¡B®Ä²v¤Î¤½¥©Ê¡^¡C¹³·¥¤F§ÜÀù·sÃĪº¤K¦r½×©R¡A¤]¹³¬O§ÜÀù·sÂÂÃĪ«ªºPKÁÉ¡C¡]§O§Ñ¤FASCO«D±`¥i¯à¬O822ªì¸Õ³ÚÁnªº»R¥x¡K¡^ ì¤å¡G¡uAmerican Society of Clinical Oncology Statement¡GA Conceptual Framework to Assess the Value of Cancer Treatment Options¡vonline Jun.22, 2015 ºô§}¡G¡ujco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6706.full.pdf+html ¡v ¤K¦rµû¤Àªí¡]«¤j¯e¯f¡^¡GFig.1¡G¡ujco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6706/F1.large.jpg ¡v ¤K¦rµû¤Àªí¡]»²§UÀøªk¡^¡GFig.2¡G¡ujco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6706/F2.large.jpg ¡v §â§ÜÀù·sÃÄ»P¥DªvÀù¯gªº²{¦æ¼Ð·ÇÀøªk¤@°_µû¤ñ¡A¤À¦¨¤U¦C¥|Ó±¦V¤ñ¸û¡G 1.Àø®Ä¡]Clinical Benefit¡^ 2.°Æ§@¥Î¡]Toxicity¡^ 3.¥[¤À«GÂI¡]Bonus points¡^ 4.¶O¥Î¡]Cost¡^ ½Ð°Ñ¾\Fig.1¤K¦rµû¤Àªí¡]«¤j¯e¯f¡^¡C ¦~¬W¡]step.1¡^¡GÀø®Ä¡]Clinical Benefit¡^¡F³Ì°ª±o80¤À¡C §â§ÜÀù·sÃÄ»P²{¦æ¼Ð·ÇÀøªkÃĪ«ªºmedian OS®³¨Ó¤ñ¤@¤ñ¡C¬Ý·sªº¤ñªº¶i¨B¦h¤Ö¨Óµû©w·sÃĪº±o¤À¡C ¶i¨B´T«×¡G 0%-24%¡G±o1¤À¡C ¶i¨B´T«×¡G25%-49%¡G±o2¤À¡C ¶i¨B´T«×¡G50%-75%¡G±o3¤À¡C ¶i¨B´T«×¡G76%-100%¡G±o4¤À¡C ¶i¨B´T«×¡G¤j©ó100%¡G±o5¤À¡C ¦A§â±o¤À¼¥H16¡]OS¥[Åvp¤À16¿¡^«á¡A±o¨ìOS Score¡Fstep.1³Ì°ª±o¤À¬O80¤À¡C¥[Åvªº¤ñ«¬O¸g¹LASCO±M®aÌ°Q½×«áÀòPªº¦@ÃÑ¡C Á|¨Ò¨Ó»¡¡AªvÀøÂಾ©Ê«D¤p²ÓMªÍÀùÃĪ«Bevacizumab¡]¨£Fig.3-A¤ÎTable.A2¡^¡A ¹êÅç²Õ¡uBevacizumab+ Carboplatin+ Paclitaxel¡v»P¼Ð·ÇÀøªkªº¡uCarboplatin+ Paclitaxel¡v¹ï·Ó²Õ°µ¤ñ¸û¡G ¹êÅç²ÕªºOS¬O12.3Ó¤ë¡F¼Ð·ÇÀøªkªºOS¬O10.3Ó¤ë¡C ¶i¨B´T«×¡G¡]12.3-10.3¡^/10.3=19% ¤¶©ó0%-24%¡G±o1¤À¡A step.1 .OS Score¡G1x16=16/80¤À¡C Y¸Ó·sÃĨS¦³median OS¼Æ¾Ú¥i¥Î«ç¿ì¡H«h§ï¥Îmedian FPS¡A¦A§â±o¤À¼¥H11«á¡]PFS¥[Åvp¤À11¿¡^¡A±o¨ìPFS Score¡F³Ì°ª±o¤À¬O55¤À¡C Y³smedian PFS¤]¨S¦³¡A§ï¥Î¤ÏÀ³²vRR¡]Response Rate¡×CR+PR¡^¡A ¶i¨B´T«×¡G 0%-20%¡G±o1¤À¡C ¶i¨B´T«×¡G21%-40%¡G±o2¤À¡C ¶i¨B´T«×¡G41%-60%¡G±o3¤À¡C ¶i¨B´T«×¡G61%-80%¡G±o4¤À¡C ¶i¨B´T«×¡G81%-100%¡G±o5¤À¡C ±o¤À¼¥H8«á¡A±o¨ìRR Score¡F³Ì°ª±o¤À¬O40¤À¡C ¥Ñ¦¹¥iª¾¡A§ÜÀù·sÃĪºÀø®Äº«OS¡A¥u¬O¦]¬°°lÂܮɵ{±N©Ôªø¡A¦b¬ãµo®É®Ä/¸g¶O¤W³£¬O°ÝÃD¡A¤~¬ãµo¥X´À¥N«ü¼ÐPFS¡BRR¡BTTP¡]time-to-progression¡^µ¥¡C¡]³o¹ï©óPFS¤£¬O¨º»òÅå¤H¡AOS¬Û¹ï«GÄRªº822«Ü¦³§Q¡^ ¤ë¬W¡]step.2¡^¡G°Æ§@¥Î¡]Toxicity¡^¡F³Ì°ª±o20¤À¡C §â§ÜÀù·sÃÄ»P²{¦æ¼Ð·ÇÀøªkÃĪ«²£¥Íªº«¤j°Æ§@¥Î¡]grade.3-5¡^®³¨Óºâ¤@ºâ¡A¦U§Opºâ¦³¦h¤ÖºØªº«¤j°Æ§@¥Î¡C¬Ý·sÃĤñÂÂÃĪº«¤j°Æ§@¥ÎºØÃþ¡u¼Æ¥Ø¡v´î¤Ö¤F¦h¤Ö¦Ê¤À¤ñ¨Óµû¤À¡C ºØÃþ¼Æ¥Ø¼W¥[75%-100%¡A±o-20¤À¡C ºØÃþ¼Æ¥Ø¼W¥[50%-74%¡A±o-10¤À¡C ºØÃþ¼Æ¥Ø¼W¥[´T«×<49%©Î´î¤Ö´T«×<49%¡A±o0¤À¡C ºØÃþ¼Æ¥Ø´î¤Ö50%-74%¡A±o10¤À¡C ºØÃþ¼Æ¥Ø´î¤Ö75%-100%¡A±o20¤À¡C ©Ó¤W¨Ò¡A¹êÅç²Õªºgrade.3-5«¤j°Æ§@¥Î¦³22¶µ¡]Fig.3-A¤ÎTable.A2¡^¡F¼Ð·ÇÀøªkªºgrade.3-5«¤j°Æ§@¥Î¦³15¶µ¡C ¨âªÌºØÃþ¼Æ¥Ø¼W´î¡G¡]22-15¡^/15=47%¡F¼W¥[´T«×<49%¡Astep.2±o0/20¤À¡C ¤é¬W¡]step.3¡^¡G¥[¤À«GÂI¡]Bonus points¡^¡F³Ì°ª±o30¤À¡C §ÜÀù·sÃĪº¬ãµo¹Lµ{¤¤Y¦³²Îp¤W§e²{¦³·N¸qªºÀù¯g¬ÛÃö¯gª¬½w¸Ñ¡]pallia |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/4/12 ¤W¤È 08:07:30²Ä 1359 ½g¦^À³
|
·PÁ§g¤j´£¨ÑÄ_¶Q¸gÅç¡C |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2016/4/12 ¤W¤È 06:48:02²Ä 1358 ½g¦^À³
|
Cliff1 ¤j¡G ±M§Qªº«e¥b³¡¬O»¡©ú®Ñ¡A¤@¯ë¬Û¦üªº·|¼gªº¤@¼Ë¡A¬Æ¦Ü¦³»¡©ú®Ñ¼gªº«Ü¤j¡A¤@Ó»¡©ú®Ñ³£Ó®×¥ó³£¥Î¦P¤@¥÷¡A ¯u¥¿ªº®t§O¤£¦b»¡©ú³¡¥÷¡A¦Ó¦b³Ì«áªºªk«ß¥Î»yªº¥Ó½Ð¶µ claims ¤W¡A·|¦³¨Ç¤£¦P¡A¦ý¦³®É¤S·|«Ü¹³¡A³o¬O¦] ¬°³o¥u¬O°e¥ó«á´¦ÅSì½Z¡A·í¼f¬d®É¡A·|¸ò¼f¬dû¨Ó¨Ó¦^¦^ªº¦n´X¦^¡A¨ì®É·|§R¨Ó§R¥h¡A©Î¬OÁY±M§Q½d³ò¡A ³o¨Ç¹Lµ{¨ì³Ì«áªº®³¨ì±M§Q¸¹®É¡A¥Ó½Ð¶µ claims ¤Wªº¤º®eÁÙ·|ÅÜ¡A¥Ó½Ð¤H¤@©w¬O§Æ±æ½Ð¨ì³Ì¤jªºÅv§Q½d³ò¡A ¦ý¦b¼f¬d¤Hû¤W¤@©w¬O§Æ±æÁY¨ì¦X²zªº±M§Q½d³ò¡A©Ò¥H¡A¯u¥¿¦³»ùªº¤@¨Ç±M§Q¡A·|¥HÀç·~¯µ±K¦u°_¨Ó¡A¤£Åý ¤H®a¬Ý¨ì¡A¦]¬°±M§Qªº¥Øªº¬O¦b«OÅ@»P§Q¥Î¡A§Æ±æ¥Ó½Ð¤H¥Ó½Ð§âµo©úªº¤èªk»¡¥X¨Ó«á¡A¦b«OÅ@´Á¤@¹L´NÅܦ¨¤½ ²³¤~¬°¤j²³¥i¥H§Q¥Î¡C |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2016/4/12 ¤W¤È 04:45:30²Ä 1357 ½g¦^À³
|
2016-2-22 «½S¡I辉·ç¬ð¯}©Ê¨Å¸¢Àù·s药Ibrance获FDA§åã¥Ñ¤@线扩¤j¦Ü¤G线ªv疗HR+/HER2-¨Å¸¢Àù ¬ü国¨î药¥¨头辉·ç¡]Pfizer¡^¬ð¯}©Ê¨Å¸¢Àù药ª«Ibrance¡]palbociclib¡A125mg胶Ån¡^ªñ¤é³ß获FDA§åã扩¤jÓì应¯g¡A联¦Xªü´µ§Q±d肿½F学药ª«Faslodex¡]fulvestrant¡A¬t维¥q¸s¡^¡A ¥Î¤_±µ¨ü内¤Àªcªv疗¦Z¯f±¡进®iªº¿E¯À¨üÊ^阳©Ê¡]HR+¡^¡B¤Hªí¥Ö¥Í长¦]¤l¨üÊ^2阴©Ê¡]HER2-¡^±ß´Á©Î转²¾©Ê¨Å¸¢Àù¤k©Ê±wªÌªºªv疗¡C Ibrance¬O¥þ²y¤W¥«ªºº个CDK4/6§í¨î剂¡C¤§«e¡AIbrance¤w¤_2015¦~2¤ë获FDA¥[³t§åã¡A联¦XFemara¡]letrozole¡A来¦±Ðü¡^ ¥Î¤_¬J©¹¥¼±µ¨ü过¨t统ªv疗¥H±±¨î±ß´Á¯f±¡ªº绝经¦Z¤k©ÊHR+/HER2-±ß´Á©Î转²¾©Ê¨Å¸¢Àùªº¤@线ªv疗¡C¨ä¤¤¡AFemara¬O诺华ªº肿½F学药ª«¡C ¦¹¦¸扩¤jÓì应¯g§åã¡A¤]标§Ó着Ibranceªv疗HR+/HER2-¨Å¸¢Àù¦¨¥\¥Ñ¤@线ªv疗扩¤j¦Ü¤G线ªv疗¡A将显着扩¤jIbranceªº±wªÌ¸sÊ^¡C 业¬É对Ibranceªº°Ó业«e´º¤]¤Q¤À¬Ý¦n¡C¦¹«e¡A¥þ²y医药¦æ业调¬ãÉóÌÛGlobalData发¥¬报§i«ü¥X¡A辉·çCDK4/6§í¨î剂Ibrance将¥D导HR+¨Å¸¢Àù¥«场¡A ¨ä2023¦~ªº销°â额将达¨ì18.5亿¬ü¤¸¡A¦Óªü´µ§Q±dªºPARP§í¨î剂Lynparza将¥D导¤T阴¨Å¸¢Àù¡]TNBC¡^¥«场¡C¡]报§i¡G2023¦~¥þ²yHER2阴©Ê¨Å¸¢Àùªv疗¥«场将达¨ì61亿¬ü¤¸¡^ ȱo¤@´£ªº¬O¡AIbranceªº2Ïú组¦X¤è®×§¡获±o¤F¬ü国国®a综¦XÀù¯gÊI络¡]NCCN¡^ªº±À¯ò¡C ¨ä¤¤¡AIbrance+Femara¡]来¦±Ðü¡^组¦X疗ªk§@为2A类¡]Category 2A¡^±À¯ò¡A¥Î¤_绝经¦Z¤k©ÊHR+/HER2-转²¾©Ê¨Å¸¢Àùªº¤@线ªv疗¡C Ibrance+Faslodex¡]¬t维¥q¸s¡^组¦X疗ªk则§@为1类¡]Category 1¡^±À¯ò¡A¥Î¤_¤w±µ¨ü内¤Àªcªv疗¦ý¯f±¡进®iªº绝经¦Z¤k©ÊHR+/HER2-转²¾©Ê¨Å¸¢Àùªºªv疗¡A ¥H¤Î¥Î¤_¥¿±µ¨ü§Z±_§í¨î¡]ªö¥Î«P黄Ê^¥Í¦¨¿E¯À释©ñ¿E¯ÀLHRH¿E动剂¡^ªº绝经«e¤k©ÊHR+/HER2-转²¾©Ê¨Å¸¢Àùªºªv疗¡C ¦¹¦¸扩¤jÓì应¯gªº获§å¡A¬O°ò¤_关键III´ÁPALOMA-3临§É¬ã¨sªº数Õu¡A该¬ã¨s¯A¤Î521¨Ò¨Å¸¢Àù±wªÌ¡A调¬d¤FIbrance¤G线ªv疗¨Å¸¢Àùªº临§É潜¤O¡C 该¬ã¨s¤¤¡AIbranceÉOFaslodex¡]fulvestrant¡A¬t维¥q¸s¡^联¦X¥Î药¡A¥Î¤_¥¿±µ¨ü©Î¤w经±µ¨ü内¤Àªcªv疗¦ý¯f±¡恶¤ÆªºHR+/HER2-转²¾©Ê¨Å¸¢Àù±wªÌªºªv疗¡C 数Õu显¥Ü¡AÉOFaslodexªv疗组¬Û¤ñ¡AIbrance+Faslodex联¦Xªv疗组无进®i¥Í¦s´Á显着©µ长¡]¤¤¦ìPFS¡G9.5个¤ë vs 4.6个¤ë¡Ap¡Õ0.0001¡^¡B ÚÌ认ªº总缓¸Ñ²v¤j´T´£°ª¡]24.6% vs 10.9%¡^¡B缓¸Ñ«ù续时间¤]±o¨ì©µ长¡]9.3个¤ë vs 7.6个¤ë¡^¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/4/11 ¤U¤È 11:27:07²Ä 1356 ½g¦^À³
|
¤W¦¸¥Xª©¤jµo²{¤¤¤åª©ªº±M§Q¬OWO2015/159118¡F¡]µù¡^ ²{¦b³o¤@¦¸ªº¬OWO2016/044326A1¡F³o¬O讳¨ìªº822ªº¥t¤@Ó²Õ¦¨±M§Q¡Aºâ¬Oè¥XÄlªº¡C ´XÓ°ÝÃD¡G 1.¡u¡K¤G»Eª«¡A¤T»EÅé¥H¤ÎKLHªº¨ä¥L¦h»EÅé³s±µ¨ì¦hÓªºGlobo H³¡¤À¡K¡v³o³¡¤Àªº±Ôz¦b«eªÌ¡]WO2015/159118¡^¤w¥X²{¹L¡A©Ò¥H¨âÓ±M§Q¥E¬Ý¤§¤U«D±`ªº¬Û¦ü¡A¨ì©³®t§O¦bþ¸Ì¡A¥Ø«e¤p§Ì©|¥¼§ËÀ´¡CˬOµo²{¤@ÓKLHY±µ75±øGH¡]±i¸³¸Ñª¼«á»¡©ú·|¡^¡A¼¤WKLH±`§Î¦¨ªº¤G¤Q»EÅé¡]didecamer¡^¡A¥¿¦n¬O1500±øGH¡]¶ÀÁ`¤WÂd«eªk»¡·|¡^¡C 2.¥i¥H½T©wªº¬O¡A³o¨Ç³£¬O¯E¹©©Ò¾Ö¦³ªº822ªº²Õ¦¨±M§Q¡A³o¥y¸Ü¬Ý°_¨Ó¥²HµL©_¡A¥i¬O·Q·Q¡A822¤£¬O¥ÑMSKCC§ÞÂà¦Ó¨Ó¡A¨ä¦¨¤À²Õ¦¨¤£¬O¤w¸g¬OGH-KLH/QS-21¤F¡A¬°¤°»òÁÙ½ü±o¨ì¤½¥q¥h¥Ó½Ð±M§Q©O¡H³o´N¬O§Ú¥ý«e¡]2014/12/14¡^ªººÃ°Ý¡A¦A¶K¤@¦¸·í®Éªº¤º®e¡G¡u¥Ó½Ð822±M§QªººÃ°Ý¡A¬°¦óMSKCCªºphase I®É¤w¸g¹B¥ÎMMCCHÁäµ²¤è¦¡¨Ó³B²zGH»PKLH¤§¶¡ªº³sµ²¤F¡A«ç»òÁÙ½ü±o¨ìÅý¤½¥q¥h¥Ó½Ð822ªº±M§Q¡Hì¨Ó³oÓ±M§Q±j½Õªº¬O¡yGH»PKLHªºÁäµ²¤ñ¨Òªº¼W¥[¡z¡A¦Ó«DMMCCHÁ䪺¦³µL¡C¡v¡A¥i¯à¬O§Q¥ÎKLH¤WªºÂ÷Ói»Ä¡]lysine¡^¡A§ïµ½GH-KLHªºÁäµ²¡A¦AÂǵÛKLH³Ì°ª¥i¥H§Î¦¨¤G¤Q»EÅ骺¯S©Ê¡A¨ÏGH¦b822¤¤ªº§t¶q±K«×´£°ª¡A¹F¨ì¡u¥O¤HÅå©_ªº´£°ª¥\®Ä¡v¡C 3.§Ñ¤F¬Oþ¦ì¦W¼L«e´X¤Ñ¦b´CÅé¤Wªºµû½×¤å³¹»¡¡A½èºÃ¦b822¤¤ÄÝ©ó¯E¹©ªº§Þ³N¦bþùؤª¤ª¡Aµª®×´N¦b³oùØ¡A¬O¥L¦Ñ¥S¤£¥Î¥\¡A¤½¥q¦¨¥ß©ó2002¦~¡A´X¦~¨Óû¤u¨¯WÆp¬ãªº¦¨ªG¬O¦³ªº¡A¥u¬O°t¦X±i¸³ªº±M§Q«O¤[ªºµ¦²¤¡A¡u«Ü«i´±¦a¡v§â±M§Q¥Ó½Ð©µ«á¨ì2013/9¤ë¡]«eªÌ¡^¤Î2014/9¤ë¡]«áªÌ¡^¤~¥h¥Ó½Ð¡A´N¬O²`ª¾³o»â°ìªº°ªªùÂe¡A§Y¨Ï±ßÓ´X¦~¦A¥h¥Ó½Ð±M§Q¨ÌµM¥i¥H¿W¨B¥þ²y¡C¨Ã«D¥u¬O§ÞÂà¦ÛMSKCC¡]GH-KLH/QS-21°t¤è¡^©Î¤¤¬ã°|¡]¤j¶q»Ã¯À-¤Æ¾Ç¦X¦¨GH§Þ³N¡^¦Ó¤w¡C 4.¤]¦]¦¹¡A¥Î©óMSKCC°µªº822¤@´ÁÁ{§É¸ÕÅç»POBI°µªº822¤G/¤T´ÁÁ{§É¸ÕÅ窺®t§O¡A°£¤F¬I¥´¾¯¶q¡B¬I¥´®Éµ{¤£¦P¤§¥~¡A¥H¤ÎÃĪ«¥Í²£¤è¦¡¤£¦P¡]GH¦X¦¨ªk¡GMSKCC¡GGlycal¦X¦¨ªk¡FOBI¡G¤@Áçªk¡^¡AÁÙ¦³ÃĪ«²Õ¦¨ªº®t²§¡A¤]´N¬OGH-KLHÁäµ²¤ñ¨Ò¤£¦P¡]OBI>MSKCC¡^¡C©Ò¥H±q¾Ç²z¤W±À´ú¡AOBI°µªº822¤G/¤T´ÁÁ{§É¸ÕÅçÀø®ÄÀ³¸Ó·|¸û¦n¡A¦ý¬O¹ê»Úªº¸ÕÅçµ²ªG²o¯A¨ì¦¬®×±wªÌªº²Õ¦¨/¤H¼Æ¬Ò¤£¦P¡]Y¦¬¨ì¸û¦hGH freeªºÓ®×¡A¸Ñª¼µ²ªG¥²¤j¨ü¼vÅT¡^¦Ó¦³©Ò®t²§¡C¤]¦]¬°¦p¦¹¡A¤@´Áµ²ªGªºOSÁö¥O¤HÅåÆA¡A¦ü¥G¤£¾A¦X§â¥¦±¾¦b¼LÃä¡A©Îª½±µ»{¬°¤G/¤T´ÁÁ{§É¸ÕÅç¤]¸Ó¥X²{¬Ûªñ¡A¬Æ¦Ü¬Û¦Pªºµ²ªG¡C¡C 5.ɥΦѥv¤j»¡¹Lªº¡A§ÚÌ«ç¯à±H±æ¨º¨ÇÀݦۧåµû¡A«o¥u¦³¥®¸X¶éµ{«×ªº¤H¡A¨Ó¤F¸Ñ¬ã¨s©Òªº¤º®e¡H¡]°|ªø»P¤½¥qªº¬ã¨sºëµØ¡^»ÝÅý®É¶¡ÃÒ©ú¤@¤Á¡F·íµM¦bµ¥«Ýªº¹Lµ{¤¤¡A¤j®a¤]n§V¤O¸ò¤W¡A§OÅý¦Û¤v´¿¸g¬ã¨s©Ò²¦·~¡A¥L¤é«o¥u³Ñ¥®¸X¶éµ{«×¡C 6.·PÁÂ¥Xª©¤j¡A3/24è®Ö㤣¤[ªº±M§Q´N³Q±z§ì¨ì¡A¼F®`¡I µù¡G¸Ô¥»ª©page5¡G¡uCliff:2015/10/27 ¤U¤È 12:10:14¡v¡B¡u°e³øªº:2015/10/27 ¤U¤È 05:12:05¡v¡B¡u¤p©_:2015/10/29 ¤U¤È 01:31:13¡v |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2016/4/11 ¤U¤È 07:49:42²Ä 1355 ½g¦^À³
|
¥m¾´¤j¡G ¤p±M§Q½d³òªºÃÄ¡A¶q¦hªº¸Ü¡A±M§Q¦a¹Ï¤]¬O«Ü¥iÆ[ªº¡A¦ý«nªº¬On¦h¦b¼Ú¬ü¤¤µ¥¥Dn°ê®a¥d¦í±M§Q¡AÁöµM¥xÆW¦³¥Ó½Ð¦ý«n©Ê¤£¤î¥xÆW¡A¥i¥H¦h§Q¥Î PPH µ¥±M§Q°ª³t¤½¸ô§Ö³t¥d¦ì¡AY¥xÆWªº¥Ó½Ð¤é¬O³Ì¦ªº¦A½Ð¥Ó½Ð¤éªºÃÒ©ú¡A·í§O°êªº¥Ó½Ð¤é¥ý°e¤J¼Ú¬ü¤¤ªº±M§Q§½·íÀu¥ýÅv¤é¡A¥t¥~©Ò¦³ªº¥Ó½Ð¬Ò»Ý¦bµoªí«e°e¤J¡A¤£µM´¦ÅS«á·|¥¢¥h·s¿o©Ê¡A¥BÁn¦W¨Æ¶µ¥u¯à±Æ°£¦Û¤w¤wµoªíªº¦Ó¤£¯à±Æ°£¥L¤H¦b¦Û¤w´¦ÅS«á»P¥Ó½Ð«eªÅÀɬۦPªºµo©ú¡A³o¨Ç³£¬Onª`·Nªº¡A¥Bn¤p¤ßªº¼g¥X¸ò°ê¤º¬Û¦P¬ã¨s³æ¦ì©Ò¼gªº½×¤å¡B±M§Qµ¥¦³©Ò¤£¦P¡A¤£µM³£·|³Q¥H¥¢¥h·s¿o©Ê®Ö»é¡A¨Ãn¶i¤@¨BÁ׶}µ²¦X¡B±M¥Îµ¥¹Hªð¶i¨B©Êªº±¡§Î¡C |
|
|
·|û¡G©`¦Ì¤p¤k¤l10141142 µoªí®É¶¡:2016/4/11 ¤U¤È 06:25:00²Ä 1354 ½g¦^À³
|
¥m¾´¤j: 6¤ëªÑªF·|¤¤±zY¥i¥H´N±M§Q³¡¥÷µ¹¤½¥q´£¿ô¤Î«Ø¨¥´N¤Ó¦n¤F....¥i¥H¶Ü? |
|
|
·|û¡Gnina999910139545 µoªí®É¶¡:2016/4/11 ¤U¤È 05:28:00²Ä 1353 ½g¦^À³
|
£«¬Â¤j: ·P®¦! ¦³¦U¦ì«e½ú¤j¤j¯u¬O¤Ó©¯ºÖ¤F!! |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2016/4/11 ¤U¤È 05:16:55²Ä 1352 ½g¦^À³
|
¤W¬P´Á¥´¹q¸Ü¥h¤½¥q°Ý¦³Ãöobi888¬ãµo°ÝÃD,¤½¥q¦^µª:obi888¬O¤½¥q¦Û¤v¬ãµo¸ò¤¤¥¡¬ã¨s°|¨S¦³§ÞÂà°ÝÃD. |
|
|
·|û¡Gnina999910139545 µoªí®É¶¡:2016/4/11 ¤U¤È 04:39:08²Ä 1351 ½g¦^À³
|
¹x¥Û¤j: ·PÁ¸Ѵb ^^ ·P®¦£° |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/11 ¤U¤È 04:30:27²Ä 1350 ½g¦^À³
|
nina¤j¡A <<¤½¦ÐÂ÷¾¹ï«áÄòOBI833¡A888µ¥¬ãµo¬O§_·|¦³©µÌX©Î¤¤Â_ªººÃ¼{?>> OBI-833ªº°ò¦±M§QÄݩ󤤬ã°|¡AÀ³¸Ó¤w¸g±ÂÅvµ¹¯E¹©¡C³o³¡¤À¤£À³¸Ó¦³ºÃ¼{¡C OBI-888¤è±¡A¦ü¥G¤¤¬ã°|¨Ã¨S¦³³o¤è±ªº±M§Q¡A¤£¹LSloan-Kettering¦b1992¦~®³¨ìªº¤@½g±M§Q (US 5,173,292) «oÅã¥Ü¥¦¯à°µ¥XSSEA-3ªº³æ®è§ÜÅé (gal-globoside´N¬OSSEA-3¡A¨£±i¸g²z2015/10³ø§i)¡A¦¹±M§Q¦¤w¹L´Á¡ASK«áÄòªº¬ãµo¦ü¥G¤]³£Â੹GH¬Ì]¬ã¨s¡A¨S¦A¬Ý¨ì¦³GH¬ÛÃö³æ®è§ÜÅ骺±M§Q¡C ¬Ý¨Óµo®i888»Ýn¾a¤½¥q¤º³¡¤Hû¬ãµo¡A±M§QWO2015/157629°µªº´N¬O³o¤è±ªº¤u§@¡C(¨£¥m¾´¤j¡Awalker¤j¶K¤å) ¨ä¹ê¯Î°|ªø¥ô´Á¥u¨ì¤µ¦~¤Q¤ë¡A¦pªG¾á¤ß¤H¨«¯ù²D¡A¯E¹©¦´N¸Ó¦b¤½¥q¤º«Ø¥ß¦Û¨¬ªº¬ãµo¤H¤O¡A¤£¯à¤@ª½¨Ì¿à¤¤¬ã°|¡C ¤p§Ì³o¼Ë»¡¦³½M¤lºN¶Hªº¶ûºÃ¡A©Î³\³oÓ°ÝÃDÁÙ¬O¤U¦¸ª½±µ½Ð±Ð±i¸³¨Æªø¤~¯à±o¨ì¥¿½Tµª®×¡C |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/4/11 ¤U¤È 02:36:54²Ä 1349 ½g¦^À³
|
¯E³»Ãö©ó888¤@½g¡A822ªº¬O¨â½g¡C §Ú·d²V°O¿ù¤F¡A¦³²`«×ªº¬O¤¤¬ã°|¨º½g¡C ü¡A¦³ÂI±¼º£¡C ¥L±o¦h¥Î·sªºµo²{¦h¥Ó½Ð´XÓ¤p½d³òªº±M§Q¨ÓÀ~¤H¡A¦A¥ÎÃÄÃҤΪk³W¨Ó¸É±j¡C |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/4/11 ¤U¤È 12:55:01²Ä 1348 ½g¦^À³
|
¹ï¤£°_, ¦n¹³À³¸Ó¬O¥|½g, 1 ¸ò 2 À³¸Ó¸ò¬ü°ê¨º¨â½g¤@¼Ë 1. WO/2015/159118A2, A3 COMPOSITIONS OF CARBOHYDRATE VACCINE FOR INDUCING IMMUNE RESPONSE IN CANCER TREATMENT 2. WO/2014/107652A2, A3 VACCINES WITH HIGHER CARBOHYDRATE ANTIGEN DENSITY AND NOVEL SAPONIN ADJUVANT 3. WO/2015/157629A2, A3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 4. WO/2016/044326A1 IMMUNOGENIC/THERAPEUTIC GLYCOCONJUGATE COMPOSITIONS AND USES THEREOF |
|
|
·|û¡Gnina999910139545 µoªí®É¶¡:2016/4/11 ¤W¤È 11:34:20²Ä 1347 ½g¦^À³
|
¹x¥Û¤j: «_¬N½Ð±Ð±z, ¤½¦ÐÂ÷¾¹ï«áÄòOBI833.888µ¥¬ãµo¬O§_·|¦³©µÌX©Î¤¤Â_ªººÃ¼{??? |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/11 ¤W¤È 11:21:57²Ä 1346 ½g¦^À³
|
¤p§Ì¬Ý¤F¤@¤UUSPTO (¬ü°ê±M§Q§½ºô¯¸)¡A¸òGlobo-H based cancer vaccine¬ÛÃö¬ã¨sªñ´X¦~¤w¸gÀò±o±M§Qªº¡A°ò¥»¤W¶°¤¤¦bSloan-Kettering¡B¤¤¬ã°|¨â¦a¡C¯E¹©¬ü°ê¥À¤½¥qªº¥t¤@¦W³Ð¿ì¤HSamuel Danishefsky¬O³Ì¦h¬ÛÃö±M§Qªºµo©ú¤H¡A¨ü¯q¤H³£¬OMSKCC¡C ¥Ñ©ó¯E¹©ªº§Þ³N¨Ó¦Û©óMSKCC¥H¤Î¤¤¬ã°|¡AÀ³¸Ó¤w¸gÅn¬A¬ÛÃö±M§Q¡C ¤£²M·¡ªº¬O¡A³o¨âÓ¾÷ºc¹ï¯E¹©ªº±ÂÅv¬O¡y±MÄݱÂÅv¡zÁÙ¬O¡y«D±MÄݱÂÅv¡z¡H Y¬O«D±MÄݱÂÅv¡A«h¯E¹©¦b©Ò¨ú±oªº±ÂÅv¤W¤S¼W¥[¤F¨º¨ÇIP¡A¥i¥H¹ï¤½¥qªº§Þ³N¦³§ó¤jªº´£¤É¸ò«OÅ@¡H¬O§_´N¬Owalker¤j©Ò´£¨ìªº¤T½g¼f¬d¤¤ªº±M§Q¡H Danishefsky³Ì¦ªº±M§Q¬O°w¹ïÄáÅ@¸¢Àùªº¡A¦ý¬O¦Ü¤µ¦ü¥G¨S¤°»ò¬ð¯}¡C¦bMSKCCºô¯¸¤W¥u¦³´£¨ìcancer vaccine¦bÄáÅ@¸¢Àù»P¨ÅÀù»â°ì¦³Á{§É¹êÅç¡A¦ý¬O¹ïÄáÅ@¸¢ÀùªºÁ{§É¹êÅç¨S¦³¶i¤@¨B°T®§¡C ÁÙ¦³¤£¤Ö±M§Q¬O¥Îcation lipid¨Ó§@¬°¨ë¿E§K¬Ì¤ÏÀ³ªº¸üÅé¡A¦Ó©Ò¥i¥H§¨±aªº§Üì«h¬O¥]ù¸U¶H¡AGlobo-H¥u¬O¨ä¤¤¤§¤@¡C¦Ü©ó¸ÓÃþ¬ã¨s¬O§_¶i¤J¥iÀ³¥Î¶¥¬q¡A¤p§Ì¨S¦³·§©À¡C ¦³¤@Ó¦³Ãö±M§Qªº°g«ä¡A´N¬O±M§Q¼Æ¶q¡C¥xÆW©Ò¥Ó½Ðªº±M§Q¼Æ¶q«Ü°ª¡A¦ý¬O¤@¯ë¨Ó»¡»ùȤ£°ª¡C¯u¥¿¦³»ùȪº±M§Q¡A¤@¨â½g´N°÷¤F¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/10 ¤U¤È 02:08:18²Ä 1345 ½g¦^À³
|
Âà¶Kwalker¤j¦b²Ä¤Q¤Hª©ªº°ÝÃD¡G ·|û¡Gwalker10141977 µoªí®É¶¡:2016/4/10 ¤W¤È 10:47:58²Ä 473 ½g¦^À³ ¤£ª¾¹D¦³¨S¦³¤H¤F¸Ñ¤½¥q¦b±M§Q¤Wªº¥¬§½? ¥Ø«e¬Ý¨ìÄÝ©ó¯E¹©ªº±M§Q¥Ó½Ð¥u¦³¤T½g (¤½¶}´¦ÅS¶¥¬q) ¤jÁçªk¬O¯Î±Ò´fªº, ¦pªG 822 ªº¤èªk¥i¦æ ·|¤£·|«Ü§Ö´N¦³¤H°jÁפ@¤U, ¤]¯à°µ¥X 822 ®ÄªGªº·sÃÄ? |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2016/4/9 ¤U¤È 08:18:14²Ä 1344 ½g¦^À³
|
Cliff¤j..³o¦³¨S¸ÑÄÀÁäµ²ªº°ÝÃD?? [023] In another embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 1. In another embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 10. In another embodiment, the ratio of Globo H moieties to KLH moiety is at least 25. In another embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 50. In a further embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 100. In a further embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 150. In yet another embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 500. In yet a further embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 750. In still another embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 1000. In still another embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 1500. In still another embodiment, the ratio of Globo H moieties to KLH moiety subunits is at least 2000. |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2016/4/9 ¤U¤È 08:12:07²Ä 1343 ½g¦^À³
|
·q§e ¤Ñ®Ñ¤@½g.®¥½Ð¦U¦ì¤jÀ°À°¬Ý¦³µL«GÂI..(¶¶«K½T»{¬O¤£¬O·sªº?) (822+834=>¤S¤@Ó·sÃÄ ??) [005]¥»µo©ú¤H¤w¸g¶}µo¥X"¥O¤HÅå©_"ªº´£°ª¥\®Äªº²Õ¦Xª«¬O¥Dn¥Ñ¤G»Eª«¡A¤T»EÅé¥H¤ÎKLHªº¨ä¥L¦h»EÅé³s±µ¨ì¦hÓªºGlobo H³¡¤Àªº¡C .....«z¶ã"¥O¤HÅå©_"ªº´£°ª¥\®Äªº²Õ¦Xª« http://www.freepatentsonline.com/WO2016044326A1.html |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/4/9 ¤U¤È 06:33:12²Ä 1342 ½g¦^À³
|
«Øcc¤j ¤p§Ì¸ÕµÛ±q¤½¥q¬ÛÃöªk»¡·|¨Ó¦^µª±zªº°ÝÃD 1¥´¬Ì]´N¯à²£¥Í§ÜÅé,¥§¡¬ù8¦¨(IgG+IgM)¡A¥Ñ©ó2ºØ§ÜÅé³£¦³±þ¦ºÀù²ÓM®ÄªG¡AY¤À§O¨Ó¬Ý¶W¹L8¦¨(¨Ò¦p: IgG7¦¨5¡AIgM8¦¨5)¡A©Ò¥H¨S¦³²£¥Í§ÜÅé¤ñ¨Ò¬ù§C©ó2¦¨ ¦Ü©ó¨Ó¤£¤Î²£¥Í§ÜÅé¡A¦]¬°¥Ñ©ó§K¬Ì¿ð©µ³Q§PPDªº¤H¼Æ¤ñ¨Ò¥¼ª¾¡A¦ý¬O¬O³y¦¨¦¹¦¸PFS¥¼¹F¼Ðªº¥Dnì¦]¡C 2¥´¥|°w(¤K©P)¡A¦³¤F¤ÏÀ³¤§«á¦A¥¿¦¡§â¥¦¯Ç¤JÁ{§É¸ÕÅ礤¡A´N¥i¥H§â§K¬Ì¿ð©µªº°ÝÃD¸Ñ¨M¡A¥t¥~¤]·|¦Ò¼{±N¨ÓÁ{§É¦p¦ó¥h°µ¡A¦p¦ó§â§Ú̥ثe¬Ý¨ìªºÁ{§ÉÀø®Ä§â¥¦¹F¨ì³Ì°ªÂI¡C ¤p§Ì»{¬°¤½¥q³z¹L¦¹¦¸Á{§ÉÀ³¤wºë·Ç´x´¤¦³§ÜÅé¤ÏÀ³±Ú¸s¡A«áÄò¤T´ÁÁ{§É±N§óºë·Ç§Ö³t¥B¦¨¥\²v¤j¤j´£¤É¡C 3YK¦³´£¨ì¡A·sªºÀøªk«D¬Ý³æ¤@¼Æ¾Ú¡A§Y¨Ï«Ü¤p±Ú¸s¡A¥unÃÒ©ú¦w¥þ¥B¦³ÃĮġA¤×¨ä¬O¯f¤H¥Í¬¡«~½è¦³©Ò¼W¶iªº¸Ü¡AFDA³£·|¸ò§Ú̦n¦n·¾³q¡A·|°µ¯S§O¦Ò¶q¡C ©Ò¥H¤p§Ìı±o¥un¼Æ¾ÚÃÒ©ú¦³Àø®Ä¡A«áÄò»PFDA·¾³qÀ³·|´Â¥¿¦Vµo®i¡C ¥H¤W¤p§Ì©å¨£¡A¨Ñ±z°Ñ¦Ò |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2016/4/8 ¤U¤È 11:58:37²Ä 1341 ½g¦^À³
|
ÁÂÁ¤ѩR®v±ß¦w |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2016/4/8 ¤U¤È 10:33:35²Ä 1340 ½g¦^À³
|
¤p§Ì½Ð°Ý¥xÁÞ®v¡DÛ´°±M®a·|ij¤£ª¾¹D¥L̦³¨S¦³¬Ý¹L822ªº¼Æ¾Ú©O¡H3Q |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/8 ¤U¤È 10:10:48²Ä 1339 ½g¦^À³
|
Âà¶K «Øcc¤j°ÝÃD¡G ·|û¡G«Øcc10140016 µoªí®É¶¡:2016/4/8 ¤U¤È 09:40:35²Ä 468 ½g¦^À³ ¤p§Ì¦³Ó°ÝÃD·Q½Ð±Ð¦U¦ì¤j¤j ¤£ª¾¾A¦X¶Kþ¤@ª©? 822¹ï²£¥Í§ÜÅé¤Ï¬M ¨S¦³²£¥Í§ÜÅé ¨Ó¤£¯Å²£¥Í§ÜÅé ³o3ºØ¤ÏÀ³ªº±Ú¸s¤£ª¾¦U¥e?%? ¤£ª¾¹D¤½¥q¦³µL¿ìªkºë·Ç´x´¤¦³§ÜÅé¤ÏÀ³±Ú¸s ¥u¦³¥´4°wªº¤è¦¡¦³§ÜÅé¤~¯d¤U¶Ü? FDA¹ïÂ榳®Ä±Ú¸s ¤£ª¾¦³µL·N¨£~ ÁÙ¬O¤p§Ìªº°ÝÃD ®Ú¥»´N¤£¬O°ÝÃD~ |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2016/4/8 ¤U¤È 08:53:31²Ä 1338 ½g¦^À³
|
¦hÁ¦U¦ì¤j¤jªº¤À¨É. |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/8 ¤U¤È 04:18:52²Ä 1337 ½g¦^À³
|
¦Ñ´¤j¡A¥xÁÞ¤j¡ALu¤j¡A ·PÁ¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/8 ¤U¤È 04:12:08²Ä 1336 ½g¦^À³
|
¦Ñ´¤j ¥X°ê®È¹C¬Ý¬ü´º ¦Y¬ü¹ ¦^°ê«á¯«²M®ð²n Æg!(¤ñ¬Ý¯E¹©»P¤½¦Ð³QK¦n¤Ó¦h «Ü¦h¤j¤j¶V¬Ý¶V¤£²n) ¤£¹L³Ìªñ´CÅé¤ñ¸û©¹¤½¥¿¤è¦V³ø¾É §Æ±æ¥¼¨Ó·|¶V¬Ý¶V²n ÁÂÁ¤À¨É off lable use ¹ê°È¸gÅç ®¥¶P Cliff¤j ¦Ñ©±·s¶} ªù®xY¥« ÁÂÁ «Ó¥v¤j ¤À¨ÉT-VECªº¬G¨Æ Æg! ÁÂÁ¹x¥Û¤j ¦³«í¤j ¤s¤¤¤j Lu¤j ·P°Ê¤j ¤Ñ©R¤j »P²³¤j¤jªñ´ÁµL¨pªº¤À¨É ÁÂÁ |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/8 ¤U¤È 03:17:43²Ä 1335 ½g¦^À³
|
¥xÁÞ¤j,Æg! ¹x¥Û¤j,±zªº²z¸Ñ¨S¦³°ÝÃD,¬O¦Ñ´»¡ªº¤£°÷²M·¡. ¥xÆWªºÂå®v¬O¬Ý°·«OªºÁy¦â¦b°µ¨Æªº,¥un©M°·«O¨S¦³Ãö«Y¨Æ±¡´N·|«Ü¶¶§Q ¹³C¨x,§A¥h¬Ý100Ó¸zG¬ìÂå®v,³£¥u·|¸ò§A»¡¥´¤zÂZ¯À(°Æ§@¥Î¤j),¨S¦³¤H·|§i¶D§A¤w¸g¦³§Ü¯f¬rÃÄ¥i¥H ªv¦n!¬°¤°»ò?¦]¬°§Ü¯f¬rÃÄ°·«O¤£µ¹¥I,¬Æ¦Ü¥xÆW®Ú¥»¦³¿ú¤]¶R¤£¨ì!¦pªGn¶Rn¦æ¤å¨ì½ÃºÖ³¡,½ÃºÖ³¡¦A ¥H°ê®aªº¦W¸q¥Î±M®×ªº¼Ò¦¡©M°ê¥~ªºÃÄ°Ó¶R¶i,3~6Ӥ몺Àøµ{¦n´X¸U¬üª÷! ¥un¯f®a¨S¦³¸gÀÙ¤Wªº°ÝÃD,Âå®v¬O«Ü¼Ö·NÀ°³oÓ¦£ªº,³o¸Ì±Âå®v®³¤£¨ì¥bÂI¦n³B,¦ýÁÙ¬O¦³«Ü¦hÂå®vÄ@ ·NÀ°¦£!«Ü¦hÂå®v¿ï¾Ü¤£§iª¾ªºì¦],¬O¦]¬°¯f®aªº¸gÀÙt¾á¤£°_,´X¦Ê¸U¥x¹ô¹ï«Ü¦h¤H¨Ó»¡°®¯Üª½±µ¦º±¼ §Ö¤@ÂI!§A¤£§i¶D¥L¥L¤£ª¾¹D¤ß¸Ì·|¤ñ¸ûµÎªA,¤zÂZ¯À°Æ§@¥Î¤j¤@ÂI¦³¤°»òÃö«Y?10~20¸U¥x¹ô´N¸Ñ¨M¤F,°· «O¤S¦³µ¹¥I,°µ¸gÀÙ¿µ¤@¼Ë¨ì¥Øªº¦a,¤£¬O¨CÓ¤H³£±o°µÀYµ¥¿µ¹À~ ¤@¼Ëªº¹D²z,¦´Á¨ÅÀù,°µ¸gÀÙ¿µ´N¦n¤F!n¤£nÂX¥Rindication,¬OÃÄ°ÓÂX®i·~°Èªº¨Æ±¡,¨S¦³Âå®v·|¥D°Ê ·d¤@Óclinical trialªº,¬°¤°»ò?¨S¦³ÃÄ°Óªº¤ä«ù,¬ã¨s¸g¶O±qþ¸Ì¨Ó?ÁÙ¦³,¥Ó½ÐIRB¬O«Ü³Â·Ðªº¤@¥ó¨Æ. ¥un¦³TFDAÃÄÃÒ,Âå°|¦³¶i³oÓÃÄ ¦b¦Û¶O,¯f®aª¾±¡¦P·N¥Bñ¸p©ñ±ó°·«OªºÅv§Q©Î¬O¨Æ«e¼f¬d«á¤£ãªº±¡ªp¤U, off label use¦b¥xÆW¤£¬O¤°»ò¤j°ÝÃD,Á{§ÉÂå®v³q±`·|¸ÑÄÀ«Ü²M·¡,¥Î¦b²Ä´X´Á¬O¦³ªÅ¶¡ªº! ¦Ü©ó¬O¤£¬O¨CÓÂå®v³£ª¾¹Dn«ç»ò°µ¡H¨º´N¤£¤@©w¤F!¦Ñ³¾¤@©wª¾¹D. ©Î¬O¦³¨ì¼f¬d©eû·|»²¾É²Õ³Ü¹L©@°Øªº¤]ª¾¹D¦]À³¤§¹D!~~ |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/4/8 ¤U¤È 03:12:46²Ä 1334 ½g¦^À³
|
²³¤j¤j¡G Àù«ä°±(Avastin)ÁٰƧ@¥Î¤@¤j°ï¡A¬Ý¨ì·|À~¤H¡I³o¨Ç°Æ§@¥Î·|Åý¤H¥Í¤£¦p¦º¡I www.kfsyscc.org/cancer/cancer-treatment/med/info/Bevacizumab ª`·N¨Æ¶µ¤Î±`¨£©ÎÄY«°Æ§@¥Î¡G P¦R©Ê¡G§C«×P¦R (§C©ó10%ªº¯f¤H·|µo¥Í¹Ã¦R)¡C °©Åè§í¨îµ{«×¡G§C«×§í¨î¡C¥X¦å(40%)¡B¥Õ¦å²y´î¤Ö(37%)¡B²`³¡ÀR¯ß®ê¶ë(9%)¡B¶Ý¤¤©Ê¥Õ¦å²y´î¤Ö(5.8-27%)¡B¦å®ê®ê¶ë(5-15.1%)¡B¦å¤pªO´î¤Ö(5%)¡CÄݼйvÃĪ«¡C¸~½F¶V¤j¡A³y¦¨¥X¦åªº¾÷·|´N¶V°ª¡A¦ýµLªk¹w¨¾¡C ¤ßŦ¦åºÞ¤è±°Æ§@¥Î¡G°ª¦åÀ£(8-34%)¡B°Ê¯ß®ê¶ë(8.5%)¡BÆ{¦å©Ê¤ß°IºÜ(2.2%)¡B¥ª¤ß«Ç·i¥X¤À²v°§C(1.7%)¡C½Ð¶i¦æ¦åÀ£ºÊ´ú¡A¨C¤H¦åÀ£ÅܤƵ{«×¤£¤@¡C¦pªG¦åÀ£¤Ó°ª¡A¥i¯à»ÝnªA¥Î°¦åÀ£ÃĪ«¡C ¥Ö½§¤è±°Æ§@¥Î¡G±¼¾v(6-32%)¡B¼vÅT¶Ë¤f¡¦X(3-15%)¡B¥Ö¯l(1-10%)¡C ¥NÁ¤Τº¤Àªc¤è±°Æ§@¥Î¡GÅé«´î»´(20%)¡B²æ¤ô(3.3-10%)¡B§C¦å¶u(4%)¡C G¸z¤è±°Æ§@¥Î¡G¸¡µh(50-61%)¡B³à¥¢¹¼¤(35-43%)¡B¤fµÄÂH½¤¯}·l(30-32%)¡B¸¡Âm(1-34%)¡BG¥X¦å(19-24%)¡B¨ýı§ïÅÜ(14-21% )¡Bäú¤ß(4.1-12%)¡B¹Ã¦R¡B«K¯µ(4%)¡BG¬ï¤Õ(2.4%)¡C §K¬Ì¨t²Î°Æ§@¥Î¡G·P¬V(3-10%)¡B¿éª`¤ÏÀ³¡]<3%¡A¨Ò¦p¡G°ª¦åÀ£¡B¯Ýµh¡BÀYµh¡^¡C³q±`¿éª`³t«×©ñºC¡A¬Ò¥iÀò±o§ïµ½¡C °©Àf¦Ù¦×¤è±°Æ§@¥Î¡G¦Ù¦×¯kµh(19%)¡BIµh(12%)¡BÃö¸`µh¡C¥i¨Ï¥Î´¶®³¯kµ¥¤îµhÃĨӴî½w¯kµh¡C ¯«¸g¨t²Î°Æ§@¥Î¡GµL¤O(70%)¡BÀYµh(50%)¡BÀY·w(19-26%)¡B·Pı¯«¸g¯fÅÜ(1-24%)¡B»jµïºô½¤¤UµÄ¥X¦å(1-5%)¡C µÇŦ¤è±°Æ§@¥Î¡G³J¥Õ§¿(4-36%)¡BµÇ¯f¯gÔ¸s(0.5%)¡C ©I§l¨t²Î°Æ§@¥Î¡G¤W©I§l¹D·P¬V(40-47%)¡B»ó¥X¦å(19-35%)¡B©I§l§xÃø(25-26%)¡B«y¦å(2.3-31%)¡BªÍ¥X¦å(2.3-31%)¡BÁnµ§ïÅÜ(6-9%)¡C°ª¾÷²vªºªÍ¥X¦å¡B«y¦å³q±`»PªÍÀù¥»¨¦³Ãö¡C ¨ä¥¦¤è±°Æ§@¥Î¡G¯hÂ(4-19%)¡C |
|
|
·|û¡GLu10141514 µoªí®É¶¡:2016/4/8 ¤U¤È 02:51:18²Ä 1333 ½g¦^À³
|
²³¤j¤j¡G ¦³¿³½ì¥i¬ã¨s¤@¤Uù¤óÃļt¶PÀù¥(Herceptin)¡BÀù«ä°±(Avastin¡AªvÀøÂಾ©Ê¤j¸zª½¸zÀù)¡B¡B¡B µ¥µ¥¡A´XÓ§ÜÀùÃÄ¡C ù¤ó(Roche)Ãļt2014¦~ªº¦~³ø www.roche.com/med-cor-2015-01-28-e.pdf Avastin Àù«ä°±³ÌÂ÷ÃСA¥u©µªø¦s¬¡¤Ó¤ë¡A¦ý¬Onªá100¸U¡I¡I www.ttcc.org.tw/wp-content/uploads/2011/05/%E6%AD%A3%E8%A6%96%E5%81%A5%E4%BF%9D%E7%B5%A6%E4%BB%98%E5%AF%A9%E6%9F%A5%E5%A4%B1%E8%A1%A1%EF%BC%BF%E5%85%AC%E8%81%BD%E6%9C%83APR29_2011.pdf ®ÄªG³o®tªºÃÄ¡A2014¦~¾P°âÃB³ºµM¦³64.2»õ¬ü¤¸¡C ¥Ñ¦¹¥i¨£¡uÂಾ©Ê¤j¸zª½¸zÀù¡v¬O´X¥GµLÃÄÂ媺¡C©Ò¥H¡AÀù«ä°±(Avastin)¤~½æªº¨º»ò¦n¡I §Úı±oOBI-822¨S¦³¦w¥þÅU¼{¡A¦Ó¥B¨ãÀø®Ä¡]Significant¡^¡AFDAÁÙ¬O·|㤩¦³±ø¥ó§åã¡]Conditional Approval¡^¡C °£«D¨º¨Ç©xû¸£¤l¶i¤ô¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/8 ¤U¤È 02:29:24²Ä 1332 ½g¦^À³
|
²³¤j¤j 1¯E¹©ªº¿ú¨¬°÷¤]¦³¯à¤O°µ¥þ²y¤T´Á,¥þ²y¤T´Á¤H¼Æ¨Ì¥Ø«e¼Æ¾Ú¥i¯à·|¤ñ¥xÆW¤T´Á¤Ö«Ü¦h ,Michael¤T¥i¯à a¨Ì¾ÚÁ{§É¼Æ¾Úµ¹»Pconditional approval ª½±µµ¹ÃÄÃÒ( Michael ¤@ ) b¥þ²y¤T´Á¤£¤@©wn±qÀY°µ¨ì§¹ ,°µ¨ì¤@¥b¼Æ¾Ú¹F¼Ðµ¹ÃÄÃÒ( Michael ¤G) c¥þ²y¤T´Á±qÀY°µ¨ì§¹¼Æ¾Ú¹F¼Ðµ¹ÃÄÃÒ (Michael ¤T) 2ªk»¡·|«á°Ýµª¤j®aÀ³¦A·Å²ß¤@¦¸,¥Ø«e±¡ªp¬O±qYK¥|±¡ªp Åܦ¨ Michael¤T¥i¯à (µ¥¯E¹©»P¬ü°êFDA®i¶}¥þ²y¤T´ÁÁ{§É¸ÕÅçpµeªº¿Ô¸ß°Q½×«á¤~ª¾¹D³Ì«áµ²ªG) Michael¤£Ä@·N¨Æ¥ý¹w´ú(³o¤TÓ±¡ªp³£¦³¥i¯à ) 3Ó¤H·P·Q: a Ó¤H»{¬°822¤w¸g¦³¤f¸O,¦b¥R¤À·Ç³Æ¤U¥þ²y¤T´Á¦¬®×³t«×·|¤ñ¥xÆW§Ö«Ü¦h,¤H¼Æ¤Ö,¦¬®×§Ö ,¨Æ¥ý·Ç³Æ¬O¥²nªºµ¦²¤, ¯E¹©´N¥i±q®e¤£¢§Ö³t§¹¦¨¥þ²y¤T´Á ,¥þ²y¤T´Á¤£¤@©wn±qÀY°µ¨ì§¹ ,¦³¥i¯à¤@±¶i¦æ¤@±µ¥¼Æ¾Ú b°ß¤@ȱo¦w¼¢ªº¬OYK 4§¹¥þ¥¢±Ñ¤w¸g±Æ°£ c¯E¹©Û´°±M®a·|ijÀò¤T´ÁÁ{§É©ú½T¤è¦V,¯E¹©±N°Ñ¦Ò³o¨Ç«Øij¡A¿n·¥®i¶}¤T´ÁÁ{§É³W¹º¡A¨Ã°t¦X¬ãµoµ¦²¤¡AÀÀq³Ì¦X¾A¤è ®×¡A¤@¤è±¤]±N¿n·¥·Ç³Æ»P¬ü°êFDA®i¶}¥þ²y¤T´ÁÁ{§É¸ÕÅçpµeªº¿Ô¸ß°Q½×¡C d Michael¤T¥i¯àªº¥ô¦ó¤@ºØ §Ú³£Ä@·Nµ¥ ¥H¤W¤À¨É ¶È´£¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤s¤¤10141474 µoªí®É¶¡:2016/4/8 ¤U¤È 02:09:11²Ä 1331 ½g¦^À³
|
¦Ñ¥v¤j ÁÂÁ¤À¨É¡A¦pªG³o¼Ë³£¯à¹L¡A¨º¯E¤ÍÌ´N¦Y¤F©w¤ß¤Y¤F¡C´N²{¦bªk»¡ªºµ²½× 1. MOA½T©w 2. µL¤£¨}°Æ§@¥Î 3. OS«Üªø 4. ¥ÎÃĬI¥´¤è«K ¨C¶µ³£Ä¹¹LT-VEC¡A³Ñ¤Uªº´N¾a§Æ±æ¦ò¦n¦n¦bASCO«Å¶Ç¤F¡CÆg!!! |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/8 ¤U¤È 01:20:38²Ä 1330 ½g¦^À³
|
¦Ñ¥v¤j¡A ºë±m¡I¡I¡I ²Ö¿n´XÓ³o¼Ëªº®×¨Ò¡Aµ¥¤»¤ëªì¤j®a¬Ý¨ì½T¹ê¼Æ¦r¡A´N¥i¥H¸ò«e±³o´XÓÀù¯gÃĨӰµ³v¶µPK¡A¨ì®É¹ï©óFDAªº¥i¯à¤ÏÀ³´N¤£Ãø²q´ú¤F¡C |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/4/8 ¤U¤È 12:10:38²Ä 1329 ½g¦^À³
|
T-VECªº¬G¨Æ 1. T-Vec¶Â¦â¯À½FÁ{§É¦@¦¬®×436¤H¡A¹ï·Ó²ÕÃĪ«¬O GM-CSF¡A¤À²Õ¤ñ¨Ò2¡G1¡A¥Dnµû¦ô²×ÂI¬O durable response rate (DRR; objective response lasting continu-ously ≥ 6 months)¡AÃöÁ䦸nµû¦ô²×ÂI(Key secondary endpoints )¬OOS»PORR¡A¥H¤U¸ê®Æ´X¥G¥þ³¡¤Þ¥Î¦ÛFierceBiotechºô¯¸¡A¤j¬ù¤Q¦h±ø·s»Dµû½×¡A¦³¿³½ì¥i¥H¥h¬Ý¥þ¤å¡C 2. 2013¦~6¤ë´Á¤¤¤ÀªR¡ADRR16%¡]®Ú¾Ú2015¦~5¤ëµoªí¦bJCO´Á¥Zªº³Ì²×¼Æ¾Ú¬O16.3%¡A©úÅãÀu©ó¹ï·Ó²Õ2.1%¡^ 3. 2013¦~11¤ë¤½§G´Á¤¤¤ÀªRªºOS23.3Ó¤ëÀu©ó¹ï·Ó²Õªº19Ó¤ë¡AWe look forward to the mature overall survival data expected in the first half of next year¡A¹wp2014¦~¤W¥b¦~·|¦³¦¨¼ôªºOS¼Æ¦r¡A¥«³õ»á¬°¼ÖÆ[driving optimism that the drug can win approval 4. 2014¦~4¤ë¡A³Ì²×OSªºPÈ0.051¡A¥Î¥Õ¸Ü»¡¦Ò¤F59¤À¡A failed to extend patients¡¦ lives at a statistically significant rate. ¦ý¤½¥q»¡ but the strong trend in survival benefit supports further research of talimogene laherparepvec to better understand its role in melanoma, both as a single-agent and in combination with other therapies 5. 2014¦~6¤ë¡AAmgen¤´±N¥Ó½Ðªk³W®Öã¡A¾¨ºÞOS¥X²{¤p¥¢»~¡CBut that won¡¦t stop the California company from seeking regulatory approval, T-Vec might also have a future as a partner in immunotherapy duos¡]¦b¦X¨Ö¥ÎÃĤW¤]¦³«e´º¡^¡ABecause of T-Vec¡¦s relatively favorable adverse event profile¡]¦]¬°¦b¤£¨}¤ÏÀ³¬O¦³§Qªº¡^¡A, Reese said the company thinks T-Vec could eventually be a partner for a number of other immunotherapies.¡]T-Vec¥i¥H¦¨¬°³\¦h§K¬ÌÀøªkªº¦X§@¹Ù¦ñ¡^ 6. 2014¦~7¤ë¡A¦V¬ü°êFDA´£¥æBLA¡AFDA¥²¶·¦b2015¦~4¤ë«e¦^Âбµ¨ü»P§_¡A In that study, T-Vec hit its primary endpoint with a 16% durable response rate and increased the median overall survival rate to 4.4 months. But there was one blip: That OS rate fell just short of statistical significance 7. 2014¦~9¤ë¦V¼Ú·ùEMA´£¥æBLA 8. 2014¦~12¤ë¡A©MKeytruda¦X§@¡AAmgen¡¦s cancer vaccine candidate may be awaiting FDA and EMA approval as a melanoma monotherapy, but the company isn¡¦t stopping there. Like many of its peers, it¡¦s looking to explore its prospect¡¦s po-tential as part of an immunotherapy duo 9. 2015¦~2¤ë¡A·s»D¼ÐÃDFDAÅU°Ý¹Î·|¤£·|§_¨MT-Vec¡HBut a narrow miss on one key endpoint could present a major hurdle, and Amgen will soon get a chance to defend the treatment before a panel of FDA advisers¡ATwo of the agency¡¦s independent expert committees are slated to review T-Vec on April 29, voting whether to recommend the vaccine for full approval. The FDA isn¡¦t required to follow the opinions of its advisers, but it most commonly does. The agency has promised to hand down a final decision on Amgen¡¦s candidate by Oct. 27¡Athe FDA has a well-established penchant for approving cancer treatments with much less supporting data than T-Vec--it could have a trickle-down effect on the drug¡¦s eventual value if and when it hits the market 10. 2015¦~4/27¡AFDA¹ï©óT-Vec¼Æ¾Ú«Ü¦³·N¨£¡G278 subjects dropped out of the study¡]63.7%°h¥XÁ{§É¡A¶W¸Ø±i¡^, leading the FDA to question whether investigator bias--focusing on crafting positive final data--had something to do with those decisions. Subject or investigator bias regarding the relative benefit of T-Vec and the control may have influenced the determination that it was in the best interest of the subject to stop treatment or to be given other therapy for melanoma,Is there clear evidence of a systemic response to the drug, which is designed to spur an immune response as it targets and kills cancer cells? That¡¦s hard to determine based on the data presented, says the FDA review. The review also raises questions of investigator bias in assembling the final data, excluding some patients--cherry-picking¡]³oÓµü±i¸³¥Î¹L¡^would be another way of phrasing it--in a way that may have skewed the final outcomes¡C©ó¬OFDA©Þ±¼¥¦§Ö³t®Öã¸ê®æ¡¨FDA rules out an accelerated approval¡¨¡CFDA·N¨£ÁöµM«Ü¦h¡A¦ýµû½×®a»¡¨ì¡A·íFDAn®Öã¹ñ·sÀù¯gÀøªk®É«o¤SÅܱo«D±`³q¿Ä¡AAmgen does have one big factor in its favor. The FDA has become quite accommodating when it comes to approving ne |
|
|
·|û¡G·P°Ê£®10141081 µoªí®É¶¡:2016/4/8 ¤W¤È 10:17:18²Ä 1328 ½g¦^À³
|
¹x¥Û¤j ±z»¡ªºÀ³¬O888ªº¶i«×¤£¬O822§a 888ªº·§©À«Ü¦n ¦ý«Ü¤£®e©ö°µ¥X¨Ó§a ¦pªG¨º»ò®e©ö ¨º²{¦bªÑ»ù¥i¯à¬O10¿¥H¤W¤F |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/8 ¤W¤È 10:16:31²Ä 1327 ½g¦^À³
|
©êºp¡A¬O¹ï888ªº¶i«×¤£¯à¤Ó¼ÖÆ[¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/8 ¤W¤È 10:09:58²Ä 1326 ½g¦^À³
|
888¬O³æ®è§ÜÅé¡An¥Ñ¥Íª«¤ÏÀ³°µ¥X»P¤HÅé¦ÛµM¦X¦¨§¹¥þ¬Û¦Pªº§ÜÅé¡A¬On¸g¹L¬Û·íªøªº¨BÆJªº¡A¤£¬O»¡«ö·Ó±Ð¬ì®Ñ´N¯à¶¶§Q°µ¥X°ò¦]¡BÂà´Ó¨ì¤HÅé²ÓM®è¡B¥Íª«¤ÏÀ³¾¹¶q²£³o»ò²³æªº³æ¦æ¹D¡C¬Û¹ï¦Ó¨¥¡A822ÁÞ§Ü쪺¦¨¥\¾÷²vÁöµM¸û§C¡A¦ý¬O°µ¥X»s¾¯ªº®É¶¡§Ö«Ü¦h¡C ¤p§Ì»{¬°¡A¹ï822ªº¶i«×¤£À³¹L©ó¼ÖÆ[¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/4/8 ¤W¤È 12:21:36²Ä 1325 ½g¦^À³
|
·P°Ê¤j »{¦P§Aªº¬Ýªk:³Ì¤jªº»ùÈÀ³¸Ó¬O½T»{ÁÞ¤À¤l¥i¥H·í¦¨§Üì·í¦¨¼Ð¹v¡A¥i¥H·í¦¨¬OªvÀøªº¤@ºØ«n¼Ò¦¡ ¦]¬°³o¦b¥@¬É¤WÁÙ¨S¦³³QÃÒ¹ê¡A¤]ÁÙ¬O«D±`§Nªù»P³Q¤H©¿²¤ªº¤@¤ä ¥¼¨Ó¥un¬O³QªÖ©w³Q±µ¯Ç¬°¨ä¤¤¤@ºØ«nªº Àù¯gªvÀø¤è¦¡ ¯E¹©ªº»ùÈ´N·|³Qµo²{³QªÖ©w¤F 1 ¯E¹©n°µªºÀù¯g³æ®è§ÜÅé§K¬ÌÀøªk(OBI-888)»P¥Ø«eªº³æ§ÜÃĦp¶PÀù¥¤£¦P,¬O§Q¥Î³æ®è§ÜÅéÃĪ«¨ä°ª±M¤@©Ê¡B°ªµ²¦X¤Oªº¯S©Ê¡A¿Eµo§K¬Ì¨t²Î¡AÄè·ÀÀù²ÓM, §Æ±æ§¡¬Û¤Æ«áÀø®Ä¿¼Æ´£°ª °Æ§@¥Î°¨ì³Ì§C,²{¦b¥¿¦b¥[§Ö¬ãµo¤¤,¯S§O¬O³o¦¸¤T´ÁÁ{§Éªº«¤jµo²{,¤½¥q¥þ±´£°ª¹ï822 833 888 ¦¨¥\ªº«H¤ß ²³æ»¡´N¬O·s¤@¥NªºÀù¯g³æ®è§ÜÅé§K¬ÌÀøªk 2 OBI822 ¥Î©óÀù¯g¥½´Áªº¯f±w¤j³¡¥÷³£·|²£¥Í§ÜÅé,§Ú»{ÁÙ¬O¥D¨¤, è¶}¨Ï¥ý¿z¿ï¯f±w ,µ¥¨ì³æ®è§ÜÅé§K¬ÌÀøªkOBI- 888¬ãµo¦¨¥\¦AÁp¦X¨Ï¥Î©Î¥ýÁp¦X¨ä¥LÃĪ« ,¥¼¨Ó¤]¤£¬O16ºØÀù¯g¬ãµo³£·|¦¨¥\,¦¨®Ä¤í¨Îªº¾AÀ³¯g©Î³\´N¬OÀù¯g³æ®è §ÜÅé§K¬ÌÀøªkOBI-888 µo´§ªº»R¥x 3¤j®a¶i¤Jù¤óÃļt¬Ý¬Ý¤w¶}½æªº¦³¦WÀù¯gÃĨä¾AÀ³¯g¤]¤£¬O«Ü¦h ´N¤w¸g¬O¥þ²yÀù¯gÃÄ«~½æ³Ì¦hªºÃļt Avastin® Àù«ä°±® Herceptin®¶PÀù¥® Kadcyla® ¶PÀù¹ç® Perjeta®¶P¯e§´® Xeloda®ºI½F¹F® 3 OBI-888 Globo H³æ®è§ÜÅé·sÃÄ ¥Ø¼Ð: a¥i§@¤ÆÀø©Î©ñ®gªvÀøªºªþ¥[Àøªk¡A¥i°§C¤p¤À¤lÃĪ«¾¯¶q¡A§ïµ½¥Í¬¡«~½è¡C bµLªk¹ïOBI-822©Î OBI-833²£¥Í§ÜÅ骺¯f±w¡C c§ó¥i±æ¹Å´f¤T³±©Ê±Ú¸s©MHerceptinµ¥ªvÀø¥¢±Ñ©Î´_µoªº¯f¤H¡C 4¥Î©ó¤¤¦±ß´Á©Î¹w¨¾ OBI833 ¤õ¤O¥i¯à§ó±j (ªø´Á°O¾Ð) ¥H¤W¤À¨É ´£¨Ñ°Ñ¦Ò |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/8 ¤W¤È 12:09:53²Ä 1324 ½g¦^À³
|
HerceptinÁ{§É¹êÅç®É·f°tªº¤ÆÀøÃĪ«¨ì¤µ¤ÑÁÙ¦b¼Ð·Ç»s¾¯·í¤¤¡C¬Ý¨Ó822¸Ìªºcyclophosphamide¤]·|¸ò¥Lªø¬Û¥ª¥k¡C |
|
|
·|û¡G·P°Ê£®10141081 µoªí®É¶¡:2016/4/7 ¤U¤È 10:56:59²Ä 1323 ½g¦^À³
|
¥xÁÞ¤j ±z´£¨ìªºOBI-888¨ä¹ê´N¬O§Ú¤§«e¦³½Ð±Ð¹LCliff¤jªº¨ä¤¤¤@Ó°ÝÃD ¨ä¹ê¥HÀù¥½¯f¤H¦Ó¨¥¡A³Q°Ê¦¡§K¥HÀøªk¨ä¹ê¤ñ¥D°Ê¦¡Àøªk§ó¾A¦X¡A§ó¤Á¦X»Ý¨D ¦]¬°¦Ü¤Ö¤£»Ýn¦³¨âÓ¤ë¥H¤Wªº¤ÏÀ³´Á¡A³o¹ï¤w¸g¨S¦³®É¶¡ªºÀù¥½¯f¤H¦Ó¨¥¡A¤~¯à¦³¥ß§Y³QªvÀøªº¾÷·|¡A¤×¨ä¬O¤ñ¸û¤¿²rªºÀù¯g ¦Ó¥B°£¤F²£¥Í§ÜÅ骺¤ÏÀ³®É¶¡©µ¿ð¤§¥~¡AµLªk²£¥Í§ÜÅé©Î²£¥Í§ÜÅé¶q¤£°÷ªº°ÝÃD¤]¥i¥H¸Ñ¨M ¤]´N¬O¥un¯f¤H¦³GLOBO-H¨t¦C¹L«×ªí²{ªº²{¶H¡A¨ä¹ê´N·|¦³«Ü¦nªºÀø®Ä¡A¤]´N¬O¦³¾÷·|¾AÀ³¤K¦¨¥H¤Wªº¯f¤H ·Q·Q¦pªG¯u¬O³o¼Ë¡A³o¦¨ªG·|Åý¤H¦h»ò¿³¾Ä¡A¦ñÀHªº°Ó¾÷·|¦³¦h¤j ©Ò¦³Àù¯g·sÃÄ´X¥G³£¬O¥ÑÀù¥½¶}©l±À®i¡A¦]¬°¯f¤H³Ì»Ýn·sÃĨӴ£°ªÀø®Ä¡AÃļtªº¹êÅ禨¥»¤]³Ì§C ©Ò¥H«ÈÆ[¦Ó¨¥¡A¨ä¹ê¯E¹©·íªìÀ³¸Ó¥ý¥Hµo®i¢·¢·¢·³oºØ²£«~¬°¥D¡A¤~·|¦³°÷ºë·ÇªºªvÀø®ÄªG©MÃø¥H·Q¹³ªºÃe¤j¥«³õ ¦ý¥i¯à·íªì¥DÆ[ªº±ø¥ó¥u¯à¥H¢·¢±¢±³oºØ¥D°Ê²£«~¬°¥D ¥u¬O¤£ºÞ¬O¢·¢±¢±©Î¢·¢²¢²¡A¨äªvÀø®ÄªGÀ³¸Ó³£ÁÙ¬O¤ñ¤£¤W¢·¢·¢·³oºØ²£«~ ¢·¢±¢±¡D¢·¢²¢²³oºØ²£«~À³¸Ó¬On©¹«e´Á±À¡A©Î¹³¯Î°|ªøªº·Qªk¬O°µ¹w¨¾©Ê²£«~À³¸Ó¬O§ó¾A¦Xªº ·íµM¥D³Q°Ê²£«~ªº¦¨¥»À³¸Ó¤£¦P ¦Ó¥B¾AÀ³¯gªº¦õ¾¯»P¬I¥´¤è¦¡¬O¤£¬OÀ³¸Ó¤£¦P¡A³o´Nn¦A½Ð±Ð¦U¦ì¤F ·íµM¤]¤£¬O²{¦b¥ß§Y©Êªº°ÝÃDªº ©Ò¥H³o¦¸¸Ñª¼´N§ÚªºÆ[ÂI¨Ó¬Ý¡A¦pªG¥¼¨Ó¦b¥«³õ¤W¬Ý¨Óºâ¦¨¥\ªº¸Ü ³Ì¤jªº»ùÈÀ³¸Ó¬O½T»{ÁÞ¤À¤l¥i¥H·í¦¨§Üì·í¦¨¼Ð¹v¡A¥i¥H·í¦¨¬OªvÀøªº¤@ºØ«n¼Ò¦¡ ¦]¬°³o¦b¥@¬É¤WÁÙ¨S¦³³QÃÒ¹ê¡A¤]ÁÙ¬O«D±`§Nªù»P³Q¤H©¿²¤ªº¤@¤ä ¥¼¨Ó¥un¬O³QªÖ©w³Q±µ¯Ç¬°¨ä¤¤¤@ºØ«nªºÀù¯gªvÀø¤è¦¡ ¯E¹©ªº»ùÈ´N·|³Qµo²{³QªÖ©w¤F ©Ò¥Hn¬Ý¬Ý¢Ï¢á¢Ñ¢Ý¤½§Gªº¼Æ¾Ú¦p¦ó¡A¤j®aªº¤ÏÀ³¦p¦ó¤F |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/4/7 ¤U¤È 10:39:05²Ä 1322 ½g¦^À³
|
¦Ñ´¤j¡A ¤p§Ì¤£¬O¹ï©¤¹L¨Óªº¡A±z³oºÙ©I°Z¤£¬O§é·Ù¤p§Ì¡I «ö·Ó±zªº»¡ªk¡A¦ü¥GÂå®v³£ª¾¹D¸Ó(¥i¥H)«ç»ò°µ¡A¤£¹L³Ì«áÁÙ¬O money talks ¡C¤p§Ì¾\Ū´úÅç¨S¦³¤£¤Î®æ§a¡H |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/4/7 ¤U¤È 10:36:54²Ä 1321 ½g¦^À³
|
leo¤j,°O±o¥xÁÞ¤j©Mcliff¤j³£¦³¤À¨É¹L,low dose cyclophosphamide ¬O¬°¤F´£°ª§K¬Ì¤O¿Eµo§ÜÅé,©Ò¥H¤£ª¾¹D±N¨Ón¤£n¤]¤@°_¥Î!²{¦b¬Ý°_¨Ó«Ü¿Ø¨ë,Åý±Ð¥D¶^¯}²´Ã誺¤TÂI¤§¤@,´N¬Olow dose cycloªº¥\¯à¡AÅý¹ï·Ó²Õ¤]²£¥Í¤FgG&IgM¨Ï±o¨â²Õªº®t¶Z©Ô¤£¶}! |
|
|
|